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I. Introduction 
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I.1. Acquired ImmunoDeficiency Syndrome (AIDS) 
 
The AIDS epidemic is one of the most significant health-related events of the 20th 
century. Acquired immunodeficiency syndrome was first recognised as a new disease in the 
United States when clinicians in New York, Los Angeles, and San Francisco began to see 
young, homosexual men with Pneumocystis carinii pneumonia (PCP) and Kaposi's sarcoma 
(KS), unusual diseases for young adults not known to be immunosuppressed. The first report 
in the medical literature that alerted the world to this new immunodeficiency syndrome 
appeared in June of 1981 and described five young, homosexual men in Los Angeles with 
PCP1. Other reports followed of a similar syndrome in injecting drug users2. The disease was 
originally dubbed GRID, or Gay-Related Immune Deficiency, but health authorities soon 
realised that nearly half of the people identified with the syndrome were not homosexual 
men. In 1982, the Centers for Disease Control and Prevention (CDC) introduced the term 
AIDS to describe the newly recognised syndrome3. 
 
The prominence of homosexual men and injecting drug users in the early cases of 
AIDS suggested an agent that was both blood borne and sexually transmitted4. The majority 
of researchers thought that the likely agent was a sexually transmitted virus that would be 
found in the peripheral blood. The Human Immunodeficiency Virus (HIV) was first isolated 
in France in 1983 by Françoise Barré-Sinoussi in the laboratory of Luc Montagnier at the 
Pasteur Institute as lymphadenopathy-associated virus (LAV)5. Strong evidence that it was 
the AIDS virus did not appear until 1984, when four papers were published in one issue of 
Science by Robert Gallo and colleagues, who designated their isolate HTLV-III (Human T 
cell Leukemia/Lymphoma Virus)6,7. The International Committee on the Taxonomy of 
Viruses chose the designation Human Immunodeficiency Virus in 19868. With the discovery 
by Montagnier's group in late 1986 of the related HIV-2 virus in West Africa, the original 
virus became HIV-19. 
 
 Retrospective studies on frozen tissue and serum samples have identified cases 
apparently fitting the AIDS definition as early as the 1950s and 1960s10: (i) a plasma sample 
taken in 1959 from an adult male living in the Democratic Republic of Congo, (ii) tissue 
samples from a 15-year-old black male from St. Louis who died in 1969 of an aggressive, 
disseminated KS11, and (iii) tissue samples from a Norwegian sailor who died around 197610. 
In each of them an HIV infection has been detected retrospectively.   
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Since its first recognition in 1981 and according to the latest epidemiological studies 
by WHO (World Health Organization) and UNAIDS (Joint United Nations Programme on 
HIV/AIDS) in 2006, AIDS has killed more than 25 million people making it one of the most 
destructive pandemics in recorded history. Actually, 40 million people are worldwide 
infected by HIV, and the highest prevalence is observed in Sub-Saharan Africa (Figure 1)12.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Global estimates of HIV/AIDS infections as of December 2006. 
 
 
In 2006 alone, AIDS claimed an estimated 4.3 million lives, of which more than 
530’000 were children. It is estimated that about 0.6% of the world’s living population is 
infected with HIV. According to current estimates, HIV is set to infect 90 million people in 
Africa, resulting in a minimum estimate of 18 million orphans. Routine access to 
antiretroviral medication is not available in all countries, leading to still sharply rising levels 
of infection. Globally and in every region, more adult women (15 years or older) than ever 
before are now living with HIV (17.7 million or 44.8%).  
 
 
An overview of HIV information about classification, virion structure, viral genome, 
regulation of expression and tropism is provided in the Background chapter at the end. 
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I.2. HIV Immunopathogenesis 
 
Whereas HIV replication is thought to take place in activated CD4+ T-lymphocytes in 
lymphoid tissue, other cell populations may become infected and play a role in infection 
persistence, like resting T-cells in the G0 phase. Virtually every arm of the immune response 
may be affected by HIV infection: CD4+ and CD8+ T-cells, B lymphocytes, monocytes and 
macrophages, dendritic cells, and natural killer cells. Nevertheless the best indicator of 
disease course is the number of CD4+ T-cells, which roughly defines the onset of AIDS when 
it reaches 200 cells/µL (the normal value is 1000-1200 cells per mL). The magnitude of HIV 
replication, reflected by plasma HIV RNA levels, is the second predictor of disease 
progression. The stage of infection can be determined by measuring the patient's CD4+ T cell 
count, and the level of HIV in the blood. The initial infection with HIV generally occurs after 
contact with body fluids from an infected person. The first stage of infection, the primary, or 
acute infection, is a period of rapid viral replication that immediately follows the individual's 
exposure to HIV leading to an abundance of virus in the peripheral blood with levels of HIV 
commonly exceeding one million particles per mL (Figure 2)13. This response is 
accompanied by a marked drop in the number of circulating CD4+ T cells. This acute viremia 
is associated in virtually all patients with the activation of CD8+ T cells, which kill HIV-
infected cells, and a subsequent immune response, or seroconversion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Relationship between HIV copies (viral load) and CD4 counts over the 
average course of an untreated HIV infection; any particular individual's disease course may 
vary considerably.  
[http://www.edinformatics.com/biotechnology/hiv.htm] 
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 The CD8+ T cell response is thought to be important in controlling virus levels, 
which peak and then decline, as the CD4+ T cell counts rebound to around 800 cells per mL. 
A good CD8+ T cell response has been linked to slower disease progression and a better 
prognosis, though it does not eliminate the virus14. During this period (usually 2-4 weeks 
post-exposure) most individuals (80 to 90%) develop an influenza- or mononucleosis-like 
illness called acute HIV infection syndrome. Because of the non-specific nature of these 
illnesses, they are often not recognised as signs of HIV infection.  
The following strong immune defence reduces the number of the viral particles in the 
blood stream, marking the start of the infection's clinical latency stage. Clinical latency can 
vary between two weeks and 20 years. During this early phase of infection, HIV is active 
within lymphoid organs, where large amounts of virus become trapped in the follicular 
dendritic cells (FDC) network15. The surrounding tissues that are rich in CD4+ T cells may 
also become infected, and viral particles accumulate both in infected cells and as free virus. 
Individuals who are in this phase are infectious and can transmit HIV.  
When CD4+ T cell numbers decline below a critical level, cell-mediated immunity is 
lost, and infections with a variety of opportunistic microbes appear. The first symptoms often 
include moderate and unexplained weight loss, recurring respiratory tract infections (such as 
sinusitis, bronchitis, otitis media, pharyngitis), skin rashes, and oral ulcerations. Common 
opportunistic infections and tumors, most of which are normally controlled by robust CD4+ T 
cell-mediated immunity, then start to affect the patient.  
Like other infectious diseases many factors determine AIDS course and onset: the 
route and the size of the inoculum but also the virulence of the virus and the nature of the 
host16. Especially for viruses, heterogeneities in viral replicative capacity are more 
determinant than virulence itself. Concerning HIV, the parenteral entry is the most 
dangerous. The risk after transmucous infection varies according to the site of exposure, with 
risks of transmission through rectal exposure exceeding the risks of transmission through 
vaginal exposure and both of the above exceeding the risks of transmission across oral 
mucus. Mother-to-infant transmission is enhanced in women with high levels of plasma HIV 
RNA, which means that the viral load (VL) influences the clinical course17. Furthermore, data 
have been collected linking host genes with the course of AIDS (summarised in Background, 
HIV tropism).  
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I.3. Replication Cycle of HIV  
 
I.3.1. Binding and Fusion 
 
HIV is a complex retrovirus that is able to enter into macrophages and CD4+ T cells 
by the absorption of glycoproteins on its surface to receptors on the targeted cell. gp120 is a 
glycoprotein embedded in the HIV envelope, and the first step in fusion involves the high-
affinity attachment of its CD4 binding domains to CD4. Once gp120 is bound to the CD4 
protein (Figure 3A), the envelope complex undergoes a structural change, exposing the 
chemokine binding domains of gp120 and allowing them to interact with the target 
chemokine receptor (generally either CCR5 or CXCR4 but others are known to interact) 
(Figure 3B). This leads to a more stable two-pronged attachment, which allows the N-
terminal fusion peptide gp41 to penetrate the cell membrane (Figure 3C). Repeat sequences 
in gp41, HR1 and HR2 then interact, causing the collapse of the extracellular portion of gp41 
into a hairpin. This loop structure brings the virus and cell membranes into close proximity 
(Figure 3D), allowing fusion of the membranes and subsequent entry of the viral capsid18,19. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Schematic representation of the binding and fusion events between the HIV 
particle and CD4+ T cells.  
[http://www.medscape.com/viewarticle/468807_2] 
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Once HIV has bound to the target cell, the HIV RNA and various enzymes, including 
reverse transcriptase (RT), integrase (IN), ribonuclease (RNase) and protease (PR), are 
injected into the cell18. 
 
 
I.3.2. Reverse Transcription 
 
Among the various characteristics of retroviruses, they are (+) RNA viruses whose 
genome can not serve directly as mRNA. This latter is produced by the cellular machinery 
without any contribution from viral polymerases. Once the viral capsid enters the cell, an 
enzyme called reverse transcriptase liberates the single-stranded (+) RNA from the attached 
viral proteins and copies it into a complementary DNA20. For this purpose, a particular 
cellular tRNA (usually W, P, or K), packaged in the capsid is essential to prime reverse 
transcription (Figure 4, step 1). The reverse transcriptase then makes a complementary DNA 
strand to form a double-stranded viral DNA intermediate (vDNA). The cDNA produced by 
reverse transcription is slightly longer than vRNA, due to the particular mechanism 
retroviruses use to transcribe RNA into DNA (Figure 4, steps 4 and 9). The vDNA is then 
transported into the cell nucleus.  
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Reverse transcription in vivo can be divided into ten sequential steps (Figure 4). 
 
 
1. A tRNALys hybridises with the 
complementary PBS (Primer Binding Site) 
region;  
 
2. A DNA segment is extended upstream 
from the tRNA; 
 
3. Viral R and U5 sequences are removed by 
the RNaseH catalytic domain of RT; 
  
4. First RT jump: DNA hybridises with the 
remaining R sequence at 3' end; 
 
5. A DNA strand is extended from 3' end; 
  
6. Most viral RNA except a polypurine tract 
is removed by the RNaseH; 
  
7. A second DNA strand is extended from the 
viral RNA; 
 
8. Both tRNA and the remaining viral RNA 
are removed by the RNaseH; 
  
9. Second RT jump: the PBS region of the 
second strand hybridises with the PBS 
region of the first strand;  
 
10. Extension on both DNA strands.   
 
 
Figure 4. HIV reverse transcription in vivo results in two direct long terminal repeats 
at the ends of the genome. 
 
This process of reverse transcription is extremely error-prone, and it is during this step 
that mutations may occur. In fact, HIV-1 is a quasispecies containing innumerable variants 
related to the original infecting strain. About 1% of all nucleotide positions in the RT and 
protease isolates from persons receiving antiretroviral therapy have detectable mixtures 
identified by population based-sequencing21. During antiretroviral therapy, mixtures occur at 
a higher rate (about 5%) at positions associated with drug resistance.  
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I.3.3. Integration 
 
Multiple steps in this integration process are catalysed by the HIV-1 integrase20. The 
integration of HIV-1 DNA into the host chromosome is achieved by the integrase protein 
performing a series of DNA cutting and joining reactions (A-C).  
 (A) The first step in the integration process is a 3' processing. This step 
requires linear double-stranded DNA with sequence specific 3' ends (CAGT), synthesised by 
reverse transcription from the viral RNA genome. The integrase protein removes two 
nucleotides from each 3' end of this viral DNA, leaving recessed CA-OH at the 3' ends.  
 (B) In a second step, termed strand transfer, the integrase protein incises 
chromosomal DNA at a non-defined site and produced staggered cuts, 5 bp apart. A Y-
shaped, gapped, recombination intermediate results, with the 5' ends of the viral DNA strands 
and the 3' ends of target DNA strands remaining unjoined, flanking a gap of 5 bp. 
 (C) The last step involves host DNA repair synthesis in which the 5 bp gaps 
between the unjoined strands are filled in and then ligated. Since this process occurs at both 
cuts flanking the HIV genome, a 5 bp duplication of host DNA is produced at the ends of 
HIV-1 integration.  
 
 
(A)     (B)          (C) 
 
 
 
 
 
 
 
 
Figure 5. Sequence of events during HIV-1 integration.  
A) integrase-catalysed 3' processing; B) integrase-catalysed strand transfer; C) DNA repair 
by cellular enzymes. Parts of the donor DNA that become integrated are shown in red. The 
acceptor DNA is shown in white. Parts of acceptor DNA repaired following the strand 
transfer reaction are shown in grey. 
 
This integrated viral DNA may then lie dormant in the latent stage of HIV infection20. 
To actively produce the virus, certain cellular transcription factors need to be present, the 
most important of which is NF-κB, which is upregulated when T cells become activated22 
(summarised in Background, Regulation of HIV genome expression). This means that those 
cells most likely to be killed by HIV are in fact those currently fighting infection. 
CAGT 
TGAC 
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In this replication process, the integrated provirus is copied to mRNA which is then 
spliced, excising all possible introns, and translated in the regulatory proteins Tat (which 
encourages new virus production) and Rev. As Rev accumulates, it gradually starts to inhibit 
mRNA splicing23. At this stage, the structural proteins Gag and Env are produced from full-
length mRNA (summarised in Background, the organisation of the viral genome). The full-
length RNA is actually the viral genome; it binds to the Gag protein and is packaged into new 
virus particles. 
 
 
I.3.4. Budding and Polyprotein Processing 
 
The final step of the viral cycle, assembly of new HIV-1 virions, begins at the plasma 
membrane of the host cell. The Env polyprotein (gp160) goes through the endoplasmic 
reticulum (ER) and is transported to the Golgi complex where it is cleaved by a protease and 
processed into the two HIV envelope glycoproteins gp41 and gp120 (Figure 6). They are 
transported to the plasma membrane of the host cell where gp41 anchors the gp120 to the 
membrane of the infected cell. The Gag (p55) and Gag-Pol (p160) polyproteins also associate 
with the inner surface of the plasma membrane along with the HIV genomic RNA as the 
forming virion begins to bud from the host cell.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. The HIV-1 assembly and release pathway. 
 [http://www.retrovirus.info/Freed_figure.html]  
 
Maturation either occurs in the forming bud or in the immature virion after it buds 
from the host cell. During maturation, HIV proteases cleave the polyproteins into individual 
functional HIV proteins and enzymes. The various structural components then assemble to 
produce a mature HIV virion which is now ready to infect another cell. 
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I.4. Anti-HIV Therapy and Drug resistance 
 
I.4.1. Highly Active Anti-Retroviral Therapy (HAART) 
 
In 1987 the U.S. Food and Drug Administration (FDA) approved the first antiviral 
drug zidovudine (ZDV; AZT) for use in preventing HIV replication by inhibiting the activity 
of the reverse transcriptase enzyme24. After 1991, several other nucleoside analogues became 
available, as well as a new class of anti-HIV drugs called the non-nucleoside analogue 
reverse transcriptase inhibitors (NNRTIs). Those are more quickly activated once inside the 
bloodstream because they don’t have to be phosphorylated. Next to be developed was the 
class of antiviral drugs known as protease inhibitors, which were distinctly different from the 
reverse transcriptase inhibitors in that they prevent an already infected cell from producing a 
new generation of HIV. 
However, the persistence of viral replication, the development of resistance and the 
expansion of the number of antiviral drugs necessitated a shift from monotherapy to 
combination therapy, in which drugs from two or more classes are used simultaneously. 
Theses combinations of antiretroviral drugs used in the treatment of HIV infection are called 
Highly Active Antiretroviral Therapy (HAART). Current HAART generally comprise three 
antiretroviral agents, usually two nucleoside analogues and either a protease inhibitor or a 
nonnucleoside reverse-transcriptase inhibitor25. 
 
The two classes of drugs that target the RT enzyme: 
 
- Nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs): They are 
prodrugs that only become effective after being converted to triphosphates. Nucleotide 
analogues require only two instead of three phosphorylation steps. Phosphorylated NRTIs 
compete with naturally occurring dNTPs (deoxynucleotide triphosphates) for incorporation 
into the growing DNA molecule. Because NRTIs lack a 3’OH group, their incorporation 
blocks further elongation of the proviral DNA and leads to interruption of the chain26. Today 
there are eight FDA-approved NRTIs: zidovudine, AZT (1987), didanosine, ddI (1991), 
zalcitabine, ddC (1992), stavudine, d4T (1994), lamivudine, 3TC (1995), abacavir, ABC 
(1998), tenofovir, TDF (2001) and emtricitabine, FTC (2003). 
 
- Non-nucleoside RT inhibitors (NNRTIs): They inhibit the viral enzyme reverse 
transcriptase itself. NNRTIs are small molecules that bind to the hydrophobic pocket close to 
the catalytic domain of the RT which alter the conformation of the active site, causing 
inhibition of the enzyme26. Three NNRTIs have been approved to date: nevirapine, NVP 
(1996), delavirdine, DLV (1997) and efavirenz, EFV (1998). 
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There are three other classes of HIV inhibitors which target the protease enzyme or the 
entry/fusion step: 
 
- Protease inhibitors (PIs): They bind to the active site of the viral PR hindering the 
cleavage of the viral precursor gal-pol-polyprotein by the enzyme, thereby producing 
immature, non-infectious viral particles. Ten PR inhibitors have been approved by the FDA: 
saquinavir, SQV (1995), ritonavir, RTV (1996), indinavir, IDV (1996), nelfinavir, NFV 
(1997), amprenavir, APV (1999), lopinavir, LPV (2000), atazanavir, ATV (2003), 
fosamprenavir, FPV (2003), tipranavir, TPV (2005) and darunavir, DNV (2006). 
 
- Fusion inhibitors (FIs): They differ from NRTIs, NNRTIs and PIs, which block the 
replication of HIV in the infected cell. Instead, fusion inhibitors prevent HIV from entering 
its target cells27. The fusion inhibitor enfuvirtide (T-20), approved by the FDA in 2003, is 
currently the only registered fusion inhibitor. T20 is a synthetic peptide consisting of 36 
amino acids, mimics the C-terminal HR2 domain of gp41 and competitively binds to HR1. 
Thus, interactions between HR1 and HR2 are blocked and the conformational change of gp41 
that is necessary for fusion of virions to host cells is inhibited28. A single amino acid 
substitution in gp41 can reduce the efficacy of T-20. 
 
- Entry Inhibitors/CCR5 coreceptor antagonist: Maraviroc, approved by FDA in 
August 2007, is a chemokine receptor antagonist that acts as an HIV entry inhibitor. It is 
designed to prevent HIV infection of CD4 T cells by blocking the CCR5 from binding to 
HIV. The FDA approved maraviroc for the use in combination with other antiretroviral 
medications for the treatment of CCR5-tropic HIV-1 (R5 virus) in adults whose viral loads 
remain detectable despite existing ARV treatment or who have multi-drug-resistant HIV. 
Fifty to 60 percent of treatment-experienced patients have a R5 virus. 
 
 
I.4.2. Drug Resistance 
 
HIV drug resistance must be distinguished from other causes of virologic failure such 
as non-adherence, insufficient drug levels, or inefficient combination regimens, although all 
these factors cause virologic failure. The expression “drug resistance” can be misleading, 
since it seems that resistance is an all-or-nothing phenomenon. Drug resistance is rather a 
continuous variable, where there is a continuum between a susceptible and a highly resistant 
state.  
The main drivers of the development of HIV drug resistance are the high level of 
virus production29 and the high error rate in reverse transcriptase activity30,31. These two 
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combined characteristics ensure that patients have a complex and diverse mixture of viral 
species, each differing by one or more mutations. If any of these mutations confers a selective 
advantage to the virus, such as a decrease in its susceptibility to antiviral drugs, the 
corresponding quasispecies will overtake the others, according to Darwinism32. However, it is 
not simply a case of “the survival of the fittest”; HIV infection results in survival of all major 
forms that have ever been generated within a patient, and replication favours the form that is 
fittest under the current conditions. If conditions change, previously archived variants can re-
emerge33,34. 
In patients who receive HAART as the first line of anti-retroviral therapy, emergence 
of viral resistance is possible only if HIV continues to replicate in the presence of levels of 
drugs that are insufficient to block viral replication but sufficient to exert a positive selective 
pressure on variants with decreased drug susceptibility. Under these conditions, viruses 
resistant to all the components of the regimen will gradually emerge34. However, several 
reports have also described the transmission of HIV strains with resistance to single or 
multiple ARV35-37. Although most of those cases involve the transmission of strains of HIV-1 
from patients in whom resistance has developed during therapy, some strains of HIV are 
naturally resistant to some antiretroviral drugs. For example, HIV-2 is intrinsically resistant 
to most NNRTIs38 and some subtypes of HIV-1 can be less susceptible to PIs or NNRTIs 
than the subtype B strain39-42. 
Reduced plasma levels of one or more anti-retroviral drugs are not necessarily the 
result of poor compliance; they can also result from others factors. Tuberculosis (TB) is one 
of the main opportunistic infections among HIV-positive patients in the world, especially in 
sub-Saharan Africa and Asia. Unfortunately, major drug-drug interactions can occur in 
patients taking TB and HIV therapies, especially between rifamycins, which are the first 
choice drugs for the TB therapy, and HIV PR inhibitors or NNRTIs43. Administration of 
rifamycins in combination with PR inhibitors (SQV, IDV or RTV) or NNRTIs (NVP or 
DLV) will greatly reduce the plasma levels of the anti-retroviral agent used43. 
Nonetheless, new drugs are becoming available that appear to be substantially active 
against strains resistant to multiple drugs. These drugs are either new members of existing 
structural classes, exhibiting increased potency and improved pharmacokinetic properties, or 
members of new classes that are not affected by cross-resistances34. The new drugs, used in 
triple class combinations, are saved for later use as salvation therapies, to be introduced in 
cases of drug resistance or if treatment is first started at a very advanced stage of infection.  
 
To better understand the HIV resistance observed for the two classes of reverse-
transcriptase inhibitors which will be described in this study, I will focus on their specific 
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mechanisms of resistance. Two distinct mechanisms are involved in HIV resistance to 
NRTIs: impairment of the incorporation of the analogue into DNA and removal of the 
analogue from the prematurely terminated DNA chain. The resistance to NNRTIs is caused 
by mutations in the hydrophobic pocket, the binding site of these drugs, which reduce their 
binding and activity. 
 
- Impairment of analogue incorporation: Several mutations or groups of mutations in 
reverse transcriptase involve steric hindrance and prevent the enzyme to incorporate a 
nucleotidic analogue into DNA leading to selective resistance. The most of those mutations 
are the M184V mutation, the Q151M complex of mutations, and the K65R mutation.  
The replacement of the methionine by a valine at position 184 of the RT is the main mutation 
that confers high-level resistance to 3TC44. Methionine 184 is located at the heart of the 
catalytic site of RT, and its change by a valine, which has a different side chain, interferes 
with the proper positioning of 3TC triphosphate in the catalytic site45.  
Similarly, the group of mutations referred to as the Q151M complex can confer high-level 
resistance to almost all NRTIs except 3TC and TDF46. This pathway arises under regimens 
containing d4T and ddI and always starts with the Q151M substitution and is followed by the 
accumulation of secondary mutations enhancing resistance and increasing enzyme activity47. 
The former residue is located in the immediate vicinity of the nucleotide binding site of RT. 
This Q151M complex is rarely found in HIV-1 but interestingly it is markedly more frequent 
in HIV-2. 
Another example is the K65R substitution which is occurring in patients treated with TDF or 
ABC. It gives resistance to most analogues, with the exception of AZT and is an antagonist 
mutation of the further described TAMs group48,49. 
 
- Removal of the analogue from the terminated DNA chain: This is associated with a 
group of mutations commonly termed “thymidine analogue mutations” (TAMs). Their 
selection is most frequent for drug combinations that include thymidine analogues such as 
AZT and d4T. They can promote resistance to almost all NRTIs including TDF50-53. These 
mutations occur gradually, and their order of emergence can vary54,55. TAMs promote 
resistance by fostering ATP- or pyrophosphate-mediated removal of nucleoside analogues 
from the 3' end of the terminated DNA strand56,57. ATP and pyrophosphate, which are 
abundant in normal lymphocytes, do not participate in the DNA-polymerisation reaction, but 
the structure of a reverse transcriptase expressing TAMs facilitates their entry into a site 
adjacent to the incorporated analogue58,59. In this position, ATP or pyrophosphate can attack 
the phosphodiester bond that links the analogue to DNA, resulting in removal of the analogue 
and continuation of strand polymerisation.  
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- Resistance to NNRTIs: The mutations that are selected for after the failure of NNRTI 
treatment are all located in the pocket targeted by these compounds and they reduce the 
affinity of the drug60-62. A single mutation can lead to high-level resistance to all NNRTIs, 
e.g. K103N and V106M, but most frequently the mutations are “drug-dependant”. For 
example, resistance to NVP is often associated with the Y181C mutation, but other mutations 
such as Y188C, K103N, G190A and V106A also occur. Initial resistance to EFV is generally 
characterized by the K103N substitution, but the Y188L mutation is also seen. A second 
generation of NNRTIs, as TMC125, seems to be active against resistant viruses presenting a 
pattern of mutations involved in the resistance to the first-generated NNRTIs. Nevertheless 
the accumulation of such mutations will also decrease the effect of the TMC125.   
For almost all mutations described above, a “cross-resistance” phenomenon can be 
observed. Its definition is a resistance to drugs to which a virus has never been exposed, 
resulting from mutations that have been selected for by the use of another drug. Cross-
resistance is always restricted to drugs within a given class of antiretroviral agents, but all 
three classes of antiretroviral drugs are affected.  
 
 
 
 
 
I.5. HIV Resistance Tests 
 
Due to the emergence of drug resistant viruses, it became necessary and obvious to 
have diagnostic tools to guide the treating physician in the selection of combination 
regimens25,63. Actually there are two established assay principles for measuring resistance or 
sensitivity of HIV to specific antiretroviral drugs: the genotypic and the phenotypic resistance 
tests64-67. Genotype assays provide information about viral mutations that may result in 
changes in viral susceptibility to a particular drug or class of drugs. Phenotype assays directly 
determine the level of susceptibility of a patient-derived virus to specific drugs in vitro. Both 
assays are commercially available. 
 
I.5.1. Genotyping 
  
HIV genotypic assays detect specific mutations or nucleotide substitutions in the gag-
pol region of the HIV-1 genome which encodes for the reverse transcriptase and protease 
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enzymes (the targets of current antiretroviral drugs). Specific gene sequences are compared 
with that of a reference (wild type) virus, and mutations associated with decreased 
susceptibility to specific antiretroviral drugs are identified. 
HIV genotyping has historically been the more commonly used technology for drug 
resistance testing and generally utilises a 2-step procedure: a polymerase chain reaction 
(PCR) step to amplify a specific region of the HIV genome and a specific mutation detection 
methodology as DNA sequencing, gene chip arrays, and a line probe assay. Direct 
sequencing is the most commonly used. Viral genome sequencing can be performed using 
cycle-sequencing based kits, such as the TrueGene™ HIV-1 Genotyping kit, by Siemens 
Diagnostics, or the ViroSeq™ kit, by Abbott Diagnostics. Several reference laboratories also 
have developed their own assays, often referred to as “home-brew” assays (Virco™TYPE 
HIV-1, Virco; GenoSure (Plus), LabCorp; or GeneSeq, Monogram Biosciences).  
The major limitation of the genotypic assays is interpretation of the results. Indeed, 
the value of Genotyping depends on an understanding of the relationships between identified 
mutations and specific drug susceptibility as well as viral fitness. Therefore, genotypic 
interpretation is an ideal application for a computerised expert system that accepts either a 
nucleotide sequence or a list of mutations and returns the predicted level of resistance. 
Combination of formidable amounts of data concerning the sequence of viral drug-target 
genes, in-vitro observations and cognate clinical outcome yielded powerful algorithms to 
model and therefore predict susceptibility/resistance to antiretroviral drugs. Difficulties arise 
in estimating the consequences of the interaction of multiple mutations on phenotype and the 
extent of cross-resistance among drugs in a class64. There are a number of on-line databases 
to assist in genotype interpretation either based on text (e.g. ANRS), score (e.g. Stanford 
DB), or fuzzy rules68. Other systems interpret genotypic mutation patterns with the aid of a 
large database of paired genotypic and phenotypic data, e.g. Geno2Pheno or virtual 
phenotype by Virco.  
 
In the present study, the genotypic interpretations performed for diagnostic purposes 
were based on the Stanford DB algorithm (accessible from hivdb.stanford.edu), which allows 
inferring levels of resistance to PIs, NRTIs, and NNRTIs after submitting PR and RT 
sequences in text format. Stanford DB algorithm compares a submitted sequence with the 
consensus subtype B reference sequence, and the resulting differences are used as query 
parameters for interrogating the HIV Drug Resistance database. Based on the alignment, 
mutations as well as unusual results like frameshifts, insertions, and deletions are easily 
determined for each sequence. For each mutation associated with drug resistance a penalty 
score is assigned, and the total score for a drug is derived from the arithmetic sum. Mutations 
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that are known to cause hypersusceptibility to a drug have a negative score. The algorithm 
classifies the total score as susceptible, potential low-level resistance, low-level resistance, 
intermediate resistance, or high-level resistance. Ultimately, Stanford DB algorithm provides 
for the user an explanation to inferred drug resistance.   
ANRS and Rega algorithms are two others genotypic interpretation systems that will 
be used in our study in comparison to the Stanford algorithm. They report their results using 
three susceptibility categories, therefore for comparison purposes, Stanford DB results need 
to be normalised (Table 1).  
 
 
Algorithm S I R 
ANRS Susceptible Potentially resistant Resistant 
Stanford DB Scores < 20 Scores between 20 and 44 Scores ≥ 45 
Rega Sensitive Advise against when other 
options available Resistant 
 
Table 1. Normalised resistance predictions to enable the comparison between ANRS, 
Stanford DB, and Rega algorithms. 
 
 
The French ANRS HIV-1 genotypic drug resistance interpretation algorithm is 
gaining recognition, because the rules of the current versions are almost exclusively based on 
data of correlation between drug resistance mutations and virological outcome from a large 
database of patients failing antiretroviral therapy. 
Rega takes into consideration mutations for which phenotypic drug resistance or 
reduced therapy response have been reported. The latest versions also took advantage from 
information obtained through data mining in the large databases of the group.  
Both are complex algorithms, taking into account known synergistic and antagonistic 
effects of combinations of mutations. 
 
The Stanford DB program allows the identification and correction of common 
sequence problems. Besides stop codons or frameshifts in PR or RT genes, presence of 
atypical mutations, that is substitutions observed in less than 0.1% of published group M 
HIV-1 sequences, is considered as suspect. At least, highly ambiguous nucleotides are 
regarded as artefacts. Indeed mixtures of two nucleotides occur commonly but the presence 
of mixtures with three or more nucleotides at the same position occurs rarely in high quality 
sequences. When a mutation at one position is present as a mixture, the algorithm assigns the 
same penalty score regardless of whether the mutation is present in pure form or as a mixture.  
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Each sequence is compared to a list of reference sequences of subtypes A, B, C, D, F, G, H, J, 
K, CRF01_AE, and CRF02_AG, and the subtype of the closest reference sequence is 
assigned to the submitted sequence. This method, however, does not accurately characterize 
uncommon recombinants, and subtype B protease sequences are occasionally misclassified as 
subtype D, because these two subtypes are very similar and PR contains less phylogenetically 
informative positions than RT. 
 
 
I.5.2. Phenotyping 
 
Like genotypic tests, current phenotypic assays also use PCR to amplify the gag-pol 
region of HIV-1. In these assays, however, a recombinant virus is created by introducing the 
protease gene and/or the reverse transcriptase gene from a clinical HIV pool into a wild type 
laboratory clone from which the corresponding gene(s) have been deleted. This pool of 
recombinant viruses is used in vitro to infect a cell line, and virus replication is measured in 
the presence and absence of a range of concentrations of different antiretroviral drugs69. The 
viral replication is reflected by the activity of a reporter gene present either in the plasmid or 
in the cell line, depending of the assay. Therefore, two techniques can be differentiated: a 
non-infectious or single cycle assay, in the former case versus a replicative assay, in the 
latter. 
Drug susceptibility results are reported as IC50 values, the drug concentration required 
to inhibit viral growth by 50%. Changes in drug susceptibility are measured quantitatively by 
comparing the IC50 value of the patient-derived virus to that of the reference (wild type 
control) virus69. The obtained value referred as Resistance factor (Rf) is compared to the so-
called cut-off value. Determination of the cut-off is crucial for the interpretation of the results 
and three different are currently used: 
- The technical cut-off is a measurement of the methodological variability of the 
assay. 
- The biological cut-off involves the inter-individual variability of wild type virus 
isolates from ART-naïve HIV patients. If the IC50 is below the biological cut-off, virological 
success is very likely. However, an IC50 above the biological cut-off does not allow 
prediction of the virological response to a drug. 
- In contrast, the clinical cut-off indicates up to which levels of IC50 virological 
success can still be expected.  
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Initially, replication-competent viruses were derived directly from patient PBMCs 
(Peripheral Blood Mononuclear Cells) by co-cultivation and used to analyse in vitro their 
resistance profiles. The technique was labour-intensive and time-consuming for routine use70. 
Therefore, the development of recombinant virus assays generated by homologous 
recombination between vectors and patient sequences raised much interest71,72. Currently, 
four main laboratories worldwide perform Phenotyping for diagnostic purposes: Eurofins 
Scientific, Inc. (ESI) in the USA (PhenoscriptTM), Virco in Belgium (AntivirogramTM), 
Monogram Biosciences in the USA (PhenoSenseTM), and InPheno in Switzerland 
(PhenoTecT). For evident reasons the majority of details regarding the employed techniques 
are not freely accessible. Among these four systems, different strategies are used to obtain 
viral PR and RT genes. For example, the two genes are taken as a unique fragment in both 
Monogram Biosciences and Virco assays72,73 whereas they are separately amplified in the 
PhenoscriptTM and the PhenoTecT systems74. A further difference lies in the assessment of 
viral activity, which is measured through expression of β-galactosidase (induced by HIV Tat) 
in both InPheno and Eurofins assays, while Virco analyses the cytopathic effect of HIV using 
tetrazolium salts, and Monogram Biosciences determines HIV survival based on luciferase 
activity. In the latter assay, the luciferase gene is inserted in the envelope gene of a 
recombinant provirus, which is therefore not viable and needs a helper virus carrying the HIV 
env gene. Evidently that system only operates for the first round of replication, when both 
viruses are co-transfected, therefore the assay is not replicative. On the contrary, Virco and 
InPheno can determine HIV subpopulations and fitness, because their assays are replicative. 
This is very important, because viruses with Resistance Associated Mutations (RAMs) that 
exhibit different in vitro replication kinetics compared to wild type (WT) have been 
reported75,76.  
 
 
I.5.3. Limitations 
 
The current genotypic and phenotypic assays require plasma with ≥ 500-1000 copies 
of HIV-1 RNA per millilitre. Thus, viral load testing remains initially the method of choice to 
monitor for drug failure.  
Furthermore, the resistance assays were developed using the more common clade B 
viruses of Europe and North America. The genetically diverse HIV strains from different 
geographic regions may be less well amplified for Genotyping and Phenotyping. This is 
particularly an important concern in DNA sequencing for genotypic assays which could 
present primer bias and therefore not providing genotypic results. 
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Disadvantages of phenotypic testing include the lengthy procedure (8 to 21 days) and 
high expense of the assay. The cost of Genotyping ranges from 350 to 500 Euro, depending 
on the assay and laboratory used. It is approximately twice as much for Phenotyping. 
Secondly, it has been described that d-drugs are difficult to assess by Phenotyping. The main 
limitation of this in vitro assay in case of d-drugs is the intracellular phosphorylation. Indeed, 
these antiretroviral agents are prodrugs that need to be phosphorylated inside cells in order to 
be effective. A suboptimal phosphorylation would render their incorporation into a DNA 
chain not possible and the termination of the transcription would not occur. This could be a 
form of cellular resistance to the drug which will prevent any detection of samples 
susceptible to d-drugs. However, the cells used in the rPhenotyping assay appear to allow an 
optimal level of phosphorylation for those drugs since in PhenoBase® a high amount of 
samples diagnosed susceptible to d-drugs are found.  
A common denominator of genotypic tests is that they cannot detect HIV 
subpopulations representing less than 15% of the total viral population. Then, clinically 
significant minor subpopulations of virus remain not detectable by actual genotypic 
methodologies whereas replicative Phenotyping could assess their presence. Similarly, 
complex patterns like mixtures of quasispecies will be individually interpreted by phenotypic 
assays, while genotypic tests will associate all mutations on a single virtual genome. And last, 
genotypic knowledge about interactions of multiple mutations need to be regularly updated as 
well as the implementation of new antiretroviral agent require previous phenotypic studies. 
The latest clinical recommendations do not favour Genotyping over Phenotyping or 
vice versa. They support both methods because they provide complementary information77. 
Many studies compared the two methods, either alone or in combination, with so-called 
standard of care treatment (SOC; no resistance test performed): NARVAL, CERT, Vihres 
(genotyping vs. phenotyping vs. SOC), VIRADAPT, GART, Havana, Argenta (genotyping 
vs. SOC), Kaiser, VIRA3001, CCTG575 (phenotyping vs. SOC)78-85. As it is often the case 
those studies are controversial and often produced opposite results, due to different genotypic 
and phenotypic systems used in different trials. In general terms, no major gain was observed 
by resistance testing. This may be due to the choice of the HIV populations: those studies 
were done in early 2000 with few drug-experienced patients and the cause of diagnosis, e.g. a 
resistant test done on primary infected patients, could favourably select for wild type patients. 
The availability of new drugs, without resistance mutation development yet, could also 
influence the gain provided by a resistance test.  
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Aims of the study 
 
 
 
 
The ability of HIV-1 to develop resistance to antiretroviral drugs has limited the 
overall efficacy of combination therapy to suppress viral replication. Consequently, drug 
resistance testing has become an integral tool for many HIV specialists, particularly when 
managing patients experiencing failure of anti-retroviral therapy. There are two principal 
methodologies for assessing resistance to antiviral agents: Genotyping and Phenotyping. The 
relative utility of the two types of resistance tests is a topic of a heated debate.  
At the very beginning, the phenotypic technique, derived directly from patient 
PBMCs, was labour-intensive and time-consuming for routine use. Nevertheless, new 
formats are currently available, as rPhenotyping, which involve the construction of 
recombinant virus genomes containing sequences from patient viruses encoding protease 
and/or reverse transcriptase genes. One aim of this study was to validate the PhenoTecT 
system, a replicative Phenotyping, as diagnostic tool applicable for detecting and assigning 
HIV resistance in clinical specimens. Furthermore, this methodology could be performed for 
special cases with known limitations for standard Genotyping, e.g. a low sensitivity level to 
detect minority species or the quasispecies misinterpretation inherent to the nature of the test.   
 
 
The questions to elucidate in this study were the following: 
 
1. Is rPhenotyping as powerful as Genotyping to reveal HIV-1 resistance in 
routine use? (Chapter I) 
 
2. Can rPhenotyping overtake the limitations of standard Genotyping?  
- How are the viral mixtures influencing the resistance tests? (Chapter 
II) 
- Are clinically critical HIV minorities revealed by replicative 
Phenotyping? (Chapter III)  
 
 
To find an answer to these questions will allow to provide more precise information to 
HIV experts and to improve our understanding of therapeutic failure. The PhenoTecT system 
could help treating physicians to optimise new therapy regimens for patients failing 
antiretroviral drugs. This study will assess the complementarity of the two methodologies, 
Genotyping and Phenotyping86,87. 
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II. Material & Methods 
 Material & Methods 
 
 
23 
II.1. Materials 
 
II.1.1. Chemicals 
 
 
 
Chemical        Supplier 
 
      
Diagnostics 
Cobas Amplicor HIV-1 Monitor™, v1.5      Roche Molecular Diagnostics 
ViroSeq™ HIV-1 Genotyping      Abbott Molecular 
 
Standard PCR   
Platinum® PCR SuperMix       Invitrogen 
iProof™ High-Fidelity DNA Polymerase     Bio-Rad 
dNTPs (dATP,dCTP,dGTP,dTTP), 10mM     Sigma 
 
RT-PCR 
SuperScript™ III Reverse Transcriptase     Invitrogen 
RNaseOUT™, Recombinant Ribonuclease Inhibitor    Invitrogen 
dNTPs (dATP,dCTP,dGTP,dTTP), 10mM     Sigma 
 
Sequencing PCR 
BigDye® Terminator v3.1 Cycle Sequencing     Applied Biosystems 
BigDye® v1.1/3.1 Sequencing Buffer (5X)     Applied Biosystems 
 
Real-time PCR 
QuantiTect SYBR Green PCR kit      Qiagen 
 
Vector Preparation 
NcoI         New England Biolabs 
XmaI         New England Biolabs 
Digestion buffers, 10X       New England Biolabs 
Bovine Serum Albumin (BSA), 10X     New England Biolabs 
Alkaline Phosphatase, Calf Intestinal (CIP)     New England Biolabs 
CH3COONa 3M, pH 5.2       Sigma   
Phenol:Chloroform:Isoamyl Alcohol (25:24:1),    Sigma 
Ethanol (100%)        Fluka 
 
Cloning 
NcoI         New England Biolabs 
XmaI         New England Biolabs 
Digestion buffers, 10X        New England Biolabs 
Bovine Serum Albumin (BSA), 10X     New England Biolabs 
Clonables 2X Ligation Premix (T4 DNA ligase)    Novagen 
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Gel Electrophoresis 
SeaKem Agarose        Cambrex 
TBE buffer, 10X        Amresco   
Ethidium bromide solution (10mg/mL)     Sigma    
Loading Dye        Invitrogen 
1kb DNA ladder (1µg/µL)       Invitrogen 
100bp DNA ladder (1µg/µL)      Invitrogen 
      
DNA Isolation and Purification 
NucleoSpin® Extract II       Macherey-Nagel  
Microcon® Centrifugal Filter Units YM-100     Millipore 
NucleoSpin® Plasmid       Macherey-Nagel 
NucleoBond® Xtra Midi Plus      Macherey-Nagel 
NucleoBond® PC 500       Macherey-Nagel 
NucleoBond® Finalizer Plus      Macherey-Nagel 
 
RNA Isolation and Purification 
NucleoSpin® RNA Virus       Macherey-Nagel 
DNaseI, RNase free (lyophilised)      Macherey-Nagel 
 
Site-directed Mutagenesis 
QuikChange® Site-Directed Mutagenesis     Stratagene 
 
Bacterial Culture, Competent Cells Preparation 
Bacto Agar (dehydrated)       Becton-Dickinson 
Bacto Tryptone (dehydrated)      Becton-Dickinson 
Bacto Yeast Extract (dehydrated)      Becton-Dickinson 
NaCl          Fluka 
Ampicillin (sodium salt)        Sigma 
Glycerol (87%)        Fluka 
CaCl2 dihydrate         Fluka 
One Shot® TOP10 cells       Invitrogen 
HB101 cells        Promega 
 
Cell Culture 
DMEM High Glucose (4.5g/L) with Stable Glutamine   BioConcept 
RPMI-1640, with 25mM HEPES (w/o L-Glutamine)    BioConcept 
L-Glutamine, 200mM (100X), liquid     Gibco 
Opti-MEM I Reduced Serum Medium (1X), liquid    Gibco 
Lipofectamine 2000         Invitrogen 
Fetal Bovine Serum (Heat Inactivated)     Gibco 
Trypsine/EDTA (w/o Ca2+/Mg2+)      Gibco  
β-Mercaptoethanol, 50mM (1000X)     Gibco 
Pen/Strep         BioConcept 
D-PBS (1X), liquid (w/o Ca2+/Mg2+)     Gibco  
Trypan Blue Stain, 0.4%       Gibco 
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Virus Inactivation and Cells Fixation 
Formaldehyde (36.5%)       Fluka 
Glutaraldehyde (25%)       Fluka 
PBS (10X)        produced at IMM 
 
Antiretrovirals 
Saquinavir pills        Hoffmann – La Roche 
Zidovudine pills        GlaxoSmithKline 
Didanosine pills        Bristol-Myers Squibb 
Zalcitabine pills        Hoffmann – La Roche 
Stavudine pills        Bristol-Myers Squibb 
Abacavir pills        GlaxoSmithKline 
Lamivudine pills        GlaxoSmithKline 
Emtricitabine pills       Gilead Sciences 
Efavirenz pills        Bristol-Myers Squibb 
Nevirapine pills        Boehringer Ingelheim 
 
ONPG-Staining 
Buffer Z         produced at InPheno 
Buffer H        produced at InPheno 
o-Nitrophenyl-β-D-Galactopyranoside (ONPG)    Amresco 
β-Mercaptoethanol (100%)      Fluka   
  
General Chemicals 
Dimethyl sulfoxide (DMSO)      Riedel-de Haën 
Ethanol (100%)        Fluka 
Isopropanol (100%)       Fluka 
Sodium hypochlorite (10%)      Fluka 
Dismozon pur        Bode Chemie 
Deconex 53 PLUS       Borer Chemie 
 
 
 
II.1.2. Cell Lines 
 
 
Cell Line  Characteristics       Source 
  
 
SX22-1  HeLa cell line, containing an integrated plasmid with an HIV-1 produced by  
  LTR driving bacterial LacZ gene; naturally expressed CXCR4  Dr. Thomas Klimkait 
  coreceptor and non-naturally expressed CD4 receptor 
   
SX-CCR5 HeLa reporter cell line, derivative of SX22-1, carrying CCR5  available through  
  coreceptor       Dr. Thomas Klimkait 
 
CEM-SS T-Lymphoblastic cell line      provided by 
          Dr. Thomas Klimkait 
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II.1.3. Primers 
 
Usually we name primers according to their 5’ end position preceded by an “F” or 
“D” for forward or direct and an “R” for reverse primers. This notation allows calculating 
directly the size of a fragment from the name of primers. For mutagenesis primers, it is 
common to write the codon to be mutated preceded by the wild type amino acid and followed 
by the mutant amino acid, and to notify by sense or antisense if it is a forward or reverse 
primer. “D67N sense” is a forward primer used to introduce in RT gene an Asparagine at 
position 67 instead of an Aspartic acid. For allele-specific PCR and real-time PCR the code 
name is different, writing the name of the gene to be quantified (PR, RT, IN), the codon and 
the amino acid (for some we added internal mutations which are figured out by their number 
at the end). 
 
 
 
Primer      Sequences 5’ → 3’ 
 
 
Standard PCR/Overlap PCR/Mutagenesis 
D-2213B      agc agg atc cga tag aca agg a 
R-2598L     cca tcc cgg gct tta att tta ctg g 
D-2582L     att aaa gcc cgg gat gga tgg ccc aa 
R-3525L     tta agt ctt tcc atg ggt cat aat a  
D67NT69D sense    gcc ata aag aaa aaa aac agt gat aaa tgg aga aaa tta g 
D67NT69D antisense    cta att ttc tcc att tat cac tgt ttt ttt tct tta tgg c 
D67N sense     cat aaa gaa aaa aaa cag tac taa atg gag 
D67N antisense     ctc cat tta gta ctg ttt ttt ttc ttt atg 
T69D sense     gaa aaa aga cag tga taa atg gag aaa att 
T69D antisense     aat ttt ctc cat tta tca ctg tct ttt ttc 
K70R sense     ac agt act aga tgg aga aaa 
K70R antisense     ttt tct cca tct agt act gt 
L74V sense     aaa tgg aga aaa gtg gta gat ttc aga gaa 
L74V antisense     ttc tct gaa atc tac cac ttt tct cca ttt 
V75M sense     aat gga gaa aat taa tgg att tca gag aac 
V75M antisense     gtt ctc tga aat cca tta att ttc tcc att 
Y181C sense     cag aca tag tca tct gtc aat aca tgg atg 
Y181C antisense     cat cca tgt att gac aga tga cta tgt ctg 
M184V sense     tca tct atc aat acg tgg atg att tgt atg 
M184V antisense     cat aca aat cat cca cgt att gat aga tga 
T215F sense     tgg gga ttt ttc aca cca gac 
T215F antisense     gtc tgg tgt gaa aaa tcc cca 
T215Y sense     tga ggt ggg gat ttt aca cac cag aca aaa 
T215Y antisense     ttt tgt ctg gtg tgt aaa atc ccc acc tca 
K219Q sense     aca cca gac cag aaa cat cag 
K219Q antisense     ctg atg ttt ctg gtc tgg tgt 
 
RT-PCR 
D-1818      aga aga aat gat gac agc atg tca ggg agt 
D-1826      tga tga cag cat gtc agg gag tgg ggg gac c 
R-3584      tgg ctc ttg ata aat ttg ata tgt cca ttg 
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Sequencing PCR 
D-2150      agc caa cag ccc cac cag 
D-2610      gtt aaa caa tgg cca ttg aca gaa gaa a 
D-3007      gga aag gat cac cag caa tat tcc a 
R-2605      ggg cca tcc att cct gg 
R-3010      cca tcc ctg tgg aag cac att g 
R-3541      ttc tgt att tct gct att aag tct ttt gat g 
 
Allele-specific PCR 
D-2213B      agc agg atc cga tag aca agg a 
D-2232      gga act gta tcc ttt agc ttc cc 
R-RT181Y3     aca tac taa tca tca agg tat tga t 
R-RT181C3     aca tac taa tca tca agg tat tga c 
R-RT184V     cag atc cta cat aca aat cat cca c 
R-RT184M     cag atc cta cat aca aat cat cca t 
R-RT184V3     cag atc gta cat atg aat cat cca c 
R-RT184M3     cag atc gta cat atg aat cat cca t 
 
Real-Time PCR 
F-3005      atg gaa agg atc acc agc aa 
R-RT181Y3     aca tac taa tca tca agg tat tga t 
R-RT181C3     aca tac taa tca tca agg tat tga c 
R-3115      aca tac taa tca tca agg tat tga 
R-RT184V3     cag atc gta cat atg aat cat cca c 
R-RT184M3     cag atc gta cat atg aat cat cca t 
R-3123      cag atc gta cat atg aat cat cca 
R-3146      tct atg ctg ccc tat ttc taa 
R-3151      ttt gtt cta tgc tgc cct att tc 
 
 
 
II.1.4. Plasmids 
 
 
 
Plasmid  Characteristics      Source 
 
 
pNL4-3  Provirus derived from NY5 (5’) and LAV    produced and provided by 
(3’) HIV-1 isolates, cloned into pUC18 at    Dr. Malcolm Martin (NIH) 
PvuII site (size: 14,877bp)88 
  
pNL-NF pNL 4-3 with reduced flanking regions of   produced by      
 cellular DNA      Dr. Thomas Klimkait 
  
pBX_ WT pNL-NF with elimination of BamHI site at position  produced by      
 8465 and introduction of BamHI/2219 and XmaI/2591 Dr. Thomas Klimkait 
 
pXN_300 Cloning cassette for the reverse transcriptase gene   produced by      
(between XmaI/2591 and NcoI/3510)    Dr. Thomas Klimkait 
 
pXN_WT Wild type version of the cloning cassette for reverse  produced by      
transcriptase gene     Dr. Thomas Klimkait 
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pNL-NF is a truncated version of pNL4-3, the wild type reference HIV-1 B subtype 
virus. To generate cloning cassette for PR and RT gene different restriction sites were 
engineered in pNL-NF. To allow cloning of PR fragment a BamHI and an XmaI site had 
been introduced upstream and downstream from PR gene, respectively; in order to have 
unique sites a BamHI site at position 8465 was eliminated in parallel. This new plasmid was 
named pBX_WT. A NcoI site downstream from RT gene was introduced in pBX_WT to 
permit RT fragment cloning. pXN_300, which contains in the place of the RT gene a junk 
DNA fragment from a reporter vector pCAT3bas, was used as cloning cassette. pXN_WT 
was produced cloning wild type RT in pXN_300. When the resulting XN_300 and XN_WT 
plasmids were transfected, the former did not produce any virus, while the latter produced 
virus in the PhenoTecT assay. The fitness of pXN_WT provirus is similar to the NL-NF and 
NL4-3 plasmids, which means that the inserted restriction sites do not have a negative impact 
on the virus life cycle. Since all plasmids contain pUC18 elements, they can be amplified in 
E. coli cells and they confer ampicillin resistance upon transformation.  
All selected mutants were constructed either on a NL4-3 background by mutagenesis 
or on pXN_WT by overlap-PCR. 
   
 
 
 
II.2. Methods 
 
II.2.1. Molecular Biology 
 
This study was mainly done on patient samples which were prepared as described in 
the diagnostic part (§ II.2.1.1.). In parallel in order to reduce cost, we used research kits to 
prepare RNA extraction or cDNA from patient samples and samples not included in the 
diagnostic process. The latter methodologies will be detailed in next parts. The order of the 
methods presented is corresponding to the “diagnostic week”: from RNA to plasmid. 
 
 
II.2.1.1. Diagnostic  
 
Sample preparation and amplification.  
Plasma samples from HIV patients were received and stored at -80°C. Virus was isolated 
from 1mL of EDTA-plasma by centrifugation at 50,000 × g for 80 min at 4°C. Pellets were 
dissolved in 600 µL of guanidinium isothiocyanate lysis buffer and RNA was extracted 
according to the Cobas Amplicor HIV-1 Monitor™, v1.5 protocol with two washing steps 
and final resuspension.  
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Reverse transcription was performed using the ViroSeq HIV-1 Genotyping kit. Reaction 
volume was 20µL. Reactions were set up as it follows: 8µL HIV RT mix, 1µL RNase 
Inhibitor, 0.4µL DTT at 100mM, 1µL of MuLV RT and 10µL RNA template (pre-
denaturated 30’’ at 65°C). The standard protocol was 1h at 42°C (reverse transcription), and 
5’ at 99°C (inactivation of RT enzyme). Reactions were set up at room temperature. 
A PCR mastermix was prepared using 29.5µL of PCR mix, 1µL UNG and 0.5µL AmpliTaq 
Gold (reagents from the ViroSeq HIV-1 Genotyping kit). 30µL of mastermix were added to 
reaction tube from the RT step. Standard cycling protocol was (in total 40 cycles): 10’ at 
50°C (UNG activation), 12’ at 93°C (AmpliTaq Gold activation), [20’’ at 93°C 
(denaturation), 45’’ at 64°C (annealing), 3’ at 66°C (extension)], and 10’ at 72°C (ends 
polishing). 
After a purification step following Microcon YM-100 Centrifugal Filter protocol, PR and RT 
sequences were amplified separately by nested-PCR with the Platinum® PCR SuperMix 
(description § II.2.1.3.). Reaction volume was 50µL. We used a forward primer containing 
either the restriction site BamHI (D-2213b) or XmaI (D-2582L) and a reverse primer 
containing either XmaI site (R-2598L) or NcoI site (R-3525L), respectively for PR and RT.  
 
These PCR products were digested by the corresponding restriction enzyme after gel 
extraction and inserted into cloning cassette to provide a recombinant virus (description § 
II.2.1.6.). These steps were similar for diagnostic and research, recombinant plasmids were 
transfected following the PhenoTecT system (description § II.2.3.3.). 
 
 
Genotypic analysis by sequencing.  
Sequencing reaction was set up as it follows: 8µL of the Microcon-purified PCR product 
(approximately 20ng) and 12µL of each primer mix (from the ViroSeq HIV-1 Genotyping 
kit). Standard cycling protocol was (in total 40 cycles): 10’’ at 96°C (denaturation), 5’’ at 
50°C (annealing), and 4’ at 60°C (extension). Sequencing reactions were precipitated with 
Ethanol prior to analysis on the Applied Biosystems 3130 Genetic Analyzer (§ II.2.1.9.). 
Genotyping and alignment to the HXB2-reference were performed with the ViroSeq system 
(Abbott Molecular). Resistance-associated mutations were identified using version 4.2.6 of 
the Stanford algorithm (http://hivdb.stanford.edu/). The sequence was sent to this software 
which returns a list of mutations and their impact on resistance for each drug. The Stanford 
analysis is based on penalties; each mutation has a score corresponding to each drug, based 
on clinical data. The addition of mutation scoring per drug gives a total which is interpreted 
by comparison to cut-off values and provides a profile of resistance for the different drugs. 
There are 5 levels: susceptible, potential low-level resistance, low-level resistance, 
intermediate resistance and high-level resistance. 
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II.2.1.2. Reverse Transcription Polymerase Chain Reaction 
 
First-Strand cDNA synthesis Step: SuperScript™ III Reverse Transcriptase.  
Some modifications were used in contrast to provided SuperScript™ III Reverse 
Transcriptase protocols. Positive and negative (RNA diluent) controls were performed in 
parallel.  
Reactions were set up for a final volume of 25µL. 12µL of isolated RNA (protocol is suited 
for 10pg-5µg) were put in PCR tubes with 3µL of gene-specific reverse primer at 1pmol/µL 
(1µM). The tubes were incubated at 70°C for 5’, and for 2’30’’ on ice (annealing of the 
primer). To each tube 8µL of master mix were added, which contains 5µL buffer (5X), 1µL 
dNTPs (10mM), 1µL DTT (0.1M) and 1µL RNaseOUT™, followed by a 2’ incubation at 
55°C. Afterwards 2µL of RT enzyme were added and reactions were incubated for 1 hour at 
55°C. Reaction inactivation was accomplished at 70°C for 15’. Tubes were incubated for 15’ 
at 4°C prior the second-strand synthesis. It is not necessary to remove the RNA strand 
through RNaseH treatment. 
 
 
 
II.2.1.3. Standard Polymerase Chain Reaction 
 
Platinum® PCR SuperMix.   
Reaction volume was 50µL. Primer stock solutions were stored at -20°C at a concentration of 
100µM. The working solutions were diluted 1:10. For 50µL reaction, 2µL of each primer 
were used, corresponding to 20pmol (final concentration of 400nM). For PCR reactions of 
smaller volume (25µL), 10pmol were used. The amount of DNA template depends on the 
molecular weight, ranging from 50ng to 10ng. The remaining volume, usually 45µL, was 
completed with the provided SuperMix.    
This mixture contains anti-Taq DNA polymerase antibody, Mg2+ (1.65mM), dNTPs 
(220µM), and recombinant Taq DNA polymerase. It is provided at a 1.1X concentration, 
which means that for a 50µL reaction, 5µL can be used for primers and DNA template 
addition. Due to the presence of anti-Taq antibodies, the polymerase is inactive at room 
temperature and the reactions have to be incubated for 2’ at 95°C before starting 
amplification. A standard amplification cycle was set up as it follows (in total 30 cycles): 
[30’’ at 95°C, 20’’ at 52°C, 1’ at 72°C], and 10’ at 72°C. The extension time was calculated 
for RT gene size (around 900bp). Reactions were set up on ice to prevent unspecific primer 
annealing to the template.  
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iProof™ High-Fidelity DNA Polymerase. 
Reaction volume was 50µL. Reactions were set up as it follows: 10µL 5X iProof HF buffer, 
1µL 10mM dNTPs mix (final concentration of 200µM), 2µL of each primer at 10µM, 1µL 
DNA template (approximately 10-50ng), 0.3µL iProof DNA polymerase, and remaining 
volume was filled with sterile H2O. The standard cycling protocol was (in total 30 cycles): 
30’’ at 98°C, [10’’ at 98°C, 20’’ at 52°C, 30’’ at 72°C], and 10’ at 72°C. Reactions were set 
up on ice to prevent unspecific primer annealing to the template. 
 
After In-House RT step, the iProof™ High-Fidelity DNA Polymerase protocol was used for 
the PCR. 6µL out of 25µL (SuperScript™) of first-strand cDNA synthesis reactions were 
used. Reactions were set up as described above in a total volume of 25µL. After this reaction 
the DNA concentration was usually too low to observe a band on a gel, even when the whole 
25µL were loaded. Therefore, a second amplification reaction was performed with 3µL out of 
25µL of 1st PCR reaction. The same PCR protocol as for the first PCR may be used or 
internal primers: Nested-PCR. Reaction volume was 25µL. Microcon® Centrifugal Filters 
Unit YM-100 were used to clean the PCR product. A 1% agarose gel was run at 250V with 
5µL of purified PCR product to check for the correct size of the DNA fragment.  
 
 
 
II.2.1.4. Gel Extraction 
 
PCR DNA was extracted from agarose gel according to the Macherey-Nagel protocol. The 
DNA concentration was not quantified at this step, since the measurement was not very 
reproducible, due to low yield. At low concentrations this measurement has a qualitative 
rather than a quantitative character.  
 
 
 
II.2.1.5. Vector Preparation 
 
For maximal cleavage efficiency the plasmid to be cut was incubated at the optimal 
temperature for enzyme activity (usually 37°C) for 2 hours. 40µg of plasmid were digested in 
order to have a good yield. Enzymes were put in slight excess to increase digestion 
efficiency. However, excessive enzyme or glycerol concentrations (>5% v/v) can trigger star 
activity. The standard digestion was as follows: 40µL plasmid DNA (1µg/µL), 3µL 
Restriction enzyme 1 (30 units), 3µL Restriction enzyme 2 (30 units), 10µL BSA 10X, 10µL 
Buffer 10X and 34µL sterile H2O. Afterwards 10 units of CIP phosphatase were added to 
remove 5´ phosphates from the cut plasmid, which prevents vector re-circularisation. The 
reaction was incubated for 30’ at 37°C. Protein contaminations were further removed from 
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DNA using phenol, which denatures proteins that fall between the organic phase and the 
aqueous, DNA containing phase. CHCl3 was used to further denature proteins and to stabilise 
the aqueous/organic boundary. Isoamyl alcohol was used to reduce foaming. A high-quality 
solution containing phenol, chloroform, and isoamyl alcohol in ratio 25:24:1 is typically 
used. It is saturated with TE to avoid DNA partition in the phenolic phase, and it does not 
contain oxidation products of phenol (damaging DNA). One volume of phenol-chloroform-
isoamyl alcohol was added to 200µL DNA solution and the whole mixture was strongly 
vortexed and centrifuged. Supernatant, corresponding to the aqueous phase, was transferred 
into a new tube. In presence of monovalent cations (Na+) and ethanol, DNA forms a pellet. 
Thus, 20µl 3M CH3COONa (pH 4.6) was added together with 600µL 100% ethanol. The 
reaction was incubated 30’ at -80°C and then centrifuged for 10’ at 20,800 × g and 4°C. After 
supernatant removal, the DNA pellet was dried and resuspended in 100µL warm elution 
buffer. The entire 100µL were loaded on a 0.6% agarose gel and run at 150V, which allows a 
good spatial resolution. The band was then extracted according to the usual gel extraction 
protocol of Macherey-Nagel. 
 
 
 
II.2.1.6. Cloning and Transformation  
 
All inserts were digested for 1 hour with the appropriate combination of restriction enzymes 
at optimal temperature for enzyme activities (usually 37°C). Reaction was set up as follows: 
32µL insert (5-10ng/µL), 0.3µL of each restriction enzyme, 4µL buffer 10X, 4µL BSA 10X. 
The enzymes were inactivated at 80°C for 20’. The theoretical molar ratio between insert and 
vector should be approximately 3:1. 50-70ng of vector were ligated to 3µL insert (5-
10ng/µL). An equivalent volume of Clonables 2X Ligation Premix was added and the 
reaction was incubated at 16°C for 20’. A negative control containing the vector alone was 
always performed to estimate the background of vector self-ligation.  
Afterwards, 100µL of fresh thawed competent cells (either HB101 or One Shot® TOP10) 
were added to the ligation mix and the tubes were incubated on ice for 30’ (bacteria were 
resuspended only few times to avoid mechanical lysis). Bacteria were heat-shocked at 42°C 
for 1 min and put back on ice for 10’. Depending on the aim of the experiment, bacteria were 
either cultured in liquid LB medium or plated on LB agar. On one side, if a mixture of 
different inserts was cloned and had to be preserved, bacteria were incubated in 700µL LB 
medium w/o ampicillin for 1 hour (recovery phase) and then transferred into 2mL liquid LB 
medium with ampicillin at 150µg/mL and incubated overnight at 37°C on a shaking platform. 
On the other side, if single clones had to be isolated after heat-shock, bacteria were plated on 
LB agar plates containing ampicillin and incubated overnight at 37°C. The next day colonies 
were picked and grown in liquid culture. 
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II.2.1.7. Plasmid DNA Purification 
 
DNA plasmid extraction was performed according to Macherey-Nagel protocol. For a 
miniprep, the starting amount of LB culture was 3 mL, for a midiprep 100mL, and for a 
maxiprep 250mL. The DNA content was quantified by UV spectrometry at 260nm using 
NanoDrop® ND-1000.  
 
 
 
II.2.1.8. Restriction Digestion 
 
1µL of plasmid DNA (300ng/µL) was digested with 0.3µL of each enzyme, 1µL of buffer 
10X, 1µL of BSA 10X, and 6.4µL H2O (total volume of 10µL). The reaction was incubated 
at 37°C for 1 hour. Subsequently 2µL loading dye 6X were added and the solution was 
loaded in a 0.8% agarose gel with a Size Ladder 1kb and/or 100bp in parallel.    
 
 
 
II.2.1.9. DNA Sequencing 
 
Sequencing for research was performed in-house using an Applied Biosystems 3130 Genetic 
Analyzer and the corresponding sequencing kit. Sequencing primers were ordered as HPLC 
purified. DNA denaturation before starting sequencing may help for long templates with 
complex sequences. Table 2 summarises the “rule of thumb” to prepare a dye terminator 
sequencing reaction. Usually plasmid DNA (about 13kb) or PCR fragments (about 1500bp) 
were used as template. Since the RT gene is relatively small, 4µL of Big Dye were sufficient. 
 
 
Template size 
dsDNA 
(ng) 
Primer 
(pmole) 
Big Dye 
(µL) 
Buffer 5x 
(µL) 
H2O  
(µL) 
100bp 10 3 4 2 to 20 
1kb 80 3 4 2 to 20 
10kb 800 3 6 2 to 20 
 
Table 2. Typical protocol for sequencing PCR. 
 
The PCR cycling was set up as follows (in total 40 cycles): 20’’ at 96°C, 20’’ at 50°C, and 4’ 
at 60°C. For subsequent purification ethanol precipitation was the best solution for our 
purposes. Cold ethanol and temperature controlled lab conditions may improve results. 
Moreover, the use of glycogen may enhance DNA precipitation. For one sample, a fresh 
“stop-solution” containing 2µL 3M CH3COONa (pH = 4.6) and 2µL 100mM EDTA was 
prepared. EDTA is not strictly required but can prevent enzyme mediated DNA degradation. 
After vortexing, 50µL of 100% ethanol were added and the solution was well mixed. 
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PCR products were distributed in a 96well plate (normally sequencing reactions are more 
than 10; hence it is more comfortable to work with a 96well format). 54µL (52µL if EDTA 
was not used) of “stop-solution” were added to the PCR products. The plate was covered with 
a plastic film and well mixed. Afterwards, it was centrifuged for 30’ at 4,000 × g. Supernatant 
was removed by turning the plate and placing it on an absorbent paper. 150µl of ethanol 75% 
were added to wash the pellet; plate was centrifuged as before for 5’. After removal of the 
supernatant the plate was put in vacuum for 10’. Pellet was resuspended with 30µL of either 
H2O or formamide (as a denaturant); the mixture was let 10’ at room temperature to ensure 
that DNA was well solved. The polymer itself used in the sequencing machine contains ~7M 
urea as denaturing agent and was run at ~70°C to eliminate all hydrogen bonding associations 
in ssDNA.  
 
 
 
II.2.1.10. Site-directed Mutagenesis 
 
This method was used to introduce individual point mutations into a plasmid and was 
performed according to the Stratagene protocol. Briefly, the basic procedure utilises a 
supercoiled double-stranded DNA (dsDNA) plasmid with a target site for mutation and two 
synthetic oligonucleotide primers containing the desired mutation. The oligonucleotide 
primers, each complementary to opposite strands of the plasmid, were extended during 
temperature cycling by PfuTurbo DNA polymerase. Incorporation of the oligonucleotide 
primers generated a mutated plasmid containing staggered nicks. Following temperature 
cycling, the product was treated with DpnI. The DpnI endonuclease (target sequence: 5´-
Gm6ATC-3´) is specific for methylated and hemimethylated DNA and is used to digest the 
parental DNA template and to select for mutation-containing synthesised DNA. The nicked 
plasmid DNA containing the desired mutations was then transformed into XL1-Blue 
supercompetent cells 
 
 
 
II.2.1.11. Overlap-PCR 
 
This reaction, also called fusion PCR, was used to introduce site-specific mutations in a target 
gene. It was normally set up in two different PCR steps. The first step was performed to 
produce two small fragments (Reaction 1 and 2 in Figure 7A) which were then joined by 
another PCR step (Reaction 3 Figure 7B). For the first reaction, a forward wild type primer 
annealing at the leftmost part (Primer 2) was used together with a reverse mutant primer 
(Primer 1a). For the second reaction a reverse wild type primer (Primer 3), this time 
annealing at the rightmost part, was used with a primer that is complementary to the mutant 
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one used in the first reaction (Primer 1b). Thus four different primers were used and the 
mutant primers were annealing in the middle relative to the two external wild type primers.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7A 
 
Then a second PCR step was performed using the two small fragments produced during the 
first step and the two external primers (Figure 7B). In this way the two fragments were joined 
by polymerisation and further amplified.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7B 
 
 
Figures 7A, B. Basic scheme of overlap-PCR (refer to text for more details). 
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The first step of PCR was assembled according to the standard iProof™ High-Fidelity DNA 
Polymerase protocol, since the enzyme lacks terminal nucleotide transferase activity. This 
was absolutely necessary, otherwise the two fragments would end up with an extra nucleotide 
that was not complementary to the template sequence, usually an adenine (“A” in brackets in 
7A, B). In this case, the second PCR amplification would fail, because there would be a 
mismatch exactly at the 5’ end, where the enzyme should start polymerisation, unless the two 
fragments were produced to exactly anneal before a thymine (arrow in Figure 7A, B). To 
avoid this complication, it was sufficient to use for the first PCR step those enzymes which 
are known to have no terminal nucleotide transferase activity. For the second PCR step, this 
expedient was no longer necessary and enzymes with terminal nucleotide transferase activity 
were tolerated as well (e.g. Platinum® PCR SuperMix). 
 
The protocol for reaction 3 was as follows: 3-4µL of fragment 1, 3-4µL of fragment 2, 2µL 
of each primer, 38-40µL master mix. The actual amount of the two fragments should ideally 
be equimolar. Yet, since their concentrations were relatively low, it was tricky to assess the 
mole amount. Under non-equimolar concentrations it is possible to result in more than one 
band after the PCR reaction (one corresponding to the coupled and the others to the 
uncoupled fragments) but using good resolution agarose gel electrophoresis allows to isolate 
the desired product.   
 
 
 
II.2.1.12. Allele-specific PCR 
 
This method was used to determine qualitatively the presence of resistant minorities with a 
mutated primer specific of the region of interest. The plasmid DNA was amplified 
simultaneously in two parallel reactions, by using a common upstream primer wild type and 
either one of two downstream primers with 3’ ends matching either the wild type or the 
mutant sequence. In addition the mutant primer was required to also contain about three 
internal mutations89. The Platinum® PCR SuperMix was used for this purpose. Reactions 
were set up as follows (in total 25µL):  0.5µL plasmid DNA at 2ng/µL, 1µL forward primer 
(10µM), 1µL reverse primer (10µM) and 22.5µL Platinum SuperMix. The amplification was 
performed for 27 cycles at 95°C for 15 s, 62°C for 15 s, and 72°C for 1 min 30 s after an 
initial denaturation of 2 min. The crucial step was to find the optimal annealing temperature 
to be able to discriminate authentic from inauthentic annealing; e.g. the primer containing 
mutated sequence should not allow any amplification of the wild type template. 
Specific amplification of the DNA fragment was verified by subsequent gel electrophoresis. 
For each specific PCR a negative and a positive control of specificity for amplification had to 
be included: wild type pNL4-3 as well as single mutated plasmid. 
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II.2.1.13. Mutation-specific real-time PCR assay 
 
The amplification was performed with a QuantiTect SYBR Green PCR Kit for 50 cycles at 
95°C, 10 s; 57°C, 15 s; and 72°C, 20 s after an initial 2 min step at 50°C and denaturation for 
10 min at 95°C. Five microliters of the cDNA products, generated with the Viroseq HIV-1 
Genotyping kit, were added to the Master mix containing: 2X QuantiTect SYBR Green PCR 
Master Mix , RNase-Free Water, and 7.5 pmole of each primer designed to quantify the total 
amount of virus as well as the percentage of specific mutant. The forward primer was 
designed to bind to a conserved region of pol, and reverse primers were designed either to 
quantify equally wild type and mutant template (the latter primer ends 5’ to the mutant 
position), either to match specifically the wild type or the mutant template. Fluorescent 
quantification of amplicons was mediated using the Rotor-Gene™ 3000 system (Corbett Life 
Science). The cycle number, at which the fluorescence passed a fixed threshold line, is 
defined as the threshold cycle number (Ct). Copy numbers were calculated for wild type and 
mutant variants by interpolation of the experimentally determined threshold cycle onto 
standard regression curves. To ensure an accurate quantification for both, a separate standard 
curve was generated for each template. The distance between the Ct observed with authentic 
and inauthentic priming was called ∆Ct and reflected the discriminatory ability. 
Precise dilutions of cDNA were prepared in independent repeat experiments, and for each 
specimen two replicate reactions were performed for internal standard. Experiments were 
performed on pre-prepared mixes of wild type and mutant variants virus preparation to 
validate the method prior to the use on patient-derived samples. As previously described, the 
relative amount of mutated sequences was calculated as the ratio of the quantity of mutated 
sequences in the sample and the quantity of total sequences in the sample90. 
 
 
II.2.2. Microbiology 
 
II.2.2.1. Bacterial Culture 
 
LB medium with ampicillin 
5g NaCl, 10g Bacto Tryptone, and 7g Bacto Yeast Extract were dissolved in 1L milliQ H2O 
and autoclaved. When the solution was at room temperature, 1mL ampicillin (150mg/mL) 
was added: final antibiotic concentration was 150µg/mL. 
 
LB agar plates with ampicillin 
2.5g NaCl, 5g Bacto Tryptone, 3.5g Bacto Yeast Extract, and 6g Bacto Agar were dissolved 
in 0.5L milliQ H2O and autoclaved. After cooling down the solution, 0.5mL ampicillin 
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(150mg/mL) was added: final antibiotic concentration was 150µg/mL. Approximately 20mL 
medium were poured in each Petri dish. 
 
 
 
II.2.2.2. Preparation of Competent Cells 
 
Both HB101 and One Shot® TOP10 competent cells are AmpS and contain a recA mutation, 
which prevents undesirable recombination events. In addition, One Shot® TOP10 bacteria 
have an endA mutation that prevents carry-over of nucleases. Both cells as purchased have 
been made chemically competent. 
Cells from this commercial source were plated on LB agar w/o ampicillin and incubated over 
night at 37°C. The next day one single colony was inoculated in 5mL LB medium and 
incubated overnight on a shaker. The over night culture was transferred into 1L LB medium; 
growth was followed until an OD260 of 0.2-0.5. 
Afterwards cells were transferred in 50mL tubes and placed immediately on ice for 10’. 
Centrifugation was done at 4°C for 20’ (1,600 × g). Supernatant was removed and cells were 
resuspended in 25mL ice cold 100mM CaCl2 and centrifuged under the same conditions as 
before. After resuspending cells in 10mL ice cold 100mM CaCl2, they were left on ice for 30’ 
and then centrifuged as before. Following supernatant removal, cells were well resuspended 
in 50mL ice cold 100mM CaCl2 with 10% glycerol and then aliquoted into PCR tubes, which 
were stored at -80°C. Bacteria were plated on LB agar with and w/o ampicillin to check for 
contaminations and concentration; moreover a transformation test with 10ng pNL-NF was 
done to check their transformation efficiency.  
 
 
II.2.3. Cell Culture  
 
II.2.3.1. Cell preparation 
 
SX22-1 and SX-CCR5 are adherent cells and are grown in DMEM High Glucose (4.5g/L). 
CEM-SS cells are non-adherent human T-lymphocytes, which need RPMI for optimal 
growth. All cells were split three times a week. According to their growth kinetics SX22-1 
cells were split 1:7 and SX-CCR5 cells 1:5. CEM-SS cells were diluted in an approximate 
way. Before splitting, cells were examined under an inverted microscope to judge their 
degree of confluence. For passaging adherent cells, medium was removed and cells were 
washed with PBS w/o Ca2+ and Mg2+, and trypsinised. After removing the trypsin EDTA, the 
cells were incubated at 37°C for 5’ and then resuspended in DMEM. A part of it was put in a 
new flask with fresh medium. Every two months a fresh vial of cells was thawed and the old 
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ones were discarded. Since cells were used for a longer period of time, separated media were 
used for each cell line to avoid cross-contaminations.  
All three cell lines were stored in 1mL aliquots at -196°C (liquid nitrogen). They were 
thawed at 37°C and quickly transferred in culture medium, to dilute the toxic high DMSO 
concentration in the freezing medium to below 0.5%. Freezing solution always needs to be 
sterile filtrated.  
 
 
 
II.2.3.2. Preparation of Antiretrovirals 
 
Drug stocks were typically prepared from clinical formulation and were diluted in two 
formats, either as 6 or as 10 concentrations depending on the experiment. Drugs were diluted 
according to their solubility in polar solvents, H2O or DMSO, at 0.25% final concentration. 
The stock solutions were prepared at 10 mM. Moreover, each drug had its own range of 
concentrations depending on the IC50 value, in order to accurately extrapolate the inhibition 
curve.  
 
 
 
II.2.3.3. Cell Transfection: PhenoTecT format 
 
Since the PhenoTecT system has not yet been patent protected only limited information can 
be shared. For additional information contact Dr. Klimkait.  
 
Transfection was performed in 2mL Eppendorf tubes. For each reaction 1-3µg plasmid DNA 
was diluted in 75µL Opti-MEM® and mixed gently. Lipofectamine™ 2000 was diluted 1:50 
in Opti-MEM® and incubated for 5’. The solution containing Lipofectamine™ 2000 was then 
added to DNA; after a short shaking, tubes were incubated at room temperature for 25’. 
Afterwards, a precise amount of SX22-1 cells, counted with a Neubauer chamber, was 
pipetted into each tube and incubated at 37°C on a rocking platform for few hours (batch 
transfection). Meanwhile, drugs were distributed in 96well plates. RTIs and PIs were 
prepared in a six dilutions range and a positive control, an active drug against a gene from the 
wild type plasmid cassette, was included in each plate. After transfection, reporter and CEM-
SS cells were added (according to a precise ratio) and cells were distributed in the 96well 
plates, containing the drugs to be analysed. Plates were incubated at 37°C and 7% CO2 for 
four days, which corresponds to four HIV replication cycles.  
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II.2.3.4. Virus Inactivation and Cell Fixation 
 
Cells were fixed in 1X PBS containing 2% formaldehyde and 0.2% glutaraldehyde. 
Aldehydes are additive fixatives, which link membranes: the aldehyde group can combine 
with nitrogen atoms of proteins forming a methylene bridge. The combination of 
formaldehyde with glutaraldehyde takes advantage of the rapid penetration of CH2O and the 
thorough cross-linking by glutaraldehyde. Furthermore, aldehydes quickly inactivate viruses. 
The cells, now fixed on the bottom of the wells, were washed with 1X PBS and dried. 
 
 
 
II.2.3.5. ONPG Assay  
 
Since the PhenoTecT system has not yet been patent protected only limited information can 
be shared. For additional information contact Dr. Klimkait.  
 
The reporter cells carry an HIV-1 LTR-LacZ construct, which drives β-galactosidase 
expression when activated by HIV-1 Tat. In the presence of β-galactosidase, o-nitrophenyl-β-
D-galactopyranoside (ONPG) is converted to galactose and o-nitrophenol (ONP). Reporter 
cells contain no enzymes capable of degrading ONP further. ONP is colourless like ONPG at 
neutral or acid pH, but in an alkaline solution it turns yellow. The amount of yellow colour is 
measured in a spectrophotometer at 405 nm reflecting the amount of ONP formed in a given 
time. Since ONP is a product of β-galactosidase activity, the spectrophotometric 
measurements may be used as an assay for the enzyme, which is in turn related to the amount 
of alive viruses (Figure 8). 
Prior to measuring light absorbance, a mixture with buffer H, buffer Z, ONPG, and β-
mercaptoethanol was prepared. Before adding 80µL of this solution to each well, it was 
gently swirled. 96well plates were then incubated for 1 hour at 37°C. The highest 
concentration of the positive control, an active drug against wild type gene from the plasmid 
cassette, was used in order to subtract the absorbance measured in this well to the one of the 
remaining wells. In this way background optical density can be subtracted. 
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Figure 8. Principle behind PhenoTecT assay. 
 
 
 
 
II.2.3.6. RNA Isolation and Purification 
 
To extract HIV RNA from virions the standard Macherey-Nagel protocol was followed. 
Since viral supernatant came from wells containing plasmid DNA that was used to transfect 
SX22-1 cells, it was necessary to remove it from the RNA of the viruses. Thus, a new step 
was implemented in the standard protocol: after binding the viral RNA to the column, an on-
column digestion was performed with DNase. DNaseI was prepared mixing 540µL RNase-
free H2O to one vial containing the lyophilised enzyme; aliquots were stored at -20°C. 10µL 
of the reconstituted DNaseI were added to 90µL of reaction buffer, the solution was mixed by 
flicking the tube and 95µL of it were put on each silica membrane. The column was then 
incubated at room temperature for 15’. Afterwards the standard protocol for viral RNA 
isolation was followed with three washing steps and final elution. The RNA content could 
only be qualitatively assessed by UV spectrometry at 260nm, since carrier tRNA and not 
glycogen was used to precipitate RNA in ethanol, leaving a background signal. On-column 
digestion was chosen because no re-purification of RNA with diethylpyrocarbonate (DEPC)-
treated CH3COONa would be needed after elution. 
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III. Chapter I – Comparative study of the results 
from different HIV resistance assays 
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III.1. Evaluation of replicative Phenotyping versus genotypic 
analysis based on PhenoBase® 
 
Many laboratories in the world provide Genotyping expertise to assess resistance 
profiles for HIV patients. In Switzerland, there are four centres dedicated for this service: 
Geneva, Lausanne, Zurich and Basel. All data are collected in a common Base of the Swiss 
HIV cohort, to create a data-logistic network for research in the field of HIV. In Basel, new 
patient samples are received every week to determine their genotypic profile with the 
Stanford database. In parallel, a second test is performed for each patient on the 18 currently 
available drugs using a replicative Phenotyping (rPhenotyping system). Both resistance tests 
have been detailed in the introduction. The results of HIV-patients diagnosed for drug-
resistance by both methodologies (>1’000 pairs of genotypic-phenotypic determinations) are 
computed. This helped to build the matched database ‘PhenoBase®’. All information 
concerning each patient (personal data, physician, treatment, VL, CD4 count) are stored and 
are accessible in PhenoBase®, which thereby lends itself as basis to compare Genotyping and 
rPhenotyping. 
 
Genotypic predictions of the Stanford DB algorithm are subdivided in 5 levels of 
resistance: susceptible (score 0-9), potential low-level resistance (score 10-14), low-level 
resistance (score 15-29), intermediate resistance (score 30-59) and high-level resistance 
(score ≥ 60); whereas rPhenotyping creates three categories: susceptible (S), intermediate (I) 
and resistant (R). To compare both diagnoses, I decided arbitrarily to also reduce Genotyping 
to only three classes, depending on the total scoring for all mutations:  
 
- “Susceptible” if scoring is less than 20; 
- “Intermediate” between 20 and 44; 
- “Resistant” if scoring is superior or equal to 45. 
 
 
In the whole study genotypic results will be presented as either Susceptible, 
Intermediate or Resistant, respectively footnoted Geno-S, Geno-I and Geno-R. In the same 
manner, phenotypic results will be introduced as Pheno-S, Pheno-I and Pheno-R. 
 
 
To interrogate PhenoBase® on data from patients analysed between years 2002 and 
2007 we re-interpreted the sequences with the last updated version of Stanford (version 
4.2.6). In parallel, the phenotypic data were evaluated for the level of sensitivity with the cut-
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offs re-calculated in December 2006. We observed an overall good agreement between 
Genotyping and Phenotyping especially concerning the RTIs (N= 1260 except for FTC, new 
drug, N= 465 and ddC, N= 690).  The range of concordance for ten clinically used Reverse 
Transcriptase Inhibitors was from 72.3% (ABC) to 92.2% (NVP) (Figure 9). The NRTI ddC 
was out of this range with only 53.2% of concordance.  
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Percentage of concordance and discordance between Stanford Genotyping 
and rPhenotyping for each NRTI and NNRTI clinically used. 
 
 
 
Four drugs presented a small percentage of discordance (around 10%): 3TC, FTC, 
NVP and EFV; while the second group showed less than 80% of concordance: d-drugs, AZT, 
ABC and TDF. Moreover, we observed a higher amount of Geno-R/Pheno-R in the former 
case. The resistance to the first group of RTIs (3TC, FTC, NVP and EFV) is mainly due to 
one strong mutation in the reverse transcriptase which prevents the incorporation of the drug, 
e.g. M184V for 3TC and FTC; K103N, V106M, Y188L and G190X for EFV and NVP. In 
other cases, the addition of several “weaker” mutations in the same gene leads to resistance, 
e.g. d-drugs, AZT, ABC and TDF. In order to better discriminate the major discordances 
Sensitive and Resistant, the histogram in Figure 10 was used to display the percentage of 
these discordances in a discrepant population.  
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Figure 10. Percentage of major discordance in the population presenting any 
discordance between Stanford Genotyping and rPhenotyping for each RTI. 
 
 
 
The above histogram shows the percentage of major discordance within a population 
of patients having different results for genotypic and phenotypic analysis on ten RTIs. Two 
groups of drugs are easily distinguishable separated by a blue dashed line: 
 
- In the left part of the histogram, a higher amount of discordance is observed 
for the samples presenting a genotypic resistance with, at the same time, 
susceptibility by Phenotyping. It is particularly true for AZT and d-drugs: 
between 30% (d4T) and 40% (ddI) of the discordant population correspond to 
a prediction Geno-R/Pheno-S whereas the percentage of Geno-S/Pheno-R 
represents less than 6%.  
- This distribution is completely inverted for the drugs plotted in the right part 
of the histogram which are the RTIs presenting the best correlation between 
Genotyping and Phenotyping. The most frequent category observed for these 
four ARVs is Geno-S/Pheno-R: between 12.5% (EFV) and 40% (FTC). The 
samples, for which Genotyping interprets resistance while in contrast 
Phenotyping predicts sensitivity, correspond to less than 10% of the discordant 
population except for NVP (14.3%). 
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III.2. Evolution of a Genotyping Algorithm over time 
 
For new drugs like FTC, Stanford DB algorithm has even after many years not 
reached a “steady state” yet. FTC was added in Stanford DB v.3.9 on March 25, 2004 but 
seven months after, on October 27, 2004 many penalty scores were updated: E44A/D 8→5, 
T69A/I/S 5→2, T69insertion 30→20, V118I 8→5. In the version 4.1 (March 17, 2005) four 
further amino acid changes were included (M41L, L210W and T215Y/F), even though with 
rather minor scores (0→4). In addition the mutation K65N was added with a score of 15 on 
May 24, 2006. A similar situation is also observed for other better characterized RTIs and 
PIs. 
The scores of EFV and NVP (NNRTIs) are more stable and in general very high 
(between 30 and 60). Nevertheless, several additional scores were updated: K101P (EFV and 
NVP) 10→20→30 on March 25, 2004 and January 20, 2006 respectively; K103T/S 30→50 
for EFV and 30→60 for NVP on July 10, 2003; Y181V 10→20 for EFV and 30→60 for 
NVP on October 27, 2004 and G190V/T 50→60 for EFV on January 20, 2004 and for NVP 
on February 24, 2006. More remarkable changes were improved on amino acid V106M with 
a score of 15→50→60 for EFV on September 16, 2003 and April 05, 2005 respectively. It 
means that a given patient with just this substitution was susceptible to EFV in 2002 but 
intermediate resistant in 2003 and even resistant in 2005. 
There is another kind of mutation which had a highly increased penalty score: the 
deletion at positions 67 and 69. This change had an impact on four drugs: ABC, AZT, d4T 
and ddI. In Stanford DB v.4.0 on October 27, 2004 the score of the deletion at position 67 
was updated: 10→25 (ABC), 18→30 (AZT), 12→30 (d4T) and 5→25 (ddI). The deletion at 
position 69 had a stronger penalty score in January 20, 2006: 15→25 (ABC and ddI) and 
15→30 (AZT and d4T). The new scoring for these deletions leads to an intermediate 
resistance level to each of the four mentioned RTIs while it was susceptible prior to the latest 
update. 
Other remarkable examples were the addition of new mutations. In July 2003 two 
mutations were implemented: K103Q with a score of 5 for NNRTIs and K65R with a score of 
15 for d4T; in March 2004 there were E44A/D and V118I with a score of 2 for ABC, AZT, 
d4T, ddI and TDF. In October 2004 the mutations T215S/C/E/D and K65R were added with 
a score of 10 for ddI and -5 for AZT respectively; in March 2005 M41L, L210W and 
T215F/Y gave a score of 4 for 3TC and FTC. The last addition seen until now for RTIs is the 
mutation K70E with a score of 8 for TDF in June 2005. Similar evolutions for PI scorings 
were observed (data not shown), which means that the variation of genotyping scores is a 
common limitation for all ARVs.  
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Since May 24, 2006 no other change has appeared for RTIs. Focusing on the major 
updates, the following changes have been made in Stanford DB algorithm from the beginning 
of our study (April 2003) until the end (December 2006):   
 
 
 Version, Date 
 
Mutation(s)       Drugs Old Score New Score 
Version 3.5, 2003-07-10 
K65R 
K103Q 
K103T/S 
 
d4T 
EFV-NVP 
EFV 
NVP 
0 
0 
30 
30 
15 
5 
50 
60 
Version 3.7, 2003-09-16 V75A/I V106M 
d4T 
EFV 
30 
15 
20 
50 
Version 3.9, 2004-03-25 
E44A/D 
V118I  
L74I 
M184V 
T215F/Y 
K101P 
ABC, AZT, TDF, ddI, d4T 
ABC, AZT, TDF, ddI, d4T 
AZT 
ddI 
ddI 
EFV-NVP 
0 
0 
-10 
20 
10 
10 
2 
2 
-8 
12 
12 
20 
Version 4.0, 2004-10-27 
D67- 
 
 
 
L74I 
 
 
K65R 
T69N 
T69G 
M184V 
T215F 
T215Y 
T215S/C/E/D 
T215C/E/D 
T215S 
V75A/I 
V75T 
K103Q 
Y181V 
 
ABC 
AZT 
ddI 
d4T 
ABC 
AZT 
ddI 
AZT 
ddI 
ddI 
ddI 
ddI 
ddI 
ddI 
d4T 
d4T 
d4T 
d4T 
EFV-NVP 
EFV 
NVP 
10 
18 
5 
12 
25 
-8 
50 
0 
20 
5 
12 
12 
12 
0 
5 
10 
20 
50 
5 
10 
30 
25 
30 
25 
30 
12 
0 
25 
-5 
10 
20 
10 
15 
20 
10 
15 
15 
10 
30 
10 
20 
60 
Version 4.1, 2005-03-17 L74I 
M41L 
L210W 
T215F/Y 
ABC 
3TC-FTC 
3TC-FTC 
3TC-FTC 
12 
0 
0 
0 
20 
4 
4 
4 
Version 4.1.1, 2005-04-05 V106M EFV 50 60 
Version 4.1.4, 2005-06-20 K70E TDF 0 8 
Version 4.1.7, 2006-01-20 
T69- 
 
L74I 
M184V 
T215F 
T215S/C/E/D 
K101P 
G190V 
ABC, ddI 
AZT, d4T 
ddI 
ddI 
ddI 
d4T 
EFV-NVP 
EFV-NVP 
15 
15 
25 
10 
15 
15 
20 
50 
25 
30 
30 
5 
20 
20 
30 
60 
Version 4.1.9, 2006-02-24 
Q151L 
V75A 
G190T 
V179F 
ABC, AZT, ddI, d4T 
d4T 
EFV-NVP 
NVP 
40 
10 
50 
5 
20 
15 
60 
25 
 
 
Table 3. Updates of the Stanford DB algorithm over the last years.  
Unchanged scores are not listed. 
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A retrospective study done in collaboration with Vincent Finel91 considered all 
previous Stanford DB versions since 2003 and PhenoTecT system to assess the resistance 
profiles of all patients in PhenoBase®. Genotypic and phenotypic predictions were compared. 
The finding was that, despite an overall stability of Genotyping over time, for some patients 
an evolution of Stanford DB predictions correlating with phenotypic results was observed. 
Figure 11 depicts this evolution for AZT in a pool of 17 patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Stanford DB algorithm variation over time set compared to the constant 
results of PhenoTecT. 
 
 
The 17 updates of Stanford DB algorithm did not have an impact on the interpretation 
of resistance for all samples. The profile of resistance by Genotyping is constant over time for 
samples 1, 2, 3, 8 and 13. Hence, this study shows that for rare samples (4, 6 and 7) the 
previous concordance observed between Phenotyping and Genotyping evolves into minor 
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discordances. The most important change pointed out in Figure 11 is the update of 
Genotyping leading to a “better” correlation with the PhenoTecT system. Samples 10, 14 and 
15 diagnosed intermediate resistant to AZT by Phenotyping have a genotyping interpretation 
which evolves from resistant to intermediate.  For samples 9, 11 and 12 susceptible to AZT 
by phenotyping, the update of penalties leads to a change from R→I (11 and 12) and I→S 
(9). The most remarkable evolution is observed for the samples 5, 16 and 17 susceptible to 
AZT by Phenotyping but resistant to the drug by Genotyping until 2004, later intermediate 
and finally susceptible in 2006. 
 
 
 
 
III.3. Three main Algorithms to assess Genotyping 
 
The Stanford DB algorithm is used in our laboratory to interpret the HIV sequences 
from patients. Many algorithms are available for the analysis of HIV sequences, and three 
main algorithms are employed by the different centres to assess Genotyping: ANRS, Rega 
and Stanford. As already described in the introduction (I.5.1.), the Stanford algorithm is 
based on addition of mutation scorings for each drug whereas Rega and ANRS algorithms 
take into account the association of these mutations (antagonistic and synergistic interaction 
effects). 
 
The growing number of distinct genotyping algorithms leads to different 
interpretations92-94 and ultimately to different HAART prescription. This demonstrates a 
weakness and a limitation of those “modelling” systems. Figure 12 shows a geometric 
translation of a comparative discordance-assessment between three methodologies freely 
available through the internet (Stanford, Rega and ANRS for Genotyping) versus 
rPhenotyping. Below they are defined as points in space, and distances equal “percent of 
discordance” between two respective systems. Thereby the base of the resulting tetrahedron 
represents the side-by-side comparison of three genotyping algorithms, and the area within 
this (blue) triangle visualises and quantifies the degree of relative discordance. The addition 
of replicative Phenotyping as a third dimension allows the independent assessment against 
every algorithmic system, quantified e.g. by the volume of the tetrahedron. 
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Figure 12. Tetrahedron model displaying genotypic and phenotypic discordances.    
 
 
                                                     
A retrospective study done in collaboration with Stéphane Hubert95 considered all 
samples analysed between 2002 and 2004 at InPheno. The sequences were re-interpreted with 
the updated version of each algorithm at that time (ANRS v.2004.09; Rega v.6.2 and Stanford 
v.4.0) and compared with the phenotypic result sent to the physicians. For each of the RTIs a 
tetrahedron has been constructed (Figure 13) (in this study they supplied also the model for 
PIs, data not shown). FTC was not implemented in the interpretation of resistance at this time 
and ddC was removed from the analysis. 
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Figure 13. Geometric translation of discordance for each of the 8 RTIs.  
The blue area represents the genotypic discordances where “x” and “y” axes delineate a 
plan. The “z” axis corresponds to the third dimension built by the phenotypic result 
compared to any Genotyping. 
 
 
Tetrahedron shapes appear “stochastic” with no obvious trends and relationships for 
drug classes with the exception of NNRTIs and 3TC. For this group the small size of the 
basis reflects a good agreement among the genotypic systems and correlates with the 
dominant role of characterized mutations at positions 103 and 184, respectively. The wider 
areas are observed mainly for ddI, d4T and ABC for which the three genotypic interpretations 
are highly discordant (20-40%). For AZT and TDF two algorithms – ANRS and Rega – give 
a similar result (less than 5% of discordance) whereas Stanford shows more discrepancies 
with both of them (~ 15%). 
 
The fourth method rPhenotyping is symbolised by the height of the tetrahedron. We 
can distinguish three categories: (i) equal distance from each of the three Genotyping (TDF, 
3TC and NNRTIs); (ii) rPhenotyping is more concordant with ANRS (ABC and ddI); (iii) 
rPhenotyping and Stanford present less discrepancies (AZT and d4T). 
 
These three main algorithms used to determine the profile of resistance of HIV reveal 
some discordances between their interpretations. One common point in their rules, which is 
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often blamed, is the unique reference to the B subtype of HIV to calculate the level of 
resistance. During several scientific conferences I attended, one of the main requests asked by 
scientists was the implementation of non-B subtype resistance data in the algorithms. In 
Switzerland the proportion of non-B subtype increases every year: 2003 & 2004 → 25%; 
2005 & 2006 → 30%; 2007 → 40%. In the study done by Hubert et al.95, the discordances 
between the three genotypic algorithms, as quantified by the base of the tetrahedron, were 
recalculated for each of the 8 RTIs independently for B and non-B subtypes. The obtained 
data reported as histogram in Figure 14 reveal a dramatic increase in disagreement between 
the prediction systems for non-B viruses (yellow bars). A possible explanation for this 
phenomenon is that mutational pattern overall differ significantly for B and non-B subtypes 
that are judged according to B-knowledge. However, due to the stringency of sample 
selection, the non-B/discordant population did not yet reach statistically exploitable 
frequency for 3TC and NNRTIs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Discordance between genotypic systems for B- and non-B subtypes. 
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III.4. Discussion chapter I 
 
Genotyping and rPhenotyping present overall a high degree of concordance in the 
resistance levels of the different RTIs. However for some samples two analyses with opposite 
diagnoses are provided and physicians are in the dilemma to choose the best treatment for 
their patients. My interest was to further analyse these discordant profiles to be able to give 
an adapted recommendation for treatment.  
 
Two subgroups of RTIs have been characterized in this chapter:  
 a first group presenting more than 20% of discordance between genotypic 
analysis and rPhenotyping and for which the major discordances were mainly 
Geno-R/Pheno-S. The related drugs were AZT, d-drugs, ABC and TDF. The 
addition of several weak mutations is necessary to prevent their action. 
 a second group for which Genotyping and rPhenotyping were discordant in 
around 10% of samples. The statistical data shown previously indicate that 
these drugs (3TC, FTC and NNRTIs) had a high percentage of samples Geno-
S/Pheno-R. In their case a single mutation in the RT gene can lead to HIV 
resistance.  
 
The comparison of three main algorithms to assess genotypic results revealed that, in 
general, any of them was more concordant with phenotypic analysis. However, for the second 
aforementioned subgroup, all genotypic algorithms were in good agreement and presented a 
low level of discrepancy with rPhenotyping. The latter observation could be explained by the 
strong impact of several single mutations recognised by all algorithms.  
 
Genotyping algorithms require regularly updating to: (i) better score the impact of 
each mutation already known; (ii) implement studied mutations newly characterized. Each 
genotypic interpretation is based on different rules (addition or association of mutations) but 
none of them implemented data from non-B subtype, which are more and more present in 
Europe and possibly soon also in North America. In general for RTIs neither one nor the 
other genotyping algorithm correlates more closely with rPhenotyping. These observations 
appear to indicate that multiple reasons could explain the discrepancies. This is what led me 
to look individually at each group of major discordance in order to identify a clinical 
explanation. In the next two chapters, I will dissect the major discordances observed between 
Stanford DB algorithm and rPhenotyping and assign them to either one of two “baskets”: 
Geno-R/Pheno-S and Geno-S/Pheno-R.  
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IV. Chapter II: Evaluation of rPhenotyping to 
detect complex patterns of mutations 
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IV.1. The presence of HIV quasispecies could influence the 
interpretation of resistance 
 
IV.1.1. Background 
 
The dynamics of HIV-1 replication are fast, and the generated viral population is also 
in vivo characterized by a high diversity96. This variation includes the inevitable and, in 
principle, predictable accumulation of mutations such as those conferring resistance to 
antiviral drugs. It leads to viral quasispecies which can coexist and present different patterns 
of mutations21. However, their detection is not at all trivial. As example, the sequencing 
methodology is based on a ‘consensus’ sequence of a single virtual virus meaning such 
Genotyping loses the ability to separate and to assign mutations to individual genomes within 
mixed populations. Genotypic algorithms thereby tend to overestimate resistances of viral 
mixtures after placing all sampled mutations into the same “virtual genome” (Figure 15).  
 
In contrast, the robust replicative Phenotyping system PhenoTecT enables viruses to 
replicate up to four times, yet restricting in vitro evolution of new viral species. This allows 
to discriminate e.g. virus mixtures in plasma. Indeed, by rPhenotyping each single virus of a 
mixture will evolve under drug pressure and those with resistance associated mutations will 
be able to replicate. This is why we hypothesised that discordant profiles with Geno-
R/Pheno-S could correspond to samples presenting a particular viral mixture. In fact, a 
homogeneous viral population should be interpreted identically by both methodologies. 
Nevertheless, for mixed populations there are two possibilities: either at least one single virus 
of the mix is resistant to the drug and the profile will be Geno-R/Pheno-R (Figure 15, Case 
3); or each single virus of the mix is susceptible but carries mutations that would lead to 
resistance if they were all in cis on a single genome. This latter case will be interpreted 
resistant by Genotyping whereas rPhenotyping will diagnose it susceptible: Geno-R/Pheno-S 
(Figure 15, Case 2).  
 
This is true for mutations with low scores, which require the presence of additional 
mutations before leading to drug resistance. In case of highly scored mutations Genotyping 
and rPhenotyping will agree in diagnosing resistance when either only “one viral species” or 
a mixture of virus is present. 
 
 
 Chapter II 
 
 
56 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Theoretical application of the addition of mutations analysed by 
Genotyping and Phenotyping for the assessment of AZT resistance.  
Case 1: three patients infected each by one virus carrying a single RT-mutation;  
Case 2: one patient presenting viral quasispecies (three single mutated virus);  
Case 3: one patient infected by one AZT-resistant virus carrying three RT-mutation in cis. 
 
 
In this section, to demonstrate the validity of our hypothesis of mixed populations, we 
will try to answer the following questions: 
 
1. Do Geno-R/Pheno-S profiles correlate with the presence of viral mixtures? 
2. Does rPhenotyping discriminate between triple/quadruple mutants and a 
viral mixture containing single mutants? 
3. Do we have clinical samples in PhenoBase® illustrating this theory? 
 
 
 
 
 
 
 
 
 
 
 
 
 
D67N
T69D
T215Y
Genotype Phenotype
D67N
T69D T215Y
S S
S S
S S
R S
T69DD67N T215Y
R R
Case 1
Case 2
Case 3
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IV.1.2. Results 
 
IV.1.2.1. Statistical data 
 
First, PhenoBase® was interrogated to see if there is a correlation between the co-
existence of at least two viruses in a sample and those patients presenting a Geno-R/Pheno-S 
profile for the RT gene. A viral mixture was defined as virus presenting a RT sequence with 
one or more characterized-mixed mutations. Samples from the years 2005 and 2006 were 
selected and each drug (NRTIs and NNRTIs) was separately evaluated for concordance 
between Genotyping and rPhenotyping (Geno/Pheno profiles). More than 5,200 distinct drug 
resistance profiles on RT were split into two categories according to whether they were 
concordant or discordant (Figure 16).  
 
 
 
 
 
 
 
 
 
  
 
 
 
        
 
 
 
 
 
 
Figure 16. Repartition of viral mixtures into concordant and discordant samples from 
the years 2005 and 2006. 
 
This first analysis (upper graph) made clear that discordance is a relatively rare 
observation among clinical samples in PhenoBase® (15%). To demonstrate our assumption 
that mixes of different viruses are one of the causes of discordance between Genotyping and 
Phenotyping, we further examined the concordant group dividing it in two subcategories 
according to whether those samples contained viral mixtures or not. We observed in 
Determ ination of Geno-Pheno profiles  2005-2006
15%
85%
Geno -P heno  co nco rdant
Geno -P heno  disco rdant
Geno-Pheno concordant profiles on RT
90%
10%
characterized m ixed sam ples
not characterized m ixed sam ples
Major Discordances in RT: 
mix/non-mix for Geno-R/Pheno-S population 
23% 77%
57%
43%
Geno-S/Pheno-R
Mixed Populations
Non-Mixed Populations
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concordant RT that 10% of the samples contained clear mixes. On the other side we 
subdivided the Geno/Pheno discordant profiles in the first pie-chart according to their type of 
major discordance, i.e. Geno-R/Pheno-S (yellow) or Geno-S/Pheno-R (red). It came out that 
the latter occurred less frequently. We looked for mixes in the Geno-R/Pheno-S group. We 
found out that 43% contained virus mixes for RT. When this value was compared to the 10% 
found before it was possible to statistically associate samples with virus mixes and Geno-
R/Pheno-S discordances.  
 
To confirm this prospective association by statistical rules the calculation of odds was 
done on RT data. The odds ratio is a measure of effect size. It is defined as the ratio of the 
odds of an event occurring in one group to the odds of it occurring in another group. These 
groups might be any dichotomous classification. If the probabilities of the event in each of 
the groups are p (first group) and q (second group), then the odds ratio is: 
 
 
 
 
An odds ratio of 1 indicates that the condition or event under study is equally likely in 
both groups. An odds ratio greater than 1 indicates that the condition or event is more likely 
in the first group. And an odds ratio less than 1 indicates that the condition or event is less 
likely in the first group. The odds ratio must be greater than or equal to zero.  
 
The first calculation of odds ratios was done based on discordant and concordant 
populations in 2005 and 2006. I looked to each amino acid of the reverse transcriptase gene 
to observe the presence or absence of mixes. In the table below, the number of samples is 
shown for each population (Geno-R/Pheno-S discordant (R/S) versus non R/S and 
concordant, and mixed versus non-mixed). The event is “viral mixture occurring in a first 
group: R/S profile and in a second group: non-R/S or concordant profiles”. 
 
         
 
 
 
Table 4. Distribution of the diagnosed samples into three groups: discordant Geno-
R/Pheno-S, non-discordant Geno-R/Pheno-S and concordant; and in two events: mixed 
population and non-mixed population.  
R/S non R/S concordant
mix 134 2767 2407
non mix 47 1947 1753
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From the given numbers we inferred the odds ratio (OR) for mixes as follows: 
 R/S versus non R/S:  OR = (134*1947)/(47*2767) = 2 
 R/S versus concordant:  OR = (134*1753)/(47*2407) = 2.1 
 
These odds ratios illustrated that a mixed viral population was more likely to occur in 
the Geno-R/Pheno-S profile than in any other category. To be interpreted resistant to a drug 
by Genotyping a virus should carry several characterized mutations. The hypothesis of the 
presence of viral mixture to explain the discrepancies Geno-R/Pheno-S would mean that 
these characterized mutations should be found in different viruses. This is why we focused on 
the specific presence of mixed characterized mutations in the studied samples. The values 
corresponding to this new request are summarised in Table 5. 
 
 
 
 
Table 5. Distribution of the diagnosed samples in two groups: discordant Geno-
R/Pheno-S and non-discordant Geno-R/Pheno-S; and in two events: population with mixes of 
characterized mutations and population without mixes of characterized mutations.  
   
From the given numbers we inferred the odds ratio for mixes as follows: 
 R/S versus non R/S:  OR = (78*4165)/(103*549) = 5.7 
  
The odds ratio was 5.7, showing that a viral mixture was much more likely to occur in 
the Geno-R/Pheno-S profile than in the non R/S profile. To conclude that it was one cause of 
this kind of discordance, I could show that for the samples Geno-R/Pheno-R the viral 
mixtures were less frequent. The values in the Table 6 represent the number of samples 
diagnosed, between the years 2005 and 2006, either identically by Genotyping and 
rPhenotyping (resistant or susceptible) or Geno-R/Pheno-S. 
  
 
 
 
Table 6. Distribution of the diagnosed samples into three groups: discordant Geno-
R/Pheno-S and concordant resistant or susceptible; and in two events: population with mixes 
of characterized mutations and population without mixes of characterized mutations.  
R/S non R/S
78 549
103 4165
characterized mix
not characterized mix
R/S  R/R S/S
78 147 236
103 318 3397
characterized mix
not characterized mix
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From the given numbers we inferred the odds ratio for mixes as follows: 
 R/S versus R/R:  OR = (78*318)/(103*147) = 1.6 
 R/S versus S/S:  OR = (78*3397)/(103*236) = 10.9 
 
Looking especially at the characterized mutations the odds ratio between Geno-
R/Pheno-S and Geno-S/Pheno-S was high: 10.9. It is due to the fact that samples sensitive to 
drugs are often, if not always, from patients with a primary infection or early-treated patients. 
They rarely have characterized mutations and multi-species, which appear under drug 
pressure. In case of samples genotypically and phenotypically resistant to ARV the odds ratio 
showed that viral mixtures were less likely to occur than in the Geno-R/Pheno-S profile. 
 
Conclusion: The odds ratios revealed a strong correlation between the presence of 
viral mixtures in a sample and a discordant profile Geno-R/Pheno-S. These data confirmed 
the relevance of the working hypothesis. In a given sample the presence of several viruses 
carrying different patterns of characterized mutations could be one of the causes of Geno-
R/Pheno-S profiles. 
 
 
 
 
IV.1.2.2. Discrimination of rPhenotyping between mixes of single mutants 
versus combinations of mutations on the same virus 
 
To determine the ability of rPhenotyping to discriminate between triple or quadruple 
mutants and a viral mixture of single mutants, several mutant plasmids will be engineered 
and tested in the phenotypic assay. Based upon PhenoBase® requests done in chapter I, the 
mutations will be selected to give genotypic resistance to AZT, which showed together with 
ddI, the higher number of Geno-R/Pheno-S profiles among the RTIs. Furthermore, resistance 
to AZT is due to the addition of at least 3 or 4 mutations, which perfectly matches the 
working hypothesis. A virus carrying less than three mutations will be genotypically 
susceptible to AZT, and the presence of several such viruses should be declared resistant by 
Genotyping and susceptible by rPhenotyping. 
 
To construct relevant HIV mutants, we looked at the list of samples resistant to AZT 
according to Genotyping but sensitive in Phenotyping: between the years 2003 and 2006, 83 
samples were diagnosed Geno-R/Pheno-S to AZT. The Table 7 summarises the distribution 
for each characterized RT mutation in the selected samples.  
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Table 7. Distribution of RT characterized mutations for the samples Geno-R/Pheno-S 
to AZT (years 2003-2006). The mutations occurring in more than 20 % are figured out in red. 
AA: Amino Acid. X: any mutation. 
 
The 10 positions highlighted in red are the amino acids more frequently mutated in 
samples having a discordant profile to AZT. Six of them correspond to the TAM. To see if 
they have all a similar impact on AZT resistance, I checked for their AZT mutation scoring in 
the Stanford databank: M41L (15), D67N (15), T69D (5), K70R (18), V118I (2), Y181C (-4), 
M184V (-8), L210W (15), T215Y/F (35) and K219Q (15). The TAMs have a penalty score 
from 15 to 35 which increases AZT resistance when they are associated. The two mutations 
T69D and V118I contribute to AZT resistance when they are present with multiple TAMs. In 
contrary, Y181C and M184V partially reverse AZT resistance caused by other AZT 
mutations (TAMs).  
 
To demonstrate practically the observations described in Figure 15, several mutants 
were engineered with one, two, three or four resistance associated mutations in an NL4-3 
background. Among the previous mutations with a positive scoring some TAMs were 
selected (67N, 215Y and 219Q) as well as one non-TAM (69D). All mutant proviruses were 
sequenced to be validated before being included in the next experiments. Phenotyping was 
performed directly on each mutant plasmid in the replicative Phenotyping system PhenoTecT 
in the presence of AZT. In addition, individual mutants were assessed as mixtures. As a 
control for the PR gene, which should not contain any mutation, viruses were grown in 
parallel in presence of the protease inhibitor SQV.  
 
Every experiment was performed in triplicate, and twelve or six drug dilutions were 
used to extrapolate the inhibition curves in a reliable way. The total amount of transfected 
provirus was the same for a single virus or a mix of virus, equal to 2.5 µg. For curve fitting 
and statistical analysis of the experimental data XLfit version 4.1.1 was used. The entire 
experiment was repeated independently five times in order to reach a good degree of 
confidence. Figure 17 below represents the inhibition curves for triple mutant 67N-69D-215Y 
(green) or the mix of the three single viruses (blue) compared to a wild type reference: pBX 
(red). 
Position 41 44 62 65 67 67 69 69 70 70 74 74 75 77 100
AA L D V/P X N -/G/E D N/G R S/E I V M/I/T X X
% (N=83) 54.2% 13.3% 4.8% 0.0% 69.9% 6.0% 20.5% 14.5% 36.1% 4.8% 12.0% 12.0% 3.6% 0.0% 0.0%
Position 115 116 118 151 181 184 210 210 215 215 215 219 219 219 333
AA F Y I M C V W F/G/V F Y V/I/C/S Q E N/R E
% (N=83) 2.4% 1.2% 32.5% 4.8% 19.3% 68.7% 34.9% 6.0% 30.1% 49.4% 10.8% 34.9% 15.7% 8.4% 10.8%
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Figure 17. Inhibition curves for one provirus carrying three mutations (green) and 
for a mix of the three single mutants (blue) show intermediate resistance to AZT and full 
susceptibility, respectively. Both viruses are SQV susceptible. Red curve = wild type virus. 
 
 
The inhibition curve corresponding to the triple mutant was shifted to the right 
comparing to the reference meaning a decrease in susceptibility to AZT. The IC50 of the 
reference was equal to 5.7 nM and for the triple mutant to 16.5 nM. The ratio of their IC50 
(Rf) was: 16.5/5.7 = 2.9. To interpret this value it was compared to a cut-off value for AZT. 
There are two values determining the threshold between susceptibility and intermediate and 
between intermediate and resistance: 2.5 for the first and 4.5 for the second. It means that the 
triple mutant 67N-69D-215Y, with a Rf of 2.9, was intermediate resistant to AZT by 
rPhenotyping. To the contrary, it is clearly shown on the graph that the addition of the three 
single mutant 67N + 69D +215Y was susceptible to AZT with an IC50 of 6.5 nM (its curve 
superimposed the reference curve). Similar curves were obtained for the quadruple mutant 
67N-69D-215Y-219Q and its respective single mutants, the shift with the reference was even 
wider (data not shown). rPhenotyping in these particular conditions was able to discriminate 
between an association of three single viruses and the derived triple mutant. 
 
To determine the level of discrimination of the phenotypic assay, different 
combinations of four mutations: D67N, T69D, T215Y and K219Q were assessed in parallel. 
The associations of proviruses were the following:  
 
- two double mutants 69D-215Y with 67N-219Q,  
- one triple mutant 67N-69D-215Y with one single mutant 219Q,  
- one quadruple mutant 67N-69D-215Y-219Q, 
- four single mutants 67N + 69D + 215Y + 219Q.  
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The inhibition curves for AZT are shown in Figure 18. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Inhibition curves for four combinations of proviruses carrying mutations 
67N, 69D, 215Y and 219Q show a decrease in susceptibility to AZT with the increase of 
mutations carried by a single virus. All viruses were susceptible to SQV. Red curve = wild 
type virus. 
 
By Genotyping (Stanford algorithm) all associations of mutated viruses are 
indifferently interpreted resistant to AZT; whereas by rPhenotyping we observed a clear shift 
between the inhibition curves. The combination of the four single mutants was fully 
susceptible to AZT (superimposition of the green curve with the red reference) with an IC50 
of 8.1 nM and a Rf of 1 (IC50 reference = 7.7 nM). When two double mutants were co-
transfected: 69D-215Y + 67N-219Q, the susceptibility to AZT was decreased compared to 
the reference and the four single mutants. Their IC50 was 11.3 nM (blue curve) giving a Rf of 
1.5 which corresponded to a susceptible virus. The addition of a third mutation on the same 
virus, 67N-69D-215Y combined with the single mutant 219Q led to a shift to the right of the 
inhibition curve (pink) which provided an IC50 of 21.1 nM and a Rf of 2.7. This mix of triple 
and single mutants was intermediate resistant to AZT. The last tested virus was carrying the 
four mutations 67N, 69D, 215Y and 219Q in cis. Its inhibition curve (brown) was to the far 
right which produced an IC50 of 40.9 nM and a Rf of 5.3, meaning resistance to AZT.  
 
The genotypic and phenotypic profiles of all the different proviruses which were 
mutated are summarised in Table 8 below. 
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mutants 
D
67
N
 
T6
9D
 
T2
15
Y
 
K
21
9Q
 
69
D
-
21
5Y
 
67
N
-
21
9Q
 
67
N
-
69
D
-
21
5Y
 
67
N
-
69
D
-
21
5Y
-
21
9Q
 
Stanford Geno S S I S I I R R 
rPhenotyping S S S S S S I R 
 
mutants 
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D
-
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-
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+
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67
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-
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D
-
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+
 
21
5Y
 
69
D
 
+
 
21
5Y
 
67
N
 
+
 
21
9Q
 
67
N
 
+
 
69
D
 
+
 
21
5Y
 
67
N
 
+
 
69
D
 
+
 
21
5Y
 
+
 
21
9Q
 
Stanford Geno R R R I I R R 
rPhenotyping S S S S  S S S 
 
Table 8. Genotypic and phenotypic profiles of resistance to AZT done for single, 
double, triple and quadruple mutants, and for the association of the corresponding single 
mutated provirus. S: susceptible, I: intermediate and R: resistant. 
 
The main conclusion is that the PhenoTecT assay is able to discriminate between a 
single virus engineered with several mutations in cis and a mixture of virus each carrying 
only one of the same mutations (Figures 17 and 18). With two of the constructed mutants we 
could easily observe a discordance of profile done by rPhenotyping when the mutations were 
either engineered on a single virus or carried by several viruses. These plasmids mutated at 
positions 67N, 69D and 215Y or 67N, 69D, 215Y/F and 219Q were intermediate or resistant 
to AZT by Phenotyping whereas the addition of their respective single mutated virus was 
susceptible. 
However, some non expected results have been observed. Indeed, according to the 
Stanford algorithm, mutation T215Y contributes to intermediate resistance for AZT (penalty 
score of 35) but the PhenoTecT test diagnosed it susceptible to AZT. This discordance could 
be either due to an overestimation of the impact of mutation T215Y on AZT resistance or due 
to an in vitro assay limitation. In fact, as described in part I.4.2., the resistance mechanism 
with TAMs mediated the removal of the analogue from the terminated DNA chain. The 
presence of such mutations will allow the binding of ATP on the reverse transcriptase and 
further the removal of the RTI. A low amount of ATP in the cells used for the phenotypic 
assay could prevent an optimal release of the drug and lead to a false interpretation of ARV 
sensitivity. The same observations have been done for both double mutants. 
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IV.1.2.3. Dissection of clinical samples by dilution cloning 
 
The working hypothesis: “Geno-R/Pheno-S profile could be due to the presence of 
viral mixture” has been demonstrated to be true for some mutated proviruses. In these 
plasmids only the selected mutations were present but the viral population in clinical samples 
may carry also additional uncharacterized mutations which could have a further influence on 
resistance profile. It is why I wanted to dissect several samples to see the clinical relevance of 
our finding. Two samples with a discordant profile Geno-R/Pheno-S for AZT were selected: 
MD1310-04 and 6016764. Both had a sequence showing clear double-peaks at determinant 
positions (Figure 19).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Electrophoregram from the RT gene of sample 6016764 showing several 
mixed amino acid (20 non silent mixed mutations). 
 
 
As an internal control, in the region surrounding the patient’s RT gene, which 
corresponds to the cloning vector, no double peak was observed and the sequence was, as 
expected, isogenic to pNL4-3.  
 
Consequently, genotypic analysis was restricted to one of the numerous possible 
combinations of the detected mutations. The penalty scores of each mutation for a drug were 
all added to give a final penalty interpreted as level of resistance. The distinction of the 
different virus strains in the initial population could not be done by Genotyping. At present, 
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there is no solution for this problem. The hypothesis that more than one species is sometimes, 
if not always, present in the same patient was easily demonstrated through dilution cloning of 
bacteria, which were previously transformed with recombinant plasmids obtained from a 
mixture of various reverse transcriptase genes. For the two samples mentioned above, eight 
separate colonies were picked and sequenced.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Alignment, using MultalinH, of eight clones derived from sample MD1310-04.  
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Figure 21. Alignment, using MultalinH, of eight clones derived from sample 6016764.  
 
 
After aligning the sequences using MultalinH, in thirty five (MD1310-04) and fifty 
three (6016764) distinct positions more than one nucleotide was detected, suggesting that 
various populations coexisted in the same patient at the time of blood draw.   
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A possible cause for the observed mutations could be that they were simply a PCR 
artefact arising during HIV cDNA amplification. For this reason, iProof High-Fidelity DNA 
polymerase (52-fold more accurate than Taq polymerase) was used to amplify the DNA, 
which was in turn produced using the Applied Biosystems kit that employs AmpliTaq Gold 
DNA polymerase (which has a slightly lower fidelity). This expedient should already reduce 
the probability to introduce errors during the amplification steps, but to rule out this 
hypothesis the RT gene of a clonal mutant, already sequenced, containing four defined 
mutations was amplified in parallel. No additional substitution, except those four, was 
detected by sequencing. Moreover, the clustering of different mutations observed in the 
clones obtained from the two patients suggests that they were not the product of a randomly 
occurring event, otherwise they would be evenly distributed across the whole gene.  
 
The genotypic profiles of the different clones for the two patients selected are 
indicated in the Table 9 below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 9. Profile of RT mutations for samples MD1310-04 and 6016764 and their 
eight clones. 
 
For sample MD1310-04 the eight clones carried the nine mutations detected in the 
mixed population. At position 215 two out of them presented the amino acid Phenylalanine 
instead of Leucine and one of these two had the mutation T69N but not T69D. Five clones 
were identical and the three others were unique meaning that four different viruses were 
selected in the eight clones.  
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In patient 6016764, Genotyping of the original sample detected 32 amino acid 
changes (13 characterized mutations and 19 uncharacterized). Twelve of them were 
unequivocal, whereas the other twenty were ambiguous because more than one residue was 
possible at the same position. This was a very representative example of the coexistence of 
more than one quasispecies in the same patient. For this patient, more than one million 
(112*220) possible different combinations could be obtained from the samples’ substitutions. 
In the most simple (and the worst) case, all mutations would be in the same virus that coexists 
with the wild type. In the most optimistic case each single substitution would be carried by a 
different virus variant. Thus, twenty single mutant species would coexist with the wild type 
virus. Probably the actual situation lies between these two extremes. In case of twenty distinct 
single mutants, the mutations would not be detected by Genotyping, since each mutant 
nucleotide would only contribute to 5% of the entire peak signal. On the other side, the 
coexistence of the wild type virus with a single variant carrying all mutations in cis is 
questionable as well due to probabilistic calculation (probability of 0.00009%).  
 The sample 6016764 demonstrated that the resistance profile assessed through 
Genotyping represented only one of many different possible combinations. Moreover this 
combination might also not correspond to even one virus existing in the patient. The real 
solution to this endless problem is Phenotyping: all quasispecies are re-generated as separate 
entities as they were in the original blood sample and their susceptibility to ARVs is 
measured directly and irrespective of the mutant composition.   
  
For the two aforementioned clinical samples and their eight isolated clones, 
phenotyping resistance profiles were assessed with AZT, ABC and ddI. SQV was used as 
control of non Reverse Transcriptase Inhibitor. The penalty scores and the Rfs corresponding 
to each clone and mixed population are summed up in the Tables 10A and 10B.  
 
 
 
 
 
 
 
 
 
Table 10A. Penalty scores (Geno) and Rfs (Pheno) of sample MD1310-04 and its 
clones for three NRTIs: AZT, ABC and ddI.  
Green: ARV susceptibility, red: ARV resistance. 
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Seven clones out of eight had the same genotypic and phenotypic profiles as the 
mixed population of sample MD1310-04 (Geno-R/Pheno-S). Only clone 17 was not 
susceptible to AZT which is not correlating with the PhenoTecT assay performed with the 
pool of RT genes. The unique difference observed between the sequences of clone 17 and the 
mixed population was at position 69, where the mutation in clone 17 was an Asparagine 
instead of a Threonine, whereas for all the other clones the mutation generated an Aspartate. 
 
 
 
 
 
 
 
 
 
Table 10B. Penalty scores (Geno) and Rfs (Pheno) of sample 6016764 and its clones 
for three NRTIs: AZT, ABC and ddI.  
Green: ARV susceptibility, yellow: ARV intermediate resistance, red: ARV resistance.  
 
 
The clonal viruses 11 and 20 from sample 6016764 were too unfit to produce interpretable 
data. The other viruses were all susceptible to AZT and ddI, as the mixed population, with 
Rfs ranging from 0.4 to 2.5 for AZT and from 0.7 to 1.8 for ddI. The intermediate resistance 
observed in mixed populations for ABC was also shown for two clones (8 and 12). Fitness 
was high with a minimum of 88%. 
These data on the samples MD1310-04 and 6016764 having a discordant profile Geno-
R/Pheno-S for AZT were not corroborating the previous work done with constructed mutants. 
Indeed, mutations leading to AZT resistance were all carried by a single clonal virus 
indicating a resistance profile by Genotyping, and though this defined virus was still detected 
susceptible by Phenotyping. Three other patients were dissected in the same way but the 
results obtained were similar (data not shown). The hypothesis that the presence of viral 
quasispecies could explain a discrepancy R/S between Genotyping and rPhenotyping is not 
invalidated but with this study I was not able to find a clinical sample which could correlate. 
It suggests that for the studied clinical samples another explanation should be found to their 
discordant profile of resistance to NRTIs. Are the TAMs overscored by genotypic 
algorithms? Do interactions between TAMs and additional resistance associated mutations 
decrease the level of resistance to AZT? 
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IV.2. Interactions between Resistance Associated Mutations 
 
IV.2.1. Introducing the subject 
 
The impact of individual mutations on viral sensitivity to a given inhibitor is regularly 
re-evaluated by the different algorithms used to provide genotypic profiles. Between the 
years 2003 and 2007, Stanford DB updated the penalty scores of characterized mutations on 
PR and/or RT 23 times (as described in chapter I, III.2.). As a consequence, an HIV sequence 
analysed retrospectively with different versions of the same algorithm could be differently 
interpreted by Genotyping. Moreover between algorithms themselves the resistance 
associated mutations can be scored variously (as described in chapter I, III.3.). Whereas 
Stanford algorithm is simply adding the penalty scores of the several mutations listed for a 
sample, ANRS considers their interactions, e.g. the presence of at least three mutations 
among M41L, D67N, K70R, L210W, T215A/C/D/E/G/H/I/L/N/S/V, K219Q/E gives 
resistance to AZT. It is even more complicated for interpretations of ddI resistance by ANRS 
because the combination of some mutations could lead to an antagonistic effect, e.g. the 
resistance is associated to a least a score of +2 among M41L, T69D, L74V, T215Y/F, 
K219Q/E (score = +1) and K70R, M184 V/I (score = -1). Thereof, a patient diagnosed in two 
centres using different algorithms could have two genotypic interpretations showing 
discrepancies. Lately the compensating secondary changes were often described in studies 
and their role appeared to be affected by the genetic background/subtype of the virus.  
Phenotyping is a cellular assay to diagnose HIV resistance. Its advantage is the direct 
quantification of drug sensitivity for a viral population. As shown previously, the viral 
heterogeneity will be kept, e.g. viral mixtures with different patterns of mutations, to assess a 
resistance profile corresponding to the clinical situation. Nevertheless, the intracellular 
nucleotide pool could matter as it could differ from the PBL (Peripheral Blood Leucocyte) 
cells. A higher amount would lead to an underincorporation of NRTIs providing a wrong 
interpretation of drug activity. In this case discordance between genotypic and phenotypic 
diagnoses could arise. To improve the cellular assay, different cell lines should be tested or a 
cellular depletion of nucleotides should be performed. Another limitation of using cellular 
assay is the intracellular phosphorylation level. Indeed ARVs, as AZT and d-drugs, need to 
be phosphorylated in the cells prior to their incorporation in the DNA neo-synthesised. A too 
low level of phosphorylation will inhibit the activity of this class of drugs. 
Stanford algorithm, as well as ANRS and Rega, is probably not perfect but which is 
closer to the in vivo situation? Does one correlate more with rPhenotyping? The tetrahedron 
model, as described in chapter I, would pinpoint the concordance between these four assays. 
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The TAMs include the mutations M41L, D67N, K70R, L210W, T215Y/F and K219Q/E and 
the association of at least three of them lead to a resistance profile to d-drugs and to AZT by 
Stanford algorithm. It is why they are interesting mutations to study as part of interactions 
between resistance associated mutations to observe how the four HIV resistance tests will 
interpret them. Their interactions will be studied interrogating Stanford, Rega and ANRS 
algorithms in parallel and compared to the PhenoTecT results done for patient samples 
carrying an association of these mutations.  
 
 
IV.2.2. Results 
 
IV.2.2.1. Evolution of TAMs’ penalty scores over years 
 
Several combinations of TAMs were interpreted with four different versions of 
Stanford algorithm to observe evolution over years (Figure 22). I selected versions which 
showed highest update on penalty scores of TAMs: version 3.3 in 2003, April 25; version 3.9 
in 2004, March 25; version 4.0 in 2004, October 27 and version 4.1.7 in 2006, January 20. 
The scoring was calculated for the resistance to ddI, presenting the strongest evolution. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. Evolution of the Stanford algorithm for ddI over years for seven mutated 
viruses. Virus A with six mutations: 41L-67N-70R-210W-215F-219Q; Virus B with five 
mutations: 41L-67N-70R-210W-215F; Virus C with four mutations: 41L-67N-210W-215F; 
Virus D with four mutations: 41L-67N-210W-219Q; Virus E with three mutations: 41L-67N-
215F; Virus F with three mutations: 67N-70R-219Q; Virus G with three mutations: 41L-
210W-215Y. Scorings below threshold line at 20 are interpreted susceptible (green surface), 
intermediate between 20 and 45 (yellow surface) and resistant above threshold line at 45 (red 
surface).  
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The impact on resistance level is not similar for every TAM with score ranges 
between 0 and 20, for 219Q and 215Y/F respectively. Virus F, a triple mutant, is interpreted 
susceptible to ddI with the four versions whereas virus G, also with three mutations, is 
susceptible to ddI with version 3.3, intermediate with versions 3.9 and 4.0, and close to 
resistant with the last version 4.1.7. Viruses A, B and C evolve from intermediate to resistant 
to ddI, and viruses D and E from susceptible to intermediate. For virus D the penalty scores 
had even decreased between the two last versions whereas all others were regularly increased.   
The same update of penalty scores did not have a significant effect on interpretation 
of AZT resistances. It could therefore not explain the Geno-R/Pheno-S profiles observed for 
AZT. For ddI the constant increase of penalty scores for TAMs would even raise the 
percentage of discrepancies Geno-R/Pheno-S since some concordant patients diagnosed 
susceptible to ddI in 2002 and 2003 would be discordant in 2007. 
 
 
 
IV.2.2.2. Interpretation of TAMs through three algorithms 
 
I selected samples in PhenoBase® from the years 2005 to 2007 which have at least 
three mutations among the main characterized TAMs (M41L, D67N, K70R, L210W, 
T215Y/F and K219Q/E). I re-interrogated three common algorithms used in diagnostics 
(ANRS, Rega and Stanford) with the sequence of each sample. The interpretation of 
resistance was done with the last updated version of each: Rega version 7.1 from March 
2007, ANRS from July 2006 and Stanford version 4.2.6 from December 2006. I compared 
the profiles of resistance for AZT, ABC, ddI and d4T, and the results obtained were grouped 
in three classes: concordance, major discordances (Geno-R/Pheno-S or Geno-S/Pheno-R) and 
minor discordances (Geno-I/Pheno-S or -R and Geno-S or -R/Pheno-I). Only AZT and ddI 
histograms are depicted as representative examples of NRTIs. 
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Figures 23 A-C. AZT resistance predictions of different algorithms (N = 92). 
 
 
Whatever the two genotypic algorithms compared for AZT resistance, we observed 
perfect concordance for samples containing at least five TAMs and more than 95% for those 
with four TAMs. Around 40 to 50% of discordances were seen for samples with three TAMs 
comparing each prediction two by two. For none of the comparisons major discrepancies 
were identified.  
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Figures 24 A-C. ddI resistance predictions of different algorithms (N = 92). 
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Like for AZT, the comparison between Stanford and Rega indicated any major 
discordances and the level of concordances was still high: around 80% (except for the 
samples with 5 TAMs, 30%). However, when ANRS was compared to one of the others, the 
maximal concordance was around 30%. Between ANRS and Stanford close to 40% of major 
discordances were observed for samples with four TAMs and 10% to 15% for those with 
three and five TAMs, respectively. The comparison of ANRS versus Rega showed also a 
high percentage of major discordances: 15% when samples were carrying three TAMs, 38% 
with four TAMs and 76% with five TAMs.  
 
For AZT, the three algorithms predicted the same impact of TAMs on resistance as 
the percentage of concordance was close to 100% (except for three TAMs). The minor 
discordances were all Intermediate/Resistant indicating anyway non-susceptible samples. 
 
In case of ddI they were less in agreement presenting many cases of major 
discrepancies which were all due to a resistance profile done by Stanford or Rega but a 
susceptibility to ddI through ANRS. This could be due to the fact that ANRS algorithm 
interprets the resistance according to the interactions between the panels of mutations. It 
would mean either that Stanford and Rega algorithms overscored the TAMs comparing to 
ANRS, or that additional mutations carried by samples with TAMs were negatively scored by 
ANRS, and not by the two others algorithms, leading to a lower penalty score.  
 
 
 
 
IV.2.2.3. Genotyping and rPhenotyping profiles for associations of TAMs  
  
The previous data showed the importance of the choice of algorithm to interpret the 
TAMs’ resistance to ddI (for AZT, genotypic profiles were similar for the three algorithms). 
Indeed, the same pattern of mutations could be interpreted susceptible to ddI by ANRS 
whereas Rega and Stanford predicted a resistance to this drug. For the samples previously 
selected (§ IV.2.2.2), a comparison of every genotypic interpretation with phenotypic results 
was performed to see if two methodologies were more concordant. All the discordances 
observed between the four methods were reported as a radar graph for easy visualisation 
(Figure 25). The scale of each radar represents the percentage of discordance observed 
between two tests (0, 20, 40, 60, 80 and 100%). From left to right the graphs correspond to 
samples carrying three, four or five TAMs. 
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Figure 25. Representation in “radars” of the percentage of discordance between 
ANRS, Rega and Stanford (Stfd) Genotyping and rPhenotyping for the NRTI ddI.  
 
 
In orange are depicted the discordance levels between genotyping algorithms and in 
brown the rPhenotyping/Genotyping discrepancies. Whatever the number of mutations, the 
highest percentage of discordance was noticed when rPhenotyping was compared to Stanford 
and Rega interpretations (around 80%) and similar results were observed between ANRS and 
Rega or ANRS and Stanford. Except for a virus with five TAMs, Stanford and Rega 
algorithms were in agreement for 72% to 87% of the analysis. The best correlation was 
shown between rPhenotyping and ANRS with 60% to 70% concordance.  
 
For clarity, the “tetrahedron display” allows to place all genotyping algorithms as one 
dimension (grey triangle) and the independent Phenotyping system as a third dimension (z 
axis). The above results are shown in Figure 26 with a tetrahedron model. 
 
 
 
 
 
 
 
Figure 26. Tetrahedron model of genotypic and phenotypic discordances shown with 
ddI. Small distance between Rega (R) and Stanford (S) shows a good concordance in 
opposite to far distances observed with ANRS (A). The tetrahedron summit corresponding to 
rPhenotyping is shift to ANRS point revealing a good agreement of these resistance tests and 
a high discordance with Stanford and Rega.    
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The ANRS algorithm takes into account the effect of each mutation on the others 
(antagonistic and synergistic interaction effects) which could be one of the explanations of 
the high degree of discordance with the two other genotypic interpretations and the great 
concordance with rPhenotyping. In chapter I, we saw that ddI and AZT were the two NRTIs 
with the highest percentage of discordance corresponding for 40% of them to major 
discordance Geno-R/Pheno-S. Therefore, the representation in the “radar graph” was done for 
AZT data (Figure 27). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27. Representation in “radar” of the discordance percentage between ANRS, 
Rega and Stanford (Stfd) Genotyping and rPhenotyping for the NRTI AZT.  
 
 
The data of the graph correspond to AZT resistance of all the samples presenting 
three, four or five TAMs. The level of discordance observed between rPhenotyping and 
Stanford Genotyping (60%) was similar comparing PhenoTecT results with either ANRS or 
Rega interpretations. The three algorithms used are in good agreement (more than 70%) and 
the discordance observed with rPhenotyping was equal whatever algorithm is compared.  
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IV.3. Discussion chapter II  
 
Drug resistance testing is now a fundamental tool regularly used for treatment of 
HIV-infected patients and approved by regulatory bodies in many countries. Actually, 
Genotyping and Phenotyping are the two HIV resistance tests available in Switzerland. 
However, discordances between diagnostic methodologies are not infrequent, and testing 
HIV-resistances to specific therapeutics does not derogate from this rule. Even using the 
same initial methodology e.g. obtaining viral sequences in a clinical sample may lead to 
conflicting diagnostic recommendations depending on the algorithm used for 
interpretation92,97,98. Therefore, it was the major aim of this study to analyse comprehensively 
the discrepancies observed between genotypic and phenotypic analysis. In this chapter, more 
particularly, the interest was on samples for which Genotyping predicts resistance to the drug 
whereas rPhenotyping did not. The results shown in this chapter are multiple and have to be 
discussed in connection with new data recently published on HIV resistance. 
 
The first working hypothesis to explain discordances Geno-R/Pheno-S – mainly 
observed for the NRTIs AZT, ddI, d4T and ABC – was the presence of viral mixtures. 
Several mutants were engineered with one to four mutations, and they were individually 
diagnosed by the Stanford algorithm and rPhenotyping as well as mixes of some of them. The 
mutations were selected to give a penalty score to AZT and d-drugs and, except for T69D, 
they belonged to the group of TAMs. The results showed easily the concordance between 
both methodologies for a virus carrying three or four of the selected mutations in cis. 
However, for a mix of single or double mutants the concordance disappears. These 
heterogeneous viral populations were misinterpreted resistant to AZT by Genotyping which 
principally adds the penalty scores of each mutation together without taking into account 
their presence on different HIV genomes. In the opposite, the PhenoTecT assay, which allows 
to measure ARV susceptibility of each individual virus species, diagnosed them susceptible. 
Viral mixtures could be one of the explanations to the discrepancies Geno-R/Pheno-S. 
However, on a small subset of “obvious samples” – carrying at least nine characterized 
mutations – it could not be verified. Indeed, in these discordant samples, one or more viral 
strains carrying enough mutations to be genotypically resistant to AZT were identified and 
their phenotypic analysis was still showing a susceptibility to the drug. 
 
The selection of mutant plasmids to engineer was done prior to the availability of 
PhenoBase®, and I chose the most represented mutations in the samples Geno-R/Pheno-S for 
AZT and d-drugs. I did not consider how they were associated. In the meantime several 
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studies suggested the existence of two distinct clusters for the TAMs99-102. Mutations that 
occur together with T215Y, including M41L, L210W and sometimes D67N, constitute the 
TAM-1 cluster; mutations that occur together with K70R, including D67N, T215F and 
K219Q, constitute the TAM-2 cluster. The constructs done in this study turned out not to 
correspond with those clusters. It had been identified retrospectively by the interrogation of 
PhenoBase®. In fact, only few samples were found to present similar patterns but every time 
in association with additional TAMs. Unfortunately, our bank contained no single virus 
similar to those engineered. A phylogenetic tree was designed, based on the mutation patterns 
of the samples in PhenoBase®, to observe the pathway of the emergence of resistance 
associated mutations. Looking only to the emergence of TAMs, Figure 28 represents the tree 
starting with the mutation T215Y.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28. Phylogenetic profile of TAMs observed in patients diagnosed between the 
years 2002 and 2007. The percentages are calculated comparing the number of patients 
carrying the indicated mutations and the total number of patients having at least one TAM. 
 
 
This model illustrates the order of appearance of mutations associated with AZT 
resistance in the HIV-1 RT gene during therapy of asymptomatic individuals. A pathway 
appears from the repartition of TAMs in diagnosed patients. In yellow are figured out the 
most frequent combinations of TAMs found in PhenoBase®: mutation T215Y is often 
followed by M41L and subsequently by L210W and D67N (corresponding to the highest 
values). This outcome corresponds to the TAM-1 cluster described previously. The quadruple 
mutant T215Y-M41L-D67N-L210W had emerged in 53 samples. 
It would have been more appropriate to engineer mutant plasmids corresponding to 
such a pathway to validate the viral mixture hypothesis. Nevertheless the discordance of 
resistance profiles observed between Genotyping and rPhenotyping could not be explained by 
the cluster of TAMs.  
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The next hypothesis that could explain the different interpretations of resistance is an 
overscoring of TAMs by genotypic algorithms. Indeed, the Stanford algorithm updated its 
penalty scores for PR and/or RT mutations twenty three times between the years 2003 and 
2007 based on new clinical studies. Some initially non-characterized mutations appeared to 
be involved in resistance mechanism and some known mutations were also updated with an 
increase or decrease of their penalty scores. To see the impact of these changes over years, 
several combinations of TAMs were interpreted with different versions of the Stanford 
algorithm for ddI and AZT resistance. Whereas the updates modified the interpretation of 
resistance to ddI, no such evolution was observed for AZT resistance. Moreover the 
comparison of three algorithms – Stanford, ANRS and Rega – to analyse similar sequences 
reflects the complexity of providing a unique rendering. It further shows that related 
methodologies may yield a discordant profile of resistance as shown for ddI but not for AZT. 
The main difference observed was ANRS susceptibility versus Rega or Stanford resistance to 
ddI. The fact that ANRS algorithm considers the interactions between mutations with either 
synergistic or antagonistic effects could be one explanation.  
 
Recently, new studies showed that other resistance associated mutations could 
suppress the AZT resistance (Review articles Larder et al., 1994, Sluis-Cremer et al., 2000 
and Goldschmidt et al., 2004103-105). The mutation L74V alone confers ddI resistance but, 
when present with T215Y, it completely suppressed AZT resistance by reducing the extent of 
its removal by ATP-dependant phosphorolysis106-108. The NNRTI resistance mutations 
Y181C and L100I are also responsible of re-sensitisation to AZT when coexpressed with 
AZT-specific substitutions109-111. In vitro drug resistance studies have revealed yet two other 
RT mutations, K65R and M184V, which reverse AZT resistance44,48,112-114. One of the 
patients selected for the dilution cloning, patient 6016764, was carrying several TAMs: 
K70KR, L210LW, T215Y/F and K219KE. The sequencing of eight clones and a parallel 
phenotypic assay revealed that the presence of different viral genomes was not the 
explanation to the discordance Geno-R/Pheno-S observed (at least one clone was carrying all 
the mutations). However, mutations M184V and Y181C were associated with these TAMs in 
eight and six clones, respectively. As mentioned above, their presence could decrease the 
level of resistance provided by the TAMs and lead to the discordant resistance profile Geno-
R/Pheno-S. To prove their possible role in the phenotypic susceptibility to AZT, I should 
revert them into wild type amino acids to observe an eventual increase in resistance. 
 
Just as a re-sensitisation to AZT can occur by interactions between TAMs and other 
mutations, another combination has been described as a mechanism of synergy to influence 
AZT resistance: mutations in the C-terminal domain of the RT may significantly enhance 
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clinical AZT resistance (E312Q, G335C/D, N348I, A360I/V, V365I and A376S). The 
proviral cassette used to generate a recombinant virus for the PhenoTecT assay does not 
allow measuring the influence of mutations in this connection domain of the HIV-1 RT since 
only the N-terminal region of the RT gene (amino acid 1 to 317) is derived from the clinical 
sample to be tested.  
Adapted versions of proviral cassettes should be considered to study by rPhenotyping the role 
of such interactions on AZT resistance. It could be interesting to reanalyse some discordant 
samples Geno-R/Pheno-S for AZT with this new version of PhenoTecT system to assess if it 
will influence the phenotypic result. An increase of the level of resistance would be expected. 
Besides, using a primer inside the RT gene, as it is in the actual format of the phenotypic 
assay, could lead to a preferential amplification of viral strains with perfect annealing unlike 
a virus carrying a mutation in the binding site of the primer. The latter viral genome will need 
a decreased annealing temperature to be amplified.  
In fact, the sample 4007559 contained a viral population carrying seven characterized 
RT mutations: M41ML, A98AS, K103N, M184MV, L210LW, T215SYT and G333E. The 
profile of resistance to AZT was discordant: Geno-R/Pheno-S with several double peaks in 
the electrophoregram indicating a mixed viral population. Fourteen clones were sequenced 
and they all missed the TAMs and the G333E. Two different viruses had A98S, K103N and 
M184V; and one of them had the additional mutation M230V, previously not detected in the 
cDNA sequence. Retrospectively, the recombinant provirus was also sequenced and a similar 
result was obtained: A98S, K103N, M184V and M230MV. These results show that 
sequencing of cDNA and plasmid preparation may yield two different genotypic profiles. A 
likely explanation of this phenomenon was a bias of primer R3525L used to amplify the RT 
gene. Figure 29 represents the alignment of cDNA sequences from sample 4007559 with the 
reverse primer R3525L. 
 
 
 
 
 
 
Figure 29. Alignment, using MultalinH, of the cDNA sequence from sample 4007559 
and the reverse primer R-3525L used for the amplification of RT gene. 
 
For cloning a primer R3525L was used which carries the restriction site NcoI. The 
cDNA sequence of the sample showed a double peak C/T (Y) in the region binding the 3’ end 
of the primer. This part of the primer is the more crucial for an efficient annealing. The 
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population with a cytosine was the most represented in the sample (higher peak) but, because 
of the mis-annealing with the primer, it will not be amplified. The alignment of the 
recombinant plasmid sequence with the primer R3525L showed a perfect match (data not 
shown) indicating that only minor species (with the thymine) could be amplified.  
For this clinical sample the genotypic profile was corresponding to a mixed 
population while the rPhenotyping was based only on a subpopulation selected by the bias of 
primer. I interrogated PhenoBase® to have an overview of the samples Geno-R/Pheno-S to 
AZT subject to present a similar result. Out of 75 samples, seven showed a mismatch with 
primer R-3525L (9.3%). This could have been avoided by using a redesigned primer derived 
from a more conserved region. It is difficult to define such region as HIV is highly 
polymorphic (subtypes, …) and rapidly mutates with time in any given patient. This is a real 
challenge for phenotypic assays. 
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V. Chapter III: Detection of clinically relevant 
HIV minority species 
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V.1. Basis for existing virus mixtures 
 
HIV infection is typically not caused by a single virus species but rather by a flurry of 
different populations of viruses that evolve independently and can overtime replace each 
other. In other words, while there may be one dominant strain of HIV, there is potentially an 
appearing, disappearing and even recombining of countless minority populations waiting for 
their selective advantage. This also means that HIV, at any time point, might have a library of 
several genotypes that it can select from and then use, in whatever capacity, for its own 
evolution. Different events could explain the presence of HIV multispecies in a patient 
sample: 
- Since HIV has a high rate of replication and the reverse transcriptase is not able to 
proofread nucleotide sequences during replication115, the genetic variability of HIV in a 
patient may be very high. During the course of viral replication, several mutations are 
accumulated leading sometimes to emerging drug-resistant mutations. The latter can replace 
the prevalent major virus, behaving as a reservoir from where new genotypes can be recruited 
depending on the pharmacological pressure; 
- Moreover, homologous recombination can occur when a cell is coinfected with two 
different but related strains. Indeed HIV, like all retroviruses, is “diploid” (each viral particle 
contains two RNA strands of positive polarity, each full length and potentially able to 
replicate). Typically both RNA strands in a retroviral particle derive from the same parent 
provirus. However, if an infected cell simultaneously harbours two different proviruses, one 
RNA transcript from each provirus can be encapsidated into a single "heterozygous" virion. 
When this virion subsequently infects a new cell, the reverse transcriptase may jump back 
and forth between the two RNA templates so that the newly synthesised retroviral DNA 
sequence is recombinant between that of the two parents116. All subsequent progeny virions 
will be of this recombinant genotype. Naturally occurring recombinant HIV strains have been 
found in infected patients in regions of the world where multiple genotypic variants 
cocirculate117; 
- Superinfection is defined as the reinfection of an individual who already has an 
established infection with a heterologous HIV strain. Worldwide, 16 cases of HIV-1 
superinfection in humans have been reported since 2002118. One of the viral strains could 
persist at a low level until viral evolution, drug treatment, or host immunity results in a fitness 
advantage for the minority strain.  
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Usually resistance development is a slow process, as it can take numerous rounds of 
replication and competition among the diversified strains to render one variant that has a 
strong survival advantage compared to other variants in the presence of the antiretroviral. 
Often the virus has to undergo several genetic changes in a target gene in order to evade 
drug-pressure119,120. But in some cases, full resistance can also be almost instantaneous, 
achieved through a single amino-acid substitution. This is best exemplified by the Methionine 
to Valine change at position 184 of the reverse transcriptase gene leading to high-level of 
resistance (>500 fold) to the two drugs 3TC and FTC44,114,121,122; several single mutations at 
others positions provide full resistance to NNRTIs as K103N/S/T, V106M, Y181C/I/V (only 
DLV and NVP), Y188L, G190A/C/E/Q/S/V/T, M230L123-125. 
 
Most in vitro studies find the dynamics of viral replication greatly affected by the 
mutation M184V126-128, whereas in general the single mutations leading to NNRTIs resistance 
are not associated with reduced replication capacity129-131. Yet clinical and animal data are 
still somewhat conflicting on the impact on the course of infection in vivo, but it may be 
expected in accord with the “survival of the fittest principle” that drug pressure will drive 
resistant variants, even when initially present only as small proportions, to outgrow a drug-
susceptible wild type. A number of reports132-136 have mostly retrospectively shown this for 
clinical situations, where individual mutations could be associated with loss of drug efficacy 
(such as NNRTI failure following a K103N change in RT). Treatment failure to an inhibitor 
with the necessarily preceding presence of low percentages of the mutant virus was taken as 
indication for retrospectively searching for the respective mutation in plasma samples already 
prior to overt clinically therapy failure. At present such minority species cannot be detected 
early enough through conventional techniques such as single-cycle Phenotyping or 
population-sequencing analysis (detection limits around 15%)137,138. A recent report then was 
able to demonstrate direct detection of a resistant virus by real-time PCR of the protease 
mutant D30N in clinical specimens that had remained undetectable by Genotyping139. A 
highly sensitive detection e.g. by allele-specific PCR is therefore principally applicable but 
the essential design of the discriminating primer requires precise knowledge of the mutation 
to be found. Yet the large number of possible relevant mutations in the target genes of 
interest, PR, RT, and others to come, renders the methodology out of reach for routine 
diagnostics. Nevertheless it would be desirable for optimal clinical management of therapy 
resistance and for most effective treatment to overcome these limitations possibly reflected 
also in discrepancies between certain genotypic profiles (i.e. apparent absence of mutation) 
and accompanying clinical course (i.e. early viral escape and eventually treatment failure). As 
alternative, a replicative Phenotyping provides drug monitoring through several cycles of 
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viral replication, which mimics the dynamics of the corresponding virus inside the patient. 
Thereby it ought to be able to reveal the presence of minority resistant species outgrowing 
drug pressure. Indeed, the format of the PhenoTecT system allows each single virus to 
replicate separately and to infect new cells. Whereas the major population, susceptible to the 
antiretroviral agent, will stop replicating, the drug- resistant minor variant will continue to 
multiply. Even with high concentration of drug a viral population will still be detectable after 
four days of replication and interpreted as resistant virus species. Suspecting a resistant 
minority species, the replicative phenotypic determination of resistance would be discordant 
to the genotypic prediction of susceptibility: Geno-S/Pheno-R (Figure 30). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30. Schema illustrating a viral mixture with ARV-resistant minority species. 
 
 
The primary objective of this chapter is to demonstrate the properties of rPhenotyping 
as “sensitive direct methodology for the detection of viral minorities in clinical samples” and, 
if so, to confirm the result by profiling the same original samples with most sensitive 
adaptations of genotyping methods such as allele-specific PCR and real-time PCR. First, 
distinct samples will be selected in PhenoBase® for which no mutation at position 184 of RT 
gene was detected following population-based sequencing despite the phenotypic assay 
indicated a resistance to 3TC. In a second step, allele-specific PCR methods and real-time 
PCR will be performed on these specific samples to identify and quantify 184V HIV variants, 
in order to confirm the phenotypic outcome. 
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V.2. Results chapter III 
 
V.2.1. Sensitivity of the replicative format of PhenoTecT 
 
The limit of detection of the rPhenotyping system was first determined for the fitness-
affecting mutant 184V (in parallel the single mutant 103N was also tested, data not shown). 
A wild type reference plasmid was point-mutagenised, and defined mixes of wild type and 
mutated plasmids were evaluated for their sensitivity against the study drug 3TC and the 
unrelated RT inhibitor AZT as control as its susceptibility should remain unaffected by the 
mutation M184V; SQV as control-PI should also retain full drug activity on both isogenic 
viruses. Mixes were denoted according to the respective proportion of mutated virus they 
contained: 0% (pure pNL4-3 reference), 0.1%, 0.3%, 1%, 3%, …, and 100% (solely the 
184V-mutant). Following four-days of viral replication, the reporter gene activity (β-Gal) was 
determined and expressed as percent of viral production. Figure 31 shows inhibition curves 
with the percent inhibition of viral replication plotted as a function of drug concentration. 
Results were confirmed in three independent experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31. Drug susceptibility of mixed populations of replicating HIV-1.  
The main graph shows the inhibition curves of viral replication for wild type alone (light 
green), 1% (dark green), 3% (purple), 10% (blue), 30% (orange), 50% (red) and 100% of 
184V (brown). The reference IC50 is indicated as green dashed line. The corresponding 
inhibition curves in the presence of AZT (top) or SQV (bottom) are shown on the right (wild 
type curve in light green). 
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Inhibition curves demonstrated that, whereas for the non-respective control drugs 
AZT and SQV increasing amounts of mutant 184V had no impact on the inhibition (graphs 
“AZT”, “SQV” on the right), the 3TC inhibition curve was significantly altered as soon as ≥ 
1% of the viral population was contributed by the 3TC-resistant mutant. The IC50 values are 
summarised in Table 11 with the Rf as the ratio between the IC50 of the sample and the one of 
the wild type. 
 
 
 
Wild type 1% 3% 10% 30% 50% 100% 
IC50 (nM) 354 1240 12’732 22’576 498’790 478’915 485’971 
Rf 1 3.5 36.0 63.8 1’408.9 1’352.7 1’372.7 
 
Table 11. IC50 values and Rfs for the wild type, the single mutant 184V and mixed 
populations. “x%”: percentage of mutant 184V. 
 
 
This finding is pinpointed in the representation shown in Figure 32 with the 
comparison between mixes re-calculated a Rf.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32. Sensitivity of PhenoTecT.  
Rfs for wild type (0%) and mixes with 184V (“x%” as indicated) are plotted for 3TC (blue 
bars), and two non-affected controls, for RTI (AZT, hatched bars) or PI (SQV, yellow bars). 
 Chapter III 
 
 
 
90 
The link of the resistance factor to an established clinically diagnosed resistance 
allowed to define a threshold (“cut-off”) value for this Rf, above which a virus is statistically 
considered non-susceptible. The calculated cut-off for 3TC is 3.0 (Figure 32, dashed line), 
indicating that in the PhenoTecT system already a proportion of 1% of mutant 184V in the 
mixed virus population yielded a relevant “decrease in susceptibility” to 3TC (intermediate). 
At low percentages of mutant the histograms of Figure 32 follow a dose-response trend as 
increasing proportions of mutant in the defined mixes result in increasing values for the 
calculated Rfs. This value reaches the plateau of full resistance once 30% of the viral 
population is contributed by the resistant variant. Of note, the resistance factors for the 
control drugs AZT and SQV remained unchanged across the entire range of mixtures. Of 
concern was a potential bias arising from possible effects of an altered replication capacity of 
the virus; however, this could be excluded as in the assay format of PhenoTecT a reduced 
replication (lower viral fitness) solely results in a lower absolute optical density but not in a 
shift in the IC50 as parameter of inhibition (in PhenoTecT the absolute readout for 184V was 
80% of the wild type). 
 
The identical mixes were in parallel subjected to genotypic assessment. The presence 
of the mutation M184V as a significant peak was confirmed unequivocally only when the 
mutated provirus represented ≥ 30% of the mix (not shown). 
 
 
 
V.2.2. Limit of detection of minorities by allele-specific PCR 
 
I next set out to define the technical lower limit of detection for a mutant virus within 
mixes. Interrogating PhenoBase® for the samples Geno-resistant to 3TC, the resulting list of 
mutations indicated that the sole change responsible of this resistance was mutation M184V 
in the RT gene (in 100% of the samples resistant to 3TC). The analysis of the sequences 
showed that, out of 291 patients, 89% had a Valine at position 184 in the RT gene, which was 
encoded by a GTG (instead of the Methionine ATG); 3.1% had a RTG meaning a mix of wild 
type ATG and mutant GTG. All together 92.1% of the patients presented a viral population 
resistant to 3TC due to a GTG codon at position 184. The others were subdivided into two 
categories: 6.9% had a GTA codon and 1% a GTR. Based on these data, the detection of 
mutant resistant to 3TC was attempted for those having a GTG codon at position 184 of the 
RT. 
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An allele-specific PCR methodology was adapted. Two oligonucleotides (R-RT184M 
and R-RT184V) were designed to carry at their respective 3’ termini a nucleotide specific for 
one or the other variant to be discriminated.  
 
R-RT184M:  5’cagatcctacatacaaatcatccat 3’   specific to the wild type 
     184M 
 
R-RT184V:  5’cagatcctacatacaaatcatccac 3’   specific to the single mutant 184V  
     184V 
 
 
The PCR was done on the wild type and mutated plasmids with a common forward 
primer D-2213B and either one of the two reverse primers separately. The melting 
temperature of these primers being approximately 59°C, it was recommended to test different 
annealing temperatures close to this value in order to maximise the specificity of 
amplification. Three different annealing temperatures were tested: 55°C, 58°C and 61°C. For 
each annealing temperature four PCR reactions were performed: wild type plasmid (green 
virus form) with either “wild type” primer R-RT184M (green dot) or “mutated” primer R-
RT184V (red dot) and 184V mutant plasmid (red virus form) with both primers as well. 
Figure 33 shows an amplification product for each condition. It confirms like in the literature 
that one unique mismatch at the 3’ end of the reverse primer is not sufficient to discriminate 
unspecific from specific amplification even with increased annealing temperature.  
 
 
 
 
 
 
 
 
 
 
Figure 33. Allele-specific PCR optimisation with reverse primers mutated at the 3’ 
end. In green are represented the template and the primer wild type, in red the template and 
the mutated primer. aT: annealing temperature; M1kb: Size Ladder. 
 
In an optimised protocol, the wild type template should be amplified only with the R-
RT184M primer whereas the R-RT184V primer should only amplify the 184V mutant. Korn 
et al. had described that the addition of further non-critical mismatches greatly contributes to 
PCR discrimination between the two specific sequences89. The two primer sets of this study 
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were further optimised by the addition of three internal mismatches to selectively amplify 
either one of the fragments containing 184M or 184V, respectively.  
 
 
R-RT184M3:  5’cagatcgtacatatgaatcatccat 3’   specific to the wild type 
     184M 
 
R-RT184V3:  5’cagatcgtacatatgaatcatccac 3’   specific to the single mutant 184V  
      184V 
 
The allele-specific PCR reaction was repeated with the new sets of primers under the 
same conditions as the previous (as annealing temperature 65°C was implemented). Figure 34 
shows the amplification products obtained at 62°C and 65°C.  
 
 
 
 
 
 
 
 
 
 
Figure 34. Allele-specific PCR optimisation with reverse primers mutated at the 3’ 
end and carrying three internal mismatches. In green are represented the template and 
primer wild type and in red the template and primer mutated. 
aT: annealing temperature; M1kb: Size Ladder. 
 
The addition of three mutations in the middle of the primer sequences destabilises 
hybridisation and increases the binding specificity. At 62°C it was possible to specifically 
amplify the wild type template with the primer R-RT184M3 and not with the R-RT184V3, 
the opposite was true for the mutated plasmid. The absence of amplification of wild type with 
mutant primer or mutant with wild type primer served as validation.  
 
As starting material for the determination of the limit of detection, the defined 
proviral mixes (see part V.2.1.) were used in the conditions described above. Figure 35 shows 
the amplification products, demonstrating that the primer specifically designed for solely 
amplifying the mutation M184V allows its detection down to 0.3% in a mixture with wild 
type. The corollary was similarly valid for the sensitivity of wild type detection by the 
specific reciprocal primer. 
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Figure 35. Discrimination power of mutation-specific PCR. 
Aliquots of precise in vitro mixes of wild type and mutant 184V as indicated in the above 
graph were amplified using a primer set for wild type (184M3, top graph) or mutant (184V3, 
bottom graph) and analysed by gel electrophoresis. M: Size Ladder (1kb). 
 
 
 
Subsequently a series of patient samples identified by their discordances of 3TC 
resistance interpretations between Genotyping and rPhenotyping were tested under the same 
conditions. The underlying hypothesis was that they might contain minor variants within a 
dominant wild type sequence. In the more recent samples from the year 2005, 18 were 
diagnosed Geno-S/Pheno-I or -R. I selected seven of them (A to G) as representatives of all 
relevant subtypes, fitness and 3TC treatment history. In the aforementioned group of 18 
samples, 39% were B subtype, 22% AE subtype, 17% AG subtype and 11% F subtype. I 
chose three samples with B subtype virus (A, D and G), two AE subtype (C and F), one AG 
subtype (B) and one F subtype (E). By rPhenotyping, their viral fitness had been estimated 
either low (e.g. 23% for sample C) or high (e.g. 100% for samples B and G) compared to the 
reference. These samples were all corresponding to patients in therapy failure which were 
either currently under 3TC treatment, previously treated with this drug, or never treated.  
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The different parameters are resumed in Table 12. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 12. Clinical parameters of the seven patients in this study. 
VL, Virus Load; nd, not determined.  a “in past” = previous treatment, not currently used. 
 
 
Figure 36 clearly demonstrates for the original viral populations isolated from each 
one of five discordant patient samples that the expected mutant fragment could be selectively 
amplified with the mutant-specific primer whereas the amplification reaction using the wild 
type control plasmid stayed negative. In contrast, initial Genotyping had given no evidence 
for the alteration. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36. PCR quantification of virus from discordant patient plasmas.  
The PCR products from seven patient-derived viruses were analysed by electrophoresis 
following amplification with the 184V3-mutant primer set (lanes A-G). ”NL4-3” and “184V 
mutant” are included as respective control lanes. M: Size Ladder (1kb). 
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This strongly suggested that in the authentic clinical plasma samples (A, B, C, D and 
G) indeed the HIV-1 mutant 184V had already been established. Further support for the 
relevance of this amplification came from applying the same PCR amplification protocol to 
three randomly selected specimens from patients diagnosed as 3TC-susceptible by Genotype 
and PhenoTecT. In all cases the protocol failed to produce a mutant-specific band on these 
RNAs (data not shown). 
 
 
 
V.2.3. Quantitative detection of minority populations with mutated 
sequences in clinical samples  
 
To quantitatively estimate the proportion of 184V variant in patient blood, I 
developed a real-time PCR protocol distinguishing between wild type and 184V-mutant. A 
selective Sybrgreen assay had to be designed for overall quantification. A set of primers was 
utilised, for which the ∆Ct between specific and non-specific annealing should be maximal 
(e.g. for mutant-specific primer: between 184M and 184V templates). The first step was the 
assay development because no assay conditions were established for the machine available in 
the lab (Corbett instrument: Rotor-Gene™ 3000). I had to optimise different parameters on 
known templates (NL4-3 and single mutant 184V) before adapting the tool for the discrepant 
samples Geno-S/Pheno-R to 3TC. The DNA used as a template of qPCR was a PCR product 
obtained from the amplification of the wild type and mutated plasmids with the primers D-
1818 and R-3584. A purification step was done prior to the real-time PCR either by gel 
extraction with Macherey-Nagel columns or directly on Microcon YM-100 Centrifugal 
Filters. 
 
 
• Design of the specific primer: 
 
Based on the allele-specific PCR results, I started to test the two sets of primers carrying a 
mismatch at 3’ end and those with the addition of three internal mutations. A forward primer 
F-3005 was designed in a conserved region at a distance of one hundred nucleotides upstream 
of the position 184. Figure 37 shows at the top the amplification of wild type (1) and 184V 
mutant (2) templates using the wild type primers R-RT184M (a) and R-RT184M3 (b); and at 
the bottom the same templates amplified with the mutant primers R-RT184V (c) and R-
RT184V3 (d). 
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Figure 37. qPCR optimisation with diverse couples of primers where the fluorescence 
is a function of the number of cycles. On top are represented the amplification curves using 
the specific primer 184M versus 184M3 on wild type and mutant templates; on the bottom 
are the curves corresponding to the specific primer 184V versus 184V3 on mutant and wild 
type templates. 
 
The top graph illustrates the discrimination observed between specific and unspecific 
amplification with the wild type primers. A threshold was fixed at 0.2 units of fluorescence. 
The first curve to appear was corresponding to the amplification of the wild type template 
with the primer R-RT184M and it crossed the threshold line at 14 cycles (Ct = 14) (dashed 
arrow). The next curve represented the amplification of mutant template with R-RT184M at 
Ct = 18. The difference between authentic and inauthentic priming is calculated as the 
distance between the Ct observed, called ∆Ct, and is reflecting the discriminatory ability. 
Using primer R-RT184M the ∆Ct value was equal to 4. The introduction of three internal 
mutations in this primer, R-RT184M3, destabilised binding, leading to a right shift of the 
curve (Ct of the wild type template = 30, instead of 14). This modification increased also the 
specificity of binding as revealed by the higher ∆Ct equal to 8 (30→38). Similar results were 
5 9
6 12
 Chapter III 
 
 
 
97 
observed with the mutated primers R-RT184V and R-RT184V3. The addition of internal 
non-critical mutations increased the number of threshold cycles (∆Ct) from 6 to 12. 
The significantly improved discrimination between the wild type sequence and the 
mutant 184V by the use of R-RT184V3 was required to easily distinguish low percentage of 
mutant in wild type background. 
 
 
• Annealing temperature: 
   
The experimental conditions were optimised and validated using different annealing 
temperatures with the set of primers F-3005 and R-RT184V3 on the 184V mutant template at 
five or three concentrations (Figure 38). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 38. qPCR optimisation with diverse annealing temperatures: 62°C on top, 
60°C in the middle and 57°C on the bottom. 
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The absolute amount of template in the reaction ranged from 4000 pg to 250 pg final 
with 2 fold dilutions. Indifferently for the three conditions, the order of apparition of the 
curves corresponded to the initial amount of template used (increase of Ct with a decrease of 
DNA template). Interestingly, the delay before the occurrence of the first curve declined with 
the decrease of the annealing temperature: the first dilution had a Ct of 37 at 62°C, 25 at 60°C 
and 20 at 57°C (dashed arrows). The shape of the curves was also better at 57°C. The choice 
to test 57°C was made following specific advice by the machine manufacturer. The optimal 
temperature to use should be between 3 and 6 degrees less than the Tm of the primers. Except 
at 62°C, the highest template concentration produced a curve’s shape which was too flat 
comparing to the others indicating that the amount of starting template was also crucial for an 
optimal amplification. 
 
 
• Template quantity: 
 
As shown in the previous part, the amount of DNA template could influence the shape of the 
amplification curves. Five quantities of 184V mutant were amplified with the R-RT184V3 
primer at 57°C (Figure 39). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 39. qPCR optimisation with five different amounts of DNA template (184V 
mutant): 5000 pg, 3500 pg, 2000 pg, 1000 pg and 200 pg. 
 
 
The highest concentrations, 5000 and 3500 pg, generated flat curves whereas between 
2000 pg and 200 pg the curves had a similar shape and the ∆Ct were reflecting the difference 
of template quantity. 
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As fourth parameter the size of the PCR product of the real-time PCR reaction was 
naturally assessed (data not shown). The results indicated that an optimal result was obtained 
for PCR product size between 100 and 150 bp. The efficiency of the qPCR was higher when 
the PCR amplicon had a size of 120 nucleotides compared to one of 150 nucleotides (with the 
primers F-3005 and R-3151). With the couple of primers used to detect the mutation M184V 
(F-3005 and R-RT184V3), the size was exactly 118 bp.  
      
 
The same conditions were then applied for deliberate mixtures of NL4-3 and mutant 
184V at different ratios in order to discriminate minority species from non-specific annealing. 
The mix was performed with PCR products obtained with the primers D-1818 and R-3584. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 40. Real-time PCR on mixed populations of wild type and 184V mutant. The 
amplification was performed at 57°C with the primers F-3005 & R-RT184V3. The 
fluorescence, representing the amount of DNA, is plotted as a function of cycle numbers 
(linear scale). 
 
 
In the graph above the first curves to appear were, as expected, for the highest 
percentage of mutant 184V; the last curves represented the lowest mutant percentage. The 
system could easily quantitatively distinguish with high discrimination minor populations 
from each other: all mixes containing between 0.1% and 30% mutant were detected. On the 
other hand, once the target virus constituted >90% of a mixed population the mutant-specific 
primer for 184V reached the upper limit of resolution of the system (data not shown). 
The respective threshold cycle for a first detection of a PCR amplicon for the 184V 
mutant was plotted as a function of the relative proportion of mutant 184V in a defined mix 
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(Figure 41). Each calculation was adjusted for the absolute quantity of a viral population 
present in the reaction by means of a second, parallel PCR using primers in regions isogenic 
for both proviral plasmids (F-3005 and R-3123). The primer R-3123 is similar to the R-
RT184V3 without the last nucleotide at the 3’ end. 
 
 
 
 
 
 
 
 
 
 
 
Figure 41. Real-time PCR results plotting for precise in vitro mixes of wild type and 
mutant the threshold value as function of the relative amount of mutant 184V. 
 
 
 
The results showed that the ∆Ct between 0.1% and 0% mutant was still more than 
two cycles and therefore discernable. This demonstrated reliable and quantitative 
identification even of small sub-populations in a mixed HIV sample. These data were 
conversely verified further by using a primer pair specific for detecting and quantifying small 
amount of wild type in a mixed sample with mutant virus (not shown). Using multiple repeats 
of duplicate determinations, as described by Hance et al.90, a lower limit of sensitivity was 
determined using pure wild type (“0% mutant”) with the mutation-specific primer pair: wild 
type and mutant could not be discriminated anymore once the mutant constituted in a mix 
less than 0.02% ± 0.03% (mean ± 2SD, n=9). These values correlated well with those 
previously reported for protease90: cut-off value of 0.05%, above which a sample was 
considered positive for a mutant.  
  
 
The settings established by this in vitro validation were applied to the five discordant 
patient samples which had already been validated as containing 3TC-resistant minority 
species by allele-specific PCR (Figure 42).  
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Figure 42. Real-time PCR on mixed populations of wild type and 184V mutant and on 
four patient samples. The amplification was performed at 57°C with primers F-3005 & R-
RT184V3. The fluorescence, representing the amount of DNA, is plotted as a function of cycle 
numbers (logarithmic scale). In red: patient G, in green: patient C, in yellow: patient D and 
in purple: patient A.  
 
Like for the range of precise in vitro mixes between wild type and mutant 184V 
(Figure 43, inset graph), the respective threshold cycle for the first detection of a PCR 
amplicon for the 184V mutant was plotted as a function of the relative proportion of mutant 
184V in a defined mix (Figure 43). Each calculation was adjusted for the absolute quantity of 
a viral population present in the reaction by means of a second, parallel PCR using primers in 
regions isogenic for both proviral plasmids. 
 
 
 
 
 
 
 
 
 
 
Figure 43. Real-time PCR results plotting for precise in vitro mixes of wild type and 
mutant and for four patient samples the threshold value as function of the relative amount of 
mutant 184V. Pat: Patient. 
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I was able to demonstrate the presence of 3TC-resistant viral species in four authentic 
clinical samples. The percent mutated sequences in the circulating pool of viruses in the 
studied patients were calculated each by duplicate determinations in four independent 
experiments. Analysis of plasma samples from patients A, C, D and G verified indeed the 
presence of the 184V-mutant in the original specimen (Table 13).  
 
 
 
 
 
 
 
 
 
 
 
Table 13. Threshold cycles for deliberate HIV mixes and for patient samples. 
From the titration curve depicted above, key values were extracted to show expected versus 
measured percentage of mutant in mixed populations (top part of table), and to quantify the 
relative amount of mutant virus in patient-derived samples G, C, D, A. 
 
 
The relative abundance of a mutant behind a wild type background was 0.25%, 
0.53%, 0.85% and 1.5% (average of 4 experiments in duplicate) for patients A, D, C and G, 
respectively. The low abundance of mutant either hints an early phase of emergence of 
mutant 184V in these clinical samples or indicates resistant viruses persisting after cessation 
of 3TC treatment. For the fifth sample, patient B, no 184V mutant could be called. Ct curves 
for quantification (non-mutant primers) were shifted to the far right and were shallower in 
shape, possibly indicating suboptimal annealing. The mutant-specific amplification curve 
could not be separated from the curve of <0.01% mutant. As a result the data could not be 
interpreted for resistance determination. This could happen e.g. in case that further mutations 
in the respective primer regions occurred.  
 
 
template-specific primer mutant-specific primer
100% 15.85 25.66 100.00
30% 15.68 28.12 24.88
10% 14.96 28.95 9.97
3% 14.21 30.02 3.02
1% 15.44 32.26 0.91
0.3% 14.74 33.38 0.28
0.1% 15.79 35.28 0.10
0% 16.41 37.82 0.02
G 17.12 32.63 1.51
C 19.97 35.34 0.61
D 17.84 34.45 0.50
A 15.72 34.16 0.23
threshold cycle (Ct)
samples % M184V 
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V.2.4. Case Report 
 
One female patient, who had been diagnosed with HIV-1 in September 1996, 
displayed a viral load of 70’004 RNA copies/mL and a CD4 count of 293 cells/mL (12% 
CD4) at baseline before starting treatment. Genotypic resistance testing was performed and 
indicated the presence of a subtype B strain with resistance mutations V179I within the RT, 
M36I and L63P within protease (interpreted according to the Stanford DB v.3.8 algorithm). It 
resulted in a resistance score of 4 for all the PIs but a null score for the RTIs. In parallel, 
rPhenotyping also diagnosed a fully susceptible virus and therefore the combination TDF + 
3TC + NVP was started in November 2003. Two years later, no response was observed 
despite good adherence to therapy. Resistance testing showed the acquisition of the mutations 
K65R, Y115F, Y181C and M184V within the RT, conferring resistance to TDF, ABC, NVP 
and 3TC, respectively. The same resistances were observed by rPhenotyping. The follow-up 
of the patient is described in Figure 44. Therapy was changed to 3TC monotherapy at month 
27 (arrow head in Figure 44) but no information on the clinical reasons was available. This 
step resulted in a continuous virological increase and a decline of the immunological 
response. In December 2006 (month 39), the viral load was detected at 6’472 RNA 
copies/mL. After a new HIV resistance test showing 3TC and NVP resistance (only by 
rPhenotyping for the second), a third-line regimen was started with the combination 3TC + 
AZT + LPV/r. Clear virologic response was indicated by an immediate drop in VL to 40 
RNA copies/mL after the first month of third-line therapy. 
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Figure 44. Follow-up of the patient. The history of CD4 count, viral load and therapy 
are depicted (the first month corresponds to October 2003). Below the graph, the presence of 
the wild type and/or mutant amino-acid at resistance-associated positions within RT as 
observed by population-based sequencing of the corresponding samples is displayed. The 
mutations M36I and L63P in the protease gene did not lead to resistance to PIs. The 
genotypic (G) and phenotypic (P) interpretations are represented for each drug having a 
decrease in susceptibility during treatment. Three levels of resistance are depicted: 
susceptible (green), intermediate resistance (yellow) and resistance (red).  
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After the cessation of TDF treatment at month 27 (arrow head in Figure 44), a mixture 
of the wild type (K) and mutant (R) amino acid at the RT position 65 was already observed 
three months later (small peak corresponding to the wild type codon and a high peak for the 
mutant, month 30 in Figure 45). For each genotypic resistance determination, an 
electrophoretic representation corresponding to the region of amino acid 65 in the RT gene is 
shown in Figure 45. At month 33, only a small peak indicating mutant amino acid (R) was 
depicted on electrophoregram. One year after the therapy change, a pure wild type was 
detected at position 65 of the RT indicating apparent TDF and ddI susceptibilities.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 45. Electrophoregram representing a part of the RT gene from the patient’s 
viral population showing mixed amino acids at position 65.  
Genotypic determinations of HIV resistance was performed: just before to start a first-line 
treatment (month 1), after two years of tritherapy (TDF + 3TC + NVP) (month 25), after 
starting a 3TC monotherapy (months 30 and 33) and one year after beginning the second-line 
treatment (month 39). 
 
 
Similarly, at position 115 of the RT the mutant amino acid (F) slowly disappeared 
(month 33) to be replaced by pure wild type (Y) at month 39 leading to ABC susceptibility 
(electrophoregrams not shown).  
 
Genotyping and rPhenotyping of the patient samples were in good agreement for the 
detection of resistance to 3TC, ABC and ddI at any resistance test. This was not the case for 
the two antiretroviral agents TDF and NVP.  
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In case of TDF resistance, genotypic and phenotypic interpretations concluded as 
intermediate resistance at month 25 but since the mixture of wild type and mutant 65R was 
pinpointed by genotypic analysis (months 30 and 33), the PhenoTecT system did not reveal 
resistance to TDF. A study had been done on pre-defined mixture of wild type and 65R 
mutant plasmids to detect the resistance to TDF by rPhenotyping (data not shown). Only a 
pure mutant population was detected resistant whereas the different mixes were all 
susceptible to the drug. A possible explanation to the non-detection of the 65R variant present 
in a viral population with wild type virus could be its low fitness (20%) compared to the 
reference140-142. Due to the format of the phenotypic assay, the transfection of the first cells, 
before further incorporation of ARV, will generate a high background of fit wild type virus 
which will prevent the good detection of the new TDF resistant minority species.  
 
Concerning the mutation Y181C, one year after the stop of NVP therapy it was not 
detected anymore by Genotyping but the PhenoTecT system was still able to detect a 
resistance to NVP (black arrow). Looking to the electrophoretic peaks at months 30 and 33, a 
wild type variant was appearing whereas the 181C variant declined progressively, as shown 
with the mutant 65R. Therefore, the discrepancy observed between Genotyping and 
rPhenotyping at month 39 could be explained by the persistence of NVP-resistant HIV-1 
species in the viral population at a level non-detectable by population-based sequencing (less 
than 15%).  
 
To demonstrate the relevance of the 181C minority species in the discordant patient 
sample at month 39, an allele-specific PCR was adapted to the Y181C mutation in the same 
way as for the detection of minor 184V variants. A reverse primer R-RT181C3 was designed 
to carry at its 3’ terminus one nucleotide specific of the variant to be discriminated and three 
internal additional mutations. In PhenoBase®, the mutation Y181C is in 92.1% due to the 
substitution of the codon TAT (Tyrosine) to TGT (Cysteine). It is also the case of this patient; 
this is why the primer designed was carrying a Cytosine in 3’ end. The forward primer used 
was D-2232. The optimisation was done on known mixes of wild type (NL4-3) and 181C 
mutant plasmids (Figure 46, right part). An unspecific amplification was observed for a 
product of approximately 1600 bp. By alignment of the primer sequence with the reference 
NL4-3, I discovered that the last nine nucleotides in the 3’ end could also anneal at the C 
terminal region of RT (around the amino acid 415). This annealing will provide a PCR 
product of 1590 bp which corresponds to the band observed on the agarose gel. The expected 
amplification product had a size of approximately 900bp (black arrow on the left). 
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Figure 46. Mutation-specific PCR of precise in vitro mixes of wild type and mutant 
181C (right side) and of plasma from the patient (left side, lanes A-D).  
Sample A was diagnosed at month 25, sample B at month 30, sample C at month 33 and 
sample D at month 39. The PCR products were analysed by electrophoresis following 
amplification with the 181C3-mutant primer (annealing at 62°C). M: Size Ladder (1kb). 
 
 
The percentages indicated on the top of the gel picture correspond to the proportion of 
mutant plasmid in the mix. The 0% (pure wild type) was not amplified validating the 
specificity of the amplification. The detection of mutant 181C was possible down to 1% in a 
mixture with wild type. In parallel four patient samples tested previously by genotypic and 
phenotypic assays were also amplified under the same conditions. The protocol revealed the 
presence of the 181C variant in all samples A, B, C and D with a poorer amplification for the 
last. The three former had been already interpreted resistant to NVP by the Stanford 
algorithm based on the presence of the mutation Y181C. But for the latter, sample D, no 
Y181C mutation had been detected at the time of population-based Genotyping while 
rPhenotyping had diagnosed a resistance to NVP. The amplification of sample D by a 
sensitive mutation-specific PCR confirmed the phenotypic result and the presence of a 
persistent minor 181C variant in the viral population. The use of NVP in a future treatment 
scheme would lead instantaneously to the re-emergence of the 181C variant as a major 
species.  
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V.3. Discussion chapter III 
 
The earliest possible detection of HIV resistance is fundamental for the HIV infected 
patient in order to adapt an appropriate therapy preventing viral escape. Even patients never 
treated are more and more diagnosed for HIV resistance. Recent evidence suggests that 1 in 
10 new infections involve resistant strains of virus143. The standard genotypic resistance test 
is an easy and rapid methodology to detect the outbreak of resistance associated mutations. 
However, its low sensitivity is a limit to the detection of virus present at less than 15% of the 
total population as in particular clinical situations e.g. minor resistant species. These minority 
populations remain therefore undetected and can continue to evolve and ultimately emerge as 
dominant viral populations leading to a rapid failure of therapy.  
 
In this study we intended to demonstrate that a replicative format of rPhenotyping was 
able to detect the otherwise missed presence of relevant, drug-resistant minority species in 
clinical specimens. Such variants in authentic clinical samples could explain a part of the 
discrepancies Geno-S/Pheno-R observed between Genotyping and rPhenotyping. The 3TC-
resistant and NNRTIs-resistant variants are good examples to study as for these antiretroviral 
agents, and not for the others, the presence of specific single mutations results in a high-level 
of resistance. An independent technical proof of the presence or absence of these unique 
mutations being available by applying a highly sensitive allele-specific real time PCR 
protocol, it is possible to confirm the high sensitivity of rPhenotyping to detect minority 
species. In this study the 3TC-resistant variant 184V was specifically used since it is the 
unique mutation responsible for this resistance. In case of the NNRTIs, several individual 
mutations exist, that can lead to resistance and which could underline the presence of 
minority species. The highly sensitive rPhenotyping answer may be of general utility for 
diagnostic use as the methodology does not require an algorithmic interpretation and is 
thereby principally applicable with no difference between the drug classes. For such special 
cases the substantial gain in sensitivity might merit the principally more complex format of 
Phenotyping. 
 
Seven patients discordant Geno-S/Pheno-I or -R for 3TC were selected in 
PhenoBase®. By a first methodology, mutation-specific PCR, five of these patient samples 
were identified as presenting 3TC-resistant variant 184V. An allele-specific real-time PCR 
confirmed in a second time the presence of such variants in four of them. When linking the 
findings of this study to treatment history as listed in Table 12 (see page 94) this further 
confirmed that a resistance to 3TC had either arisen only recently, currently in ‘statu 
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nascendi’ or as non-prominent virus representatives e.g. (still) restricted to a putative small 
compartment (patients A, C, D). In contrast, previous therapy episodes with 3TC e.g. for 
patient G suggest that resistant viruses had been selected during this time and were still 
detectable months after discontinuation.  
 
As indication for therapeutic failure, the selected patients presented detectable plasma 
virus loads between 2’400 (F) and >100’000 c/mL (A). The persisting mutant viruses were 
therefore likely to in part contribute to the unsuccessful viral suppression. In contrast, for the 
sample from patients E no 184V virus was detected, and, according to the treatment record, 
this patient had never received 3TC. This very case might illustrate the limits of a PCR-based 
verification as such a protocol is only suitable for perfectly matching sequences. M184V-
based resistance to 3TC is mainly caused by an ATG to GTG transition (for >90% of all 
matching Geno-R/Pheno-R patients in the database). Nevertheless, a small proportion of 
patient-derived resistant viruses rather carry a GTA codon (Val). This double mutated codon 
(ATG→GTA) will be missed by the chosen strategy.  
 
Similarly mismatches in forward or reverse amplification primers will prevent PCR 
amplification. For the allele-specific PCR the forward primer was annealing in the P6 region 
upstream of the protease gene. The template used to perform this amplification was the 
recombinant plasmid carrying only a part of the RT gene from the patient. Therefore the P6 
gene was “wild type” for the seven isolates. In case of the reverse primers R-RT184V3 and 
R-3123 (similar to the R-RT184V3 without the last nucleotide at the 3’ end) they were 
designed based on the sequence of the wild type NL4-3. It is likely that these two 
oligonucleotides did not hybridise to the HIV-1 targets of the patients E and F, because of a 
too high number of mismatches in the primer binding site. Indeed the sequence of subject E 
presented a mutation in codon 190 (GGG instead of GGA) and subject F had one in codon 
186 (GAC instead of GAT) (Figure 47). Although these mutations were identified in the 
major variant we can extrapolate that minor populations might carry them as well. This is 
probably the reason why no amplification was observed after allele-specific PCR for patients 
E and F. 
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Figure 47. Alignment with MultalinH of cDNA sequences corresponding to a part of 
the RT gene of patients A-G and the reference NL4-3 with the oligonucleotides F-3005 and 
R-3123. The nucleotides in pink are the three internal mutations present in the sequence of 
the primer R-RT184V3 versus the target.  
 
For the sample from patient B amplification by allele-specific PCR was successful, 
but real-time PCR repeatedly failed. Subtype analysis revealed that the virus was of AG 
subtype. As the consensus of this HIV recombinant presents with three mismatches in the 
forward quantification primer (F3005 in Figure 47) the subtype would explain the observed 
failure to quantify; this was not genotypically verified for the virus minority in sample B. The 
alignment of the population-based sequence from patient B with the reverse primer (Figure 
47) revealed as well two mis-annealing with the wild type reference. In the allele-specific real 
time PCR reaction three mismatches are needed to specifically amplify the targeted variant. 
Due to a mutated nucleotide in codon 187 (TTA instead of TTT) only two internal mutations 
are observed between reverse primer and sample B. Nevertheless a third is contributed by a 
new mutation in codon 189 (GTG instead of GTA). Finally to amplify by allele-specific PCR 
the sample from patient B, this reverse primer should be matching but it will require another 
forward primer.  
 
The last point discussed in the chapter II was the mis-annealing of the primers used to 
amplify the RT gene in the rPhenotyping protocol (D-2582L and R-3525L). This could lead 
to an arbitrary selection of a subpopulation corresponding perfectly to the primer sequence 
unlike another presenting a mismatch in this particular region; primer bias issue. The samples 
diagnosed Geno-S/Pheno-R to a drug could illustrate this issue by a preferential amplification 
of a minor variant resistant to the ARV. To ensure that detection of a minor variant is not due 
to a preselection, the sequence of the seven patients involved in the study on minority species 
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were aligned with the sequence of the two primers aforementioned. Any mismatch was 
observed meaning that the major variant is perfectly matching the primer (data not shown). 
 
The detection of viral minority species carrying mutation M184V was possible for 
samples A, C, D and G with 0.25%, 0.85%, 0.53% and 1.5%, respectively (average of 4 
experiments in duplicate). However, a small risk of underestimating one or the other HIV-1 
variant cannot completely be excluded. For patients C and D, the ordering physician had 
suspected the transmission of a resistant virus; it is why a resistance test was prescribed. In 
these cases a transmitted mutant virus will be hidden by the wild type virus which is likely to 
be more fit. Patient G had previously received 3TC treatment which might have generated a 
mutant 184V variant. This variant might even after therapy cessation still be detectable as 
minority species in the absence of 3TC pressure. Patient A is currently under 3TC treatment 
along with AZT and EFV and therapy is beginning to fail: Genotyping detected a full 
sensitive virus whereas rPhenotyping revealed a resistance to 3TC. The detection of this 
184V minor resistant virus at 0.25%, however, can not explain therapy failure but viral 
resistance due to other non-canonical, resistance-associated mutations is not unlikely. This 
patient is infected by a subtype AG strain and, as already mentioned, the algorithms on non-B 
virus are not predictive enough to ensure that non-characterized mutations which may be less 
relevant for subtype B did not have an impact on non-B variants of HIV.   
 
The allele-specific PCR and real-time PCR methodologies were able to demonstrate 
the presence of 184V minor variant in a wild type background with a limit of sensitivity of 
0.3% and 0.05%, respectively. These methods are of course not suitable for a diagnostic 
routine on patient samples. The high sequence variability of HIV-1 makes it necessary to 
adjust the primer sequences for each individual isolate and to establish standard curves for 
correct quantification with wild type and mutant template from the sample under 
investigation. In this study, they were used as a tool to prove the particular acuity of the 
PhenoTecT system in detecting therapy-threatening minorities in clinically relevant therapy 
situations. 
 
The detection and characterization of minor drug-resistant variants is important for 
the clinical management of HIV infection. Using rPhenotyping it is possible to detect viral 
populations resistant either to 3TC/FTC or to NNRTIs as minority species not observed by 
standard Genotyping. Their early detection could help avoiding viral rebound as a 
consequence of treatment with an ineffective regimen. Minor virus variants arising in a 
patient’s circulation could provide an explanation for the onset of progression towards 
therapeutic failure since their early presence may provide for viral optimisation, e.g. of a 
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viruses replicative capacity144 that could occur unnoticed in the background. It appears 
logical that in clinical settings such viral populations might be particularly prevalent in non-
compliant patients, during drug holidays, under structured treatment interruption 
strategies90,145,146, or as early events in the context of transmitted mutant HIV variants with 
suboptimal replicative fitness147,148. A significant fitness-cost would lead to a more or less 
stable balance with wild type viruses and in the absence of drug pressure prevents them from 
easily becoming the predominant virus form in a patient. It will be interesting to apply the 
technology (and hypothesis) to studies on transient therapies, e.g. the short-term 
administration of NVP to pregnant women for prevention of mother-to-child transmission for 
further investigation of the presence and persistence of viral minorities with replication 
properties inferior to wild type149-152. Additional studies are needed to determine the 
frequency of specimen variants in clinical situations.  
 
The detection of such minor resistant variants is more and more explored showing 
their importance. In fact, other methodologies have been described in several studies for 
detecting low-frequency drug resistance mutations. In 2005, Palmer et al. detected by SGS 
(Single Genome Sequencing) minor variants carrying M41L, T69N, L74V, K103N, Y181C, 
or T215Y which were not detected by standard genotyping analysis153. The AS-PCR (Allele-
Specific PCR) was also able to show the reemergence of virus present (i) before STI that 
encoded 3-drug class resistance on the same genome154 or (ii) after single intrapartum dose of 
NVP for the prevention of mother-to-child transmission of HIV151. All these numerous 
methodologies could determine the prevalence of such HIV minor variants carrying 
mutations associated to ARV resistance in authentic clinical specimens; nevertheless this 
requires knowing in advance the mutations to look for while rPhenotyping can be used as 
diagnostic tool to detect them. 
 
Another explanation to the samples with Geno-S/Pheno-R discordance could be the 
presence of mutations which previously had not been associated with drug resistance; 
uncharacterized mutations. Novel NNRTI resistance mutations have been characterized in 
patients with primary HIV infection. In fact, some studies revealed the presence of viral 
strains with reduced susceptibility to NNRTIs, which were not carrying detectable amounts 
of any of the mutations associated to NNRTIs resistance155-157. These viral strains had instead 
amino acid substitutions at positions 135 and 283 in subtype B virus158 and the mutations 
135L, 139V and 245T in an isolate of subtype D virus155. By in vitro mutagenesis studies, the 
effects of these mutations indicated a susceptibility to the drug lower than the wild type 
control NL4-3. Reverse genetics on viral population presenting those mutations led to a re-
sensitisation to the ARV. Several specific combinations of mutated amino acids at these sites 
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were tested to assess their possible synergy on drug resistance: 135L+283I, 135M+283I and 
135T+2183I40,156; 135L+245T155. All samples diagnosed Geno-S/Pheno-R to EFV and/or 
NVP in PhenoBase® were compared to those concordant Geno-S/Pheno-S for the four amino 
acids at positions 135, 139, 245 and 283. Each subtype has been separately analysed. 
Unfortunately, even if at least one of these four mutations was present in 50% to 100% of the 
samples, depending on the subtype, no correlation could be identified between their presence 
and the discordant profile Geno-S/Pheno-R. Effectively, similar mutations were also found in 
concordant Geno-S/Pheno-S samples. The presence of others mutations which could interact 
negatively on resistance level would have to be considered. The unique mutation observed in 
case of discordance Geno-S/Pheno-R, and never in susceptible concordant samples, was the 
I135R. To confirm a possible impact of this substitution at position 135 of RT gene, an in-
depth study should be performed; if so, the genotypic algorithms will have to be updated in 
order to take into account the weight of this mutation in NNRTIs resistance. 
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Concluding remarks 
 
 
 
 
The present study underscores the considerable ability of HIV-1 to generate resistance 
mutations, eventually resulting in the coexistence of numerous viral quasispecies with distinct 
resistance genotypes throughout the evolution of resistance. Thus, they appear to have played 
an active role in the development of resistance in the patients studied here and may accelerate 
the process. The development of strategies for the evaluation and treatment of patients with 
drug resistance that adequately take into consideration this additional level of complexity 
might produce clinical benefit. 
 
Genotypic algorithms are self-optimising systems that improve their performance 
over time. A significant discordance was observed between interpretations inferred by 
different genotyping algorithms. This raises the urgent requirement to define common rules 
and possibly even new criteria to be considered. This will increase coherence of results and 
therapy advices within national and international studies and cooperation between centres. 
Nevertheless some intrinsic shortcoming remain that necessitate the use of alternative 
dissecting methods such as rPhenotyping: Genotyping principally fails to assign new 
mutations or novel resistance patterns provoked by new drugs, and systems are limited in the 
ability to follow viral speciation during extended treatment periods as this leads to the 
formation of viral minorities. The evolution of a growing complexity of viral genomes in any 
given patient requires dissection and assignment of mutations to individual viral genomes. 
Data presented in this study demonstrate that the principle of a functional assessment by 
rPhenotyping can strongly detect: (i) minor HIV populations with a sensitivity level of less 
than 1%, (ii) viral mixtures by analysing each single virus separately, (iii) viruses carrying 
any known mutations for actual drug and (iv) viruses presenting mutations with synergistic or 
antagonistic interactions. This renders it, for these applications, superior to Genotyping. 
Nevertheless further studies will have to show how this gain in sensitivity will translate into 
clinical utility and improved disease management (ongoing project with the Swiss HIV 
cohort and the group of M. Battegay, USB). 
 
In the future the treatment patients should benefit from those improvements, which 
will assist in identifying new drug-options. In addition, these observations will form the basis 
for an application in other viral diseases, notably HBV and HCV, where similar issues are 
likely to arise with the introduction of potent antiviral drugs.  
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Background 
 
The Human Immunodeficiency Virus (HIV) 
 HIV classification 
 
According to the International Committee on Taxonomy of Viruses (ICTV), HIV was 
classified as a member of the genus Lentivirus, part of the family of Retroviridae. Infections 
with Lentiviruses typically show a chronic course of disease, a long period of clinical latency, 
persistent viral replication and involvement of the central nervous system. Lentiviruses are 
transmitted as single-stranded, positive-sense, enveloped RNA viruses.  The HIV genome is a 
dimer of a two (+) ssRNA molecules, which are not 100% homologous, held together by 
hydrogen bonds. The viral RNAs have a 5’ cap and a 3’ poly-(A) tail like mRNAs. Since 
HIV mutates very quickly, there are many different strains, even in a single infected person. 
Based on genetic similarities, the numerous virus strains are classified into types, groups, and 
subtypes.  
There are two principal types of HIV: HIV-1 and HIV-2. HIV-1 is thought to have 
originated in southern Cameroon after jumping from wild chimpanzees (pan troglodytes 
troglodytes) to humans during the twentieth century159,160. HIV-2 may have originated from 
the Sooty Mangabey (Cercocebus atys), an Old World monkey of Guinea-Bissau, Gabon, and 
Cameroon161. Both types are transmitted from human to human by sexual contact, through 
blood, or from mother to child, and they appear to cause clinically indistinguishable AIDS. 
However, it seems that HIV-2 is less easily transmitted, and the period between initial 
infection and illness may be longer for HIV-2. Worldwide, the predominant virus is HIV-1, 
and generally when people refer to HIV without specifying the type of virus they will be 
referring to HIV-1 (as it will be in this report). The less common HIV-2 type is concentrated 
in West Africa and is rare elsewhere.  
Using electron microscopy, HIV-1 and HIV-2 show a close morphological similarity. 
However, they differ with regard to the molecular weight of their proteins and have 
differences in their accessory genes. Both HIV-1 and HIV-2 replicate in CD4+ T-cells and are 
regarded as pathogenic in infected persons, although the actual immune deficiency may be 
less severe in HIV-2-infected individuals. 
HIV-1 can be classified into three groups: M(ajor), O(utlier) and N(ew), which was 
only discovered in 1998162. These three groups may represent three separate introductions of 
SIV Simian Immunodeficiency Virus) into humans. Group O seems to be restricted to Africa 
and group N is even rarer. The next topics will relate to HIV-1 group M only. Within group 
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M nine genetically distinct subtypes (or clades) are known: A, B, C, D, F, G, H, J, and K163 
(Figure 48). 
 
 
 
 
 
 
 
Figure 48. Phylogenetic relationship of HIV. 
 
 
Occasionally, two viruses of different subtypes meet in the same cell in an infected 
person and mix their genetic material to create a new hybrid virus (a process similar to sexual 
reproduction, and sometimes called "viral sex")164. Many of these new strains do not survive 
for long, but those that infect more than one person are known as "circulating recombinant 
forms" or CRFs. For example, the CRF A/G is a genetic hybrid of subtypes A and G. One of 
the CRFs is called A/E because it is thought to have resulted from recombination between 
subtypes A and E. However, no pure form of subtype E has been found yet. In fact, CRF A/E 
is more correctly called CRF01_AE (http://www.hiv.lanl.gov/content/hiv-
db/CRFs/CRFs.html). The HIV-1 subtypes and CRFs are very unevenly distributed 
throughout the world (Figure 49), and the most prevalent are subtypes B (found mainly in 
North America and Europe), A and D (found mainly in Africa), and C (found mainly in 
Africa and Asia). In Europe subtype B remains the most common but other subtypes are 
becoming more frequent and now account for at least 25% of new infections. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 49. Global geographical distribution of HIV-1 genetic forms. 
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 Its morphological structure  
 
HIV-1 viral particles have a diameter of 100 nm and are surrounded by a lipoprotein 
membrane. Each viral particle contains 72 glycoprotein complexes, which are integrated into 
this lipid membrane, and are each composed of trimers of an external glycoprotein gp120 and 
a transmembrane spanning protein gp41. The bonding between gp120 and gp41 is only non-
covalent and therefore gp120 may be shed spontaneously within the local environment. 
Soluble glycoprotein gp120 may also be detected in the serum165 as well as within the 
lymphatic tissue of HIV-infected patients166. During the process of budding, the virus 
incorporates different host proteins from the membrane of the host cell into its lipoprotein 
layer, such as HLA class I and II proteins, or adhesion proteins such as ICAM-1 
(InterCellular Adhesion Molecule) that may facilitate adhesion to other target cells. The 
matrix protein p17 is fixed to the inside of the viral lipoprotein membrane via a myristoilation 
anchor. The p24 core antigen contains two copies of HIV-1 RNA. The HIV-1 RNA is part of 
a protein-nucleic acid complex, which is composed of the nucleoprotein p7 and the reverse 
transcriptase p66. The viral particle contains all the enzymatic equipment that is necessary for 
replication: a reverse transcriptase, an integrase p32 and a protease p11 (overview in 
Gelderblom et al.,1989167) (Figure 50). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 50. Structure of an HIV virion particle. 
[http://highered.mcgraw-hill.com/olc/dl/120088/micro41.swf] 
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 The organisation of the viral genome 
 
Most replication competent retroviruses depend on three genes: gag, pol and env. gag 
means “group-specific-antigen”, pol represents “polymerase” and env is for “envelope” 
(overview in Wong-Staal et al., 1992168) (Figure 51). The “classical” organisational scheme 
of a retroviral genome is: 5’LTR-gag-pol-env-LTR3’. The LTR (“long terminal repeat”) 
regions represent the two end parts of the viral genome, that are connected to the cellular 
DNA of the host cell after integration and do not encode for any viral proteins. They play a 
crucial role in the regulation of the transcription. The gag and env genes code for the 
nucleocapsid and the glycoproteins of the viral membrane; the pol gene codes for the reverse 
transcriptase and other enzymes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 51. HIV and its genes.  
[ http://www.stanford.edu/group/virus/retro/2005gongishmail/HIV.html] 
 
In addition, HIV-1 contains six genes: tat, rev, nef, vif, vpr and vpu (or vpx in the case 
of HIV-2) in its approximately 9.8 kb RNA that contribute to its genetic complexity. Nef, vif, 
vpr and vpu were classified as accessory genes in the past, as they are not absolutely required 
for replication in vitro, while tat and rev are classified as regulatory genes.  
The HIV genome has nine open reading frames (leading to nine primary translation products) 
but 15 proteins are made as a result of cleavage of three of the primary products.  
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The production of several polypeptides from the same mRNA, through differential splicing 
and initiation of translation (e.g. Rev and Tat) or ribosomal frameshift, enables to compress 
maximal information into a relatively small genome. Between gag and pol genes of HIV, a 
so-called slippery sequence has been characterized: most ribosomes encountering this 
sequence, translate it without difficulty reaching finally a stop codon. Some of them will, 
however, slip back one nucleotide allowing the translation of Pol in addition to Gag but with 
a different reading frame. The slippery sequence alone is not sufficient to produce this effect; 
indeed an RNA pseudoknot downstream from it, allows ribosomes pausing longer at that 
sequence increasing frameshift frequency169,170. Ribosomal frameshift enables the production 
of an excess of Gag in comparison with Gag/Pol, which contains the protease protein needed 
to cleave Gag and Gag/Pol polyproteins at nine positions to produce structural proteins and 
additional enzymes. 
 
The structural genes: 
- The gag gene gives rise to a precursor protein of 55 kD also called p55. After 
budding of the viral particle, p55 is cleaved by the virally encoded aspartic protease (a 
product of the pol gene) during the process of viral maturation into four smaller proteins: MA 
(matrix, p17), CA (capsid, p24), NC (nucleocapsid, p7) and p6, as depicted in Figure 51171. 
- The Gag-Pol precursor (p160) is generated by a ribosomal frame shifting event169, 
which is triggered by a specific cis-acting RNA motif172. When ribosomes encounter this 
motif, they shift approximately 5% of the time to the pol reading frame without interrupting 
translation. During viral maturation, the virally encoded protease cleaves the Pol polypeptide 
away from Gag and further digests it to separate the protease (p11), RT (p51), RNaseH (p15), 
and integrase (p32) activities. These cleavages do not all occur efficiently, e.g. 50% of the RT 
protein remains linked to RNaseH as a single polypeptide (p65). 
- The 160 kD Env (gp160) is expressed from singly spliced mRNA. First synthesised 
in the endoplasmic reticulum, Env migrates through the Golgi complex for glycosylation. A 
cellular protease cleaves gp160 to generate gp41 and gp120. Functional, mature Env exists as 
a trimer on the surface of infected cells and virions173. 
 
The regulatory genes: 
- Tat is a transcriptional transactivator that is essential for HIV-1 replication174. Tat is 
a RNA binding protein, unlike conventional transcription factors which interact with 
DNA175,176. Tat binds to a short-stem loop structure, known as the transactivation response 
element (TAR), that is located at the 5’ terminus of the LTR. The binding of Tat to TAR 
activates transcription from the HIV LTR at least 1000-fold. 
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- Rev is a 13 kD sequence-specific RNA binding protein177. Produced from fully 
spliced mRNAs, Rev acts to induce the transition from the early to the late phase of HIV gene 
expression178. Rev binds to a 240-base region of complex RNA secondary structure, called 
the Rev response element (RRE), which is located within the second intron of HIV within the 
coding region of gp41179. The binding of Rev to the RRE facilitates the export of unspliced 
and incompletely spliced viral RNAs from the nucleus to the cytoplasm. 
 
The accessory genes: 
- Nef (an acronym for negative factor) is a 27 kD protein that is encoded by a single 
exon that extends into the 3' LTR. Nef, an early gene of HIV, is the first viral protein to 
accumulate to detectable levels in a cell following HIV-1 infection178. Nef has been shown to 
have multiple activities, including the downregulation of the cell surface expression of 
CD4180, the perturbation of T cell activation181-183, and the stimulation of HIV infectivity184.  
- The Vpr protein is incorporated into viral particles. Vpr plays a role in the ability of 
HIV to infect non-dividing cells such as macrophages185 and can also block cell division186. 
- The 16 kD Vpu polyprotein is an integral membrane phosphoprotein that is 
primarily localised in the internal membranes of the cell187. The two functions of Vpu, the 
down-modulation of CD4 and the enhancement of virion release, can be genetically 
separated188. 
- Vif is a 23 kD polypeptide that is essential for the replication of HIV in peripheral 
blood lymphocytes, macrophages, and certain cell lines189. 
 
 
 Regulation of HIV Gene Expression 
 
The regulation of HIV gene expression is accomplished by a combination of both 
cellular and viral factors. HIV gene expression is regulated at both the transcriptional and 
post-transcriptional levels. The HIV genes can be divided into the early genes and the late 
genes190,191. The early genes, tat, rev, and nef, are expressed in a Rev-independent manner 
after a full splicing. The mRNAs encoding the late genes, gag, pol, env, vpr, vpu, and vif are 
singly spliced or unspliced, and they require Rev in order to be exported to the cytoplasm for 
a further translation. 
 
Transcription of the proviral genome: 
HIV transcription is mediated by a single promoter in the 5’LTR. Expression from the 
5'LTR generates a 9-kb primary transcript that has the potential to encode all nine HIV genes. 
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The primary transcript is roughly 600 bases shorter than the provirus. It can be spliced into 
more than 30 mRNA species192 or packaged as full length without further modification into 
virion particles (to serve as the viral RNA genome).  
The LTRs are composed of three subregions designated U3, R, and U5193. The U3 
region (for unique 3' sequence) is approximately 450-basepairs (bp) in length and is located 
at the 5' terminus of each LTR. The central region of each LTR contains the 100-bp R (for 
repeated sequence) region and the U5 region (for unique 5' sequence) is 180-bp in length. The 
5’ LTR directs transcription, while the 3’ LTR directs cleavage of the primary transcript and 
addition of a poly-(A) tail. In the 5’LTR, the U3 region contains promoter elements 
recognised by several transcription factors involved in the formation of the transcriptional 
machinery whereas the U5 region contains the Tat binding site (TAR) and packaging 
sequences of HIV. The 3' end of U5 is defined by the location of a lysyl tRNA binding site. 
The lysyl tRNA acts as primer for reverse transcription. 
 
Regulation of Transcription: 
As illustrated in Figure 52, the 5’ LTR also functions as enhancer, containing more 
than one element recognised by cellular transcriptional activators (e.g. AP-1, NFAT-1, USF-
1, Ets-1, NF-κB, Sp1, TBP, LBP-1).   
 
 
Figure 52. Broad dissection of the 5’ HIV LTR. 
 
The key factors among the DNA binding sites required for the activation of the 
transcription of the HIV provirus are those for the NF-kappa B family of transcription 
factors194. Two adjacent NF-kappa B sites are present in the U3 region of the HIV-1 LTR. 
The NF-kappa B protein allows the virus to be responsive to the activation state of the 
infected T cell. Stimulation of the T cell receptor (TCR) causes the inactive form of NF-
kappa B, localised in the cytoplasm, to be translocated into the nucleus where it induces the 
expression of a series of T cell activation-specific genes. NF-kappa B and subsequent 
activation of HIV transcription can also be induced by the cytokines tumor necrosis factor 
alpha (TNF alpha)195 and interleukin-1 (IL-1)196. 
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The initial activation of the HIV LTR is a consequence of inducible and constitutive 
cellular transcription factors. Activation of the LTR by cellular transcription factors leads 
primarily to the generation of short transcripts up to a “strongstop” signal197. However, a low 
level of read through allows the production of the Tat protein. The trans-acting regulatory 
protein Tat then interacts with the TAR element in the U5 region of the 5’ LTR to greatly 
increase the levels of long transcription of viral RNAs, and the elongation capacity of RNA 
polymerase II is improved197,198. The Tat protein thus plays a key role in the activation and 
maintenance of high levels of transcription from the proviral DNA. Since synthesis of Tat is 
itself under the control of LTR promoters, HIV transcription results in a positive feedback.  
 
mRNA splicing and cellular localisation: 
The primary HIV-1 transcript contains multiple splice donors (5' splice sites) and 
splice acceptors (3' splice sites), which can be processed to yield more than 30 alternative 
mRNAs192. Many of the mRNAs are polycistronic; i.e., they contain the open reading frame 
of more than one protein. The polycistronic mRNAs typically express a single gene product. 
Open reading frame choice is governed by the efficiency of the initiation codon and the 
proximity of the initiation codon to the 5' end of the mRNA199.  
Tat and Rev are the two transcripts of HIV (together with Nef) to be fully spliced and 
so they are exported to the cytoplasm soon after host cell infection. As an initial event after 
cellular infection, intron-containing RNAs must be completely spliced before they can exit 
the nucleus. This regulation is essential because it prevents the translation of intronic 
sequences contained in partially spliced mRNAs. Rev binds to a secondary structure of 
unspliced or partially spliced mRNAs, the RRE, and allows their export from the nucleus 
(Rev has both nuclear import and export signals)179. This export allows those viral RNAs to 
bypass the normal "check point" of RNA splicing. The fully spliced viral mRNAs exit the 
nucleus by using the export pathway followed by the majority of cellular mRNAs.  
 
HIV-1 mRNAs fall into three size classes: 
1. Fully spliced RNA. These mRNAs have spliced out both introns of HIV and have the 
potential to express Nef, and the two-exon forms of Tat and Rev. These 
heterogeneous mRNAs do not require the expression of the Rev protein for export and 
translation. 
2. Incompletely spliced RNA. These RNAs can potentially express Env, Vif, Vpu, Vpr, 
and the single-exon form of Tat. These heterogeneous mRNAs are 4- to 5-kb long and 
retain the second intron of HIV.  
3. Unspliced RNA. The unspliced 9-kb primary transcript can be expressed to generate 
the Gag and Gag-Pol precursor proteins or be packaged into virions to serve as the 
genomic RNA. 
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Whereas the proteins encoded by the fully spliced mRNAs, Nef, Tat, and Rev, can be 
produced immediately, and are thus early viral gene products, threshold levels of Rev are 
necessary for exporting intron-containing HIV mRNAs, explaining why those encode the 
viral late gene products177,200.  
 
 
 HIV tropism 
 
The term viral tropism refers to the cell types which get infected by HIV. HIV can 
infect a variety of immune cells such as CD4+ T cells, macrophages, and microglial cells. 
HIV-1 entry to macrophages and CD4+ T cells is mediated through interaction of the virion 
envelope glycoproteins (gp120) with the CD4 molecule on the target cells and, in addition, 
with a chemokine coreceptor: generally CCR5 or CXCR4 (fusin)201. 
The former nomenclature of Macrophage strains (M-tropic) of HIV-1, or non-
syncitia-inducing strains (NSI), indicated viruses that use the β-chemokine receptor CCR5 for 
entry (and sometimes the CCR3 coreceptor). They are able to replicate in the macrophages 
and in the primary CD4+ T cells202. This CCR5 coreceptor is used by almost all primary HIV-
1 isolates regardless of the viral genetic subtype. The macrophages appear to be the first cells 
infected by HIV and perhaps the source of HIV production when CD4+ cells become depleted 
in the patient. Macrophages and microglial cells are the cells infected by HIV in the central 
nervous system.  
T-tropic isolates, or syncitia-inducing (SI) strains, replicate in primary CD4+ T cells 
and use the α-chemokine receptor, CXCR4, for entry202-204. They can also enter macrophages 
by using both CCR5 and CXCR4 coreceptors.  
Dual-tropic HIV-1 strains are thought to be transitional strains of the HIV-1 virus and 
thus are able to use either CCR5 or CXCR4 as coreceptors for viral entry. 
HIV that use only the CCR5 receptor are today termed R5-tropic, those that only use 
CXCR4 are termed X4-tropic, and those that use both, X4R5.  
 
Sexual intercourse is the major mode of HIV transmission. Both X4- and R5-tropic 
HIV are represented in the genital fluid which is passed from partner to partner. The virions 
can then infect numerous cellular targets and disseminate into the organism. However, a 
selection process leads to a predominant transmission of the R5 virus through this pathway205-
207
. How this selective process works is still under investigation. In patients infected with 
subtype B HIV-1, there is often a coreceptor switch in late-stage disease and T-tropic variants 
appear that can infect a variety of T cells through CXCR4208. These variants then replicate 
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more aggressively with greater virulence that causes rapid T cell depletion, immune system 
collapse, and opportunistic infections that mark the advent of AIDS209. Thus, during the 
course of infection, viral adaptation to the use of CXCR4 instead of CCR5 may be a key step 
in the progression to AIDS. A number of studies with subtype B-infected individuals have 
determined that between 40 and 50% of AIDS patients can harbour viruses of the SI, and 
presumably the X4, phenotype210,211.  
 
The host genes, as the chemokine receptors, can interfere in the course of AIDS. 
People homozygous for a 32bp deletion (the so-called ∆32 mutation) in the chemokine 
receptor gene for CCR5, which results in failure of surface expression of this key viral 
coreceptor, are protected nearly at 100% from an HIV infection, considering that transmitted 
viruses are mainly CCR5-tropic212. Among HIV seronegative individuals, who are at high 
risk of infection, only a minority have a homozygous ∆32 mutation, indicating that other 
mechanisms determine protection from HIV infection. Single-nucleotide polymorphisms 
(SNPs) in the CCR5 promoter have shown that alleles containing an adenine at position -2459 
display higher CCR5 promoter activities than alleles with a guanine. HIV infected individuals 
homozygous for the A allele (-2459A/A) progressed more rapidly to AIDS than those who 
were homozygous for the G allele (-2459G/G)213. A C-to-G substitution at position -28 in the 
promoter of RANTES, a ligand of the CCR5 coreceptor, supports increased expression of 
RANTES and is associated with a decreased rate of CD4+ T-cell decline in HIV infected 
people214. Moreover, people homozygous for a non-coding sequence in the gene for stromal 
cell-derived factor 1 (SDF-1), the natural ligand for the CXCR4 coreceptor, were found to 
have a delayed risk for progression to AIDS215. Certain human leucocyte antigen (HLA) 
alleles indicate greater or lesser risks of disease progression; in addition viral mutations that 
impair the binding of specific viral peptides to HLA of a given patient are correlated with a 
higher VL216.  
In general, variation in the host immune system could explain the difference in 
disease progression observed among different patients, but also the enormous adaptability of 
the viral envelope, especially the variation of its glycosylation patterns, is responsible for 
immune escape217,218.  
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 AntiRetroVirals 
 
Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)  
Brand Name Generic Name(s) Structure Manufacturer Name Approval Date 
Retrovir zidovudine, azidothymidine, AZT, 
ZDV 
Thymidine Analog GlaxoSmithKline 19-Mar-87 
Videx didanosine, dideoxyinosine, ddI Inosine Analog Bristol Myers-Squibb 9-Oct-91 
Hivid zalcitabine, dideoxycytidine, ddC  Cytidine Analog Hoffmann-La Roche 19-Jun-92 
Zerit stavudine, d4T Thymidine Analog Bristol Myers-Squibb 24-Jun-94 
Epivir lamivudine, 3TC Cytidine Analog GlaxoSmithKline 17-Nov-95 
Ziagen abacavir sulfate, ABC  Guanosine Analog GlaxoSmithKline 17-Dec-98 
Viread tenofovir disoproxil fumarate, TDF  Adenine Analog Gilead 26-Oct-01 
Emtriva emtricitabine, FTC  Cytidine Analog Gilead Sciences 02-Jul-03 
 
Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs) 
Brand Name Generic Name Manufacturer Name Approval Date 
Viramune nevirapine, NVP  Boehringer Ingelheim 21-Jun-96 
Rescriptor delavirdine, DLV Pfizer 4-Apr-97 
Sustiva efavirenz, EFV  Bristol Myers-Squibb 17-Sep-98 
 
Protease Inhibitors (PIs) 
Brand Name Generic Name(s) Manufacturer Name Approval Date 
Invirase saquinavir mesylate, SQV Hoffmann-La Roche 6-Dec-95 
Norvir ritonavir, RTV  Abbott Laboratories 1-Mar-96 
Crixivan indinavir, IDV,  Merck 13-Mar-96 
Viracept nelfinavir mesylate, NFV Agouron Pharmaceuticals 14-Mar-97 
Agenerase amprenavir, APV GlaxoSmithKline 15-Apr-99 
Kaletra  lopinavir and ritonavir, LPV/RTV Abbott Laboratories 15-Sep-00 
Reyataz atazanavir sulfate, ATV  Bristol-Myers Squibb 20-Jun-03 
Lexiva Fosamprenavir Calcium, FOS-APV  GlaxoSmithKline 20-Oct-03 
Aptivus tipranavir, TPV  Boehringer Ingelheim  22-Jun-05 
Prezista Darunavir, DNV Tibotec, Inc. 23-Jun-06 
 
Fusion Inhibitors  
Brand Name Generic Name Manufacturer Name Approval Date 
Fuzeon enfuvirtide, T-20 Hoffmann-La Roche & Trimeris 13-Mar-03 
 
Entry Inhibitors - CCR5 co-receptor antagonist  
Brand Name Generic Names Manufacturer Name Approval Date 
Selzentry maraviroc  Pfizer 06-August-07 
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   Cloning of the major capsid protein of the bacteriophage KSY1. 
 
 This project was financed by a personal grant I obtained from the 
CROUS (Centre Regional des Oeuvres Universitaires et Scolaires), 
known as: “bourse de voyage” 
  
 
 
PUBLICATION 
 
• Detection of drug-resistant HIV minorities in clinical specimens and therapy failure. 
Séverine Louvel, Manuel Battegay, Pietro Vernazza, Thomas Bregenzer, Thomas 
Klimkait, François Hamy, and the Swiss HIV cohort study. (submitted) 
 
 
 
MEETINGS 
 
• 2d European HIV drug resistance workshop, Rome, Italy, March 2004. 
Poster presentation: In vitro assessment of NRTI-discordances between Genotypic 
and Phenotypic resistance testing using defined complex mutants or viral mixtures as 
found in clinical samples.  
 
• XV International AIDS Conference, Bangkok, Thailand, July 2004. 
Poster presentation: Dissection of HIV-1 resistance profiles comparing genotypic 
analysis with replicative Phenotyping. 
 
• Saaten, Switzerland, January 2004. 
Poster presentation: Comparison of HIV-1 resistance profiles for PI and RTI using 
genotypic algorithms (ANRS, Stanford, Rega) and replicative phenotyping 
(PhenoTecT). 
 
• 3d European HIV drug resistance workshop, Athens, Greece, March 2005.  
Poster presentation: Detection of viral minority species using resistance testing.  
 
• HIV Highlights meeting, Amsterdam, Netherlands, June 2005. 
 
• 2nd Swiss Workshop on Basic HIV Research, Murten, Switzerland, May 2006. 
Poster presentation: Revealing drug resistant minority variants using replicative 
phenotyping. 
 
• HIV DART 2006 Symposium, Cancun, Mexico, December 2006. 
Poster presentation: Replicative Phenotyping (PhenoTecT) detects critical HIV 
minorities in plasma. Awarded with the chairmen’s poster award offered by Robert 
Murphy and Raymond F. Schinazi on behalf of the organising committee of HIV 
DART 2006. 
 
